{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np # Linear algebra\n",
    "\n",
    "# Data processing, CSV file I/O (e.g. pd.read_csv)\n",
    "import pandas as pd\n",
    "from pandas import DataFrame\n",
    "import csv\n",
    "\n",
    "import xml.etree.ElementTree as ET # Reading xml files\n",
    "\n",
    "# For plotting\n",
    "import matplotlib.pyplot as plt\n",
    "import pydot\n",
    "import pydotplus\n",
    "import graphviz\n",
    "from keras.utils.vis_utils import plot_model\n",
    "from keras.utils import *\n",
    "from sklearn.manifold import TSNE\n",
    "\n",
    "\n",
    "# For Modelling\n",
    "import tensorflow as tf\n",
    "from tensorflow.keras import layers, models, preprocessing, callbacks, optimizers\n",
    "\n",
    "# print(tf.VERSION)\n",
    "# print(tf.keras.__version__)\n",
    "\n",
    "from tensorflow.keras.models import Model\n",
    "from tensorflow.keras.layers import Dense, Embedding, Input, Add\n",
    "from tensorflow.keras.layers import LSTM, Bidirectional, GlobalMaxPool1D, Dropout\n",
    "from tensorflow.keras.preprocessing import text, sequence\n",
    "from tensorflow.keras.callbacks import EarlyStopping, ModelCheckpoint\n",
    "from tensorflow.keras.optimizers import Adam\n",
    "from tensorflow.keras.layers import Conv2D, MaxPooling2D, BatchNormalization\n",
    "from tensorflow.keras.layers import concatenate\n",
    "from keras.metrics import categorical_accuracy\n",
    "\n",
    "\n",
    "# For Pre-processing\n",
    "import string\n",
    "from string import digits\n",
    "import nltk\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.stem import WordNetLemmatizer\n",
    "from tqdm import tqdm\n",
    "import re\n",
    "\n",
    "# Other useful modules\n",
    "import h5py\n",
    "from statistics import mode\n",
    "import os\n",
    "import datetime\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')\n",
    "                    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "                        \n",
    "def csv_row(xml_file):\n",
    "\n",
    "    tree = ET.parse(xml_file)\n",
    "    root = tree.getroot()\n",
    "    \n",
    "    nct_text = \"\"\n",
    "    sum_text = \"\"\n",
    "    model_text = \"\"\n",
    "    ph_text = \"\"\n",
    "    title_text = \"\"\n",
    "    year_text = \"\"\n",
    "    condition_disease_text= \"\"\n",
    "    description_text = \"\"\n",
    "    failed_text_full=\"\"\n",
    "    \n",
    "    if root.iter('drop_withdraw_reason'):\n",
    "        # Only iterates through Phase 2 and 3 studies\n",
    "        for ph in root.iter('phase'):\n",
    "            ph_text = ph.text\n",
    "        if (ph_text == \"Phase 2\" or ph_text == \"Phase 3\"):\n",
    "            for date in root.iter('start_date'):\n",
    "                    year_text = date.text\n",
    "            if '2016' or '2017' or '2018' or '2019' or '2020' in year_text:\n",
    "\n",
    "                #This bit finds all roots with nct_id which is a sub_root to id_info\n",
    "                for nct in root.findall('id_info'):\n",
    "                    nctId_text = nct.find('nct_id').text\n",
    "                    nct_text =nctId_text\n",
    "                    #print(nct_text)\n",
    "\n",
    "                # This bit finds the brief summary text\n",
    "                for s in root.findall('brief_summary'):\n",
    "                    summary_text = s.find('textblock').text\n",
    "                    sum_text= summary_text\n",
    "                    sum_text = sum_text.replace('\\n', '') # Replaces newline with a whitespace\n",
    "                    sum_text = re.sub(' +',' ',sum_text) # Compresses multiple whitespaces to only one\n",
    "                    #print(\"Summary Text:\", sum_text)\n",
    "\n",
    "                # Get's the official title for the study\n",
    "                for t in root.iter('brief_title'):\n",
    "                    title_text = t.text\n",
    "\n",
    "                # This get's the type of intervention_model\n",
    "                for y in root.iter('intervention_model'):\n",
    "                    model_text = y.text\n",
    "\n",
    "                for date in root.iter('start_date'):\n",
    "                    year_text = date.text\n",
    "                    #print(year_text)\n",
    "\n",
    "                for condition in root.iter('condition'):\n",
    "                    condition_disease_text = condition.text\n",
    "                    #print(condition_disease_text)\n",
    "\n",
    "\n",
    "                for reason in root.iter('drop_withdraw_reason'):\n",
    "                    failed_text_full= failed_text_full+', ' +f'{reason[0].text}'\n",
    "                #print(\"withdraw reason\", failed_text_full)\n",
    "\n",
    "\n",
    "    total_text = \"\\\"\" + nct_text+ \"\\\"\" + \";\" + \"\\\"\"+ ph_text+ \"\\\"\" + \";\" + \"\\\"\" + condition_disease_text+ \"\\\"\" + \";\" + \"\\\"\"+ sum_text + \"\\\"\" + \";\"  + \"\\\"\" + title_text + \"\\\"\" + \";\"  +  \"\\\"\" + model_text + \"\\\"\" + \";\" + \"\\\"\"+ year_text + \"\\\"\" + \";\" + \"\\\"\"+ 'NOT COMPLETED BECAUSE OF' + failed_text_full+ \"\\\"\"\n",
    "\n",
    "    # This functions returns a text with Nct_Id, brief_summary, title and type of intervention model on the form we intended\n",
    "\n",
    "    return total_text\n",
    "\n",
    "#csv_row(\"/groups/cherkasvgrp/share/progressive_docking/pd_python_pose/clinical_trials/NCT0126xxxx/NCT01266460.xml\")# This is for checking that the function works"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "your file /groups/cherkasvgrp/share/progressive_docking/pd_python_pose/clinical_trials/.ipynb_checkpoints/Untitled-checkpoint.ipynb did not get parsed probably\n"
     ]
    }
   ],
   "source": [
    "\n",
    "rdir = '/groups/cherkasvgrp/share/progressive_docking/pd_python_pose/clinical_trials' # Folders in directory where the all the xml files are placed\n",
    "\n",
    "with open('all_clincal_trials.csv', 'w', encoding=\"utf-8\") as csvfile: # Opens a blank csv file\n",
    "    for _, dirs, _ in os.walk(rdir):\n",
    "        for dir in dirs: # Looks at  all the xml folders\n",
    "            for subdir, _, files in os.walk(os.path.join(rdir,dir)):\n",
    "                for file in files:\n",
    "                    name = os.path.join(subdir, file)\n",
    "                    try: \n",
    "                        csvfile.write(csv_row(name)) #Writes total_text into a row in to all_clinical_trials.csv\n",
    "                        csvfile.write(\"\\n\") # Skips to next line and do the same\n",
    "                    except:\n",
    "                        print(f'your file {name} did not get parsed probably')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# Earlier we saw that the returned text from our function was seperated by ';', so we use this as seperator when reading in the files\n",
    "all_clinical_trials = pd.read_csv(\"all_clincal_trials.csv\", sep=';', header=None,error_bad_lines=False, warn_bad_lines=False,\n",
    "                 lineterminator='\\n')\n",
    "\n",
    "all_clinical_trials.columns =  ['Nct_id', 'Phase' , 'Condition' , 'Summary', 'Title', \"Model\" , 'Date' , 'Failure Reason(s)']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Nct_id</th>\n",
       "      <th>Phase</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Title</th>\n",
       "      <th>Model</th>\n",
       "      <th>Date</th>\n",
       "      <th>reason</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00461123</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prostatic Hypertrophy, Benign</td>\n",
       "      <td>The greenlight laser has an absorption maximu...</td>\n",
       "      <td>Vardenafil in Greenlight(TM) Laser Surgery of ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT00462202</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetic Nephropathy</td>\n",
       "      <td>The purpose of this study is to assess the to...</td>\n",
       "      <td>Open Label Tolerability and Safety Study of KR...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>April 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00462735</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cancer of the Oral Cavity</td>\n",
       "      <td>For advanced head and neck cancer, combined r...</td>\n",
       "      <td>Fluorouracil, Hydroxyurea, Cetuximab and Twice...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>February 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00468286</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prostate Cancer</td>\n",
       "      <td>The study will have two treatment groups, eva...</td>\n",
       "      <td>Investigating Efficacy and Safety of Two Degar...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT00466856</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Pheochromocytoma</td>\n",
       "      <td>RATIONALE: Specialized radiation therapy that...</td>\n",
       "      <td>Internal Radiation Therapy in Treating Patient...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>December 2003</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NCT00462709</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hereditary Angioedema</td>\n",
       "      <td>The study objective was to evaluate the safet...</td>\n",
       "      <td>Open-Label C1 Esterase Inhibitor (C1INH-nf) fo...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 27, 2006</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Transitioned to comm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>NCT00461058</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Diabetes Mellitus Type 2</td>\n",
       "      <td>This 2 arm study will compare the safety, tol...</td>\n",
       "      <td>A Comparative Study of Aleglitazar and Actos i...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NCT00463437</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Streptococcus Pneumoniae Vaccines</td>\n",
       "      <td>The purpose of this study is to assess the sa...</td>\n",
       "      <td>Pneumococcal Vaccine Booster Study in Healthy ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 25, 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>NCT00464763</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Delirium</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>A Research Study to Evaluate the Effectiveness...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>NCT00460746</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>HIV</td>\n",
       "      <td>The purpose of this study is to examine the s...</td>\n",
       "      <td>Enfuvirtide/Current Protease Inhibitor Switch ...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>NCT00467493</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Menstruation Disorders</td>\n",
       "      <td>Aromatase inhibitors have been approved for u...</td>\n",
       "      <td>Partial Double-Blind, Placebo-Controlled Study...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>NCT00465205</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Sexually Transmitted Diseases</td>\n",
       "      <td>Over 80% of HIV-1 infected persons are also s...</td>\n",
       "      <td>HSV-2 Suppression to Reduce HIV-1 Levels in HI...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>January 2005</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>NCT00467077</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Kidney Cancer</td>\n",
       "      <td>RATIONALE: Gefitinib may stop the growth of k...</td>\n",
       "      <td>Gefitinib and PEG-Interferon Alfa-2b in Treati...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>September 2004</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>NCT00464425</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Postoperative Ileus</td>\n",
       "      <td>Postoperative ileus remains a significant med...</td>\n",
       "      <td>Electroacupuncture for Postoperative Ileus Aft...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 2008</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>NCT00466089</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>A phase II, multicenter, randomized trial of ...</td>\n",
       "      <td>Study of 3D Radiotherapy With or Without Erlot...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2006</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>NCT00463346</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>The aim of this study is to evaluate the safe...</td>\n",
       "      <td>Treatment With Acamprosate in Patients With Sc...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>September 2006</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subject</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>NCT00462540</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Chronic Obstructive Pulmonary Disease</td>\n",
       "      <td>The purpose of this study is to compare the e...</td>\n",
       "      <td>A Crossover Study in the Treatment of Patients...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>NCT00466440</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prostate Cancer</td>\n",
       "      <td>The purpose of the study is to compare the re...</td>\n",
       "      <td>A Phase 2 Study With Enzastaurin Plus Chemothe...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>NCT00460317</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>To determine if treatment with AMG 706 (motes...</td>\n",
       "      <td>MONET1-MOtesanib NSCLC Efficacy and Tolerabili...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>NCT00464347</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Age-Related Macular Degeneration</td>\n",
       "      <td>VERTACL will investigate whether a triple the...</td>\n",
       "      <td>TAC-PF, Avastin® in Combination With Photodyna...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>NCT00469885</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Tobacco Use Disorder</td>\n",
       "      <td>This study evaluates the effect of smoking re...</td>\n",
       "      <td>Reduction of Smoking in Cardiac Disease Patients</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2001</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>NCT00462384</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Anemia</td>\n",
       "      <td>This single arm study will assess the efficac...</td>\n",
       "      <td>A Study of Subcutaneous Mircera for the Treatm...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>February 2008</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>NCT00461773</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Randomized Phase II Study of Preoperative Letr...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>NCT00462267</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Overweight</td>\n",
       "      <td>This project will examine the effectiveness o...</td>\n",
       "      <td>Examining the Feasibility of Collaborative Car...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2005</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>NCT00468611</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Multiple Sclerosis, Secondary Progressive</td>\n",
       "      <td>This study will assess the efficacy and safet...</td>\n",
       "      <td>Efficacy and Safety of MBP8298 in Subjects Wit...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>NCT00467519</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Pertussis</td>\n",
       "      <td>Currently, there is no 5-component acellular ...</td>\n",
       "      <td>Safety and Immunogenicity of Tdap Vaccine Comp...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Protocol Violation, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>NCT00467844</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cachexia</td>\n",
       "      <td>The purpose of this study is to assess if Gtx...</td>\n",
       "      <td>Study of GTx-024 on Muscle Wasting (Cachexia) ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>NCT00464165</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Smoking Cessation</td>\n",
       "      <td>The primary objective is to assess the effica...</td>\n",
       "      <td>Comparison of Efficacy and Safety of Rimonaban...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>November 2002</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>NCT00468247</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Intensive Care</td>\n",
       "      <td>A multicentre, open, RCT to assess the safety...</td>\n",
       "      <td>Registration Enabling Study of the Safety and ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>NCT00469326</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Coronary Artery Disease</td>\n",
       "      <td>This study investigates potential protective ...</td>\n",
       "      <td>Atorvastatin Pre-Treatment Influences the Risk...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2005</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389454</th>\n",
       "      <td>NCT02435108</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>c-MET Positive Gastric Cancer</td>\n",
       "      <td>This is a pilot study of crizotinib in patien...</td>\n",
       "      <td>A Pilot Study of Crizotinib in Patients With c...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>May 15, 2014</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389455</th>\n",
       "      <td>NCT02433522</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>ANCA-associated Vasculitides</td>\n",
       "      <td>MAINRITSAN study compared Rituximab and azath...</td>\n",
       "      <td>Comparison Between a Long Term and a Conventio...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 31, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389460</th>\n",
       "      <td>NCT02435121</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Neoplasm Malignant</td>\n",
       "      <td>Primary Objective:\\r\\r To determine objective...</td>\n",
       "      <td>A Study Assessing Efficacy and Safety of SAR12...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>November 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389466</th>\n",
       "      <td>NCT02432534</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Vitiligo</td>\n",
       "      <td>Condition:\\r\\r Non segmental and active vitil...</td>\n",
       "      <td>Atorvastatin in Active Vitiligo</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389472</th>\n",
       "      <td>NCT02435914</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Dry Eye Syndromes</td>\n",
       "      <td>This study will evaluate the safety, efficacy...</td>\n",
       "      <td>Safety, Efficacy, Tolerability and Pharmacokin...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Ocular Adverse Event...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389490</th>\n",
       "      <td>NCT02439034</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Upper Aerodigestive Tract Neoplasms</td>\n",
       "      <td>The results of the study will permit to set u...</td>\n",
       "      <td>Paracetamol With or Without Ketoprofen in the ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389493</th>\n",
       "      <td>NCT02437812</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Epithelial Ovarian Carcinoma</td>\n",
       "      <td>Initially, the prospect of metformin as a neo...</td>\n",
       "      <td>Study of Paclitaxel, Carboplatin and Oral Metf...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>January 2014</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389502</th>\n",
       "      <td>NCT02433236</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>IGA Nephropathy</td>\n",
       "      <td>Phase 2, multi-center, open label extension s...</td>\n",
       "      <td>Open Label Study of Fostamatinib in the Treatm...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>September 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389513</th>\n",
       "      <td>NCT02431611</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Pregnancy</td>\n",
       "      <td>Phase 3 Pilot Clinical Trial.\\r</td>\n",
       "      <td>Biomarker Feedback to Motivate Cessation in Pr...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389515</th>\n",
       "      <td>NCT02438852</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-operative Pain</td>\n",
       "      <td>This randomized phase IV trial studies how we...</td>\n",
       "      <td>Continuous Infusion of Ropivacaine Hydrochlori...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 25, 2019</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389516</th>\n",
       "      <td>NCT02432846</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Renal Cell Carcinoma, Metastatic</td>\n",
       "      <td>The purpose of this study is to compare tumor...</td>\n",
       "      <td>Intratumoral Vaccination With Intuvax Pre-neph...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389520</th>\n",
       "      <td>NCT02431052</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Acne Vulgaris</td>\n",
       "      <td>The objectives of this study are to assess th...</td>\n",
       "      <td>A Dose-ranging Study of DRM01 in Subjects With...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389522</th>\n",
       "      <td>NCT02432209</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Infertility, Female</td>\n",
       "      <td>A two-arm, multicenter, prospective, randomiz...</td>\n",
       "      <td>Improving Reproductive Fitness Through Pretrea...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>August 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389541</th>\n",
       "      <td>NCT02436512</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Pulmonary Arterial Hypertension</td>\n",
       "      <td>The EAGLE study is a Phase 3, open-label, mul...</td>\n",
       "      <td>Study to Assess Acute Vasodilation Response of...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389546</th>\n",
       "      <td>NCT02433340</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Rheumatoid Arthritis</td>\n",
       "      <td>This is a Phase 2, multicenter, 24-week OLE s...</td>\n",
       "      <td>Phase 2, Multicenter, Open-Label Extension Stu...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389550</th>\n",
       "      <td>NCT02430077</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Familial Partial Lipodystrophy</td>\n",
       "      <td>Lipodystrophies are rare disorders characteri...</td>\n",
       "      <td>Phase 2 Study of Obeticholic Acid for Lipodyst...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>June 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389551</th>\n",
       "      <td>NCT02439320</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Acute Migraine</td>\n",
       "      <td>This is a prospective randomized, double-blin...</td>\n",
       "      <td>Lasmiditan Compared to Placebo in the Acute Tr...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389553</th>\n",
       "      <td>NCT02433249</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Sedentary Lifestyle</td>\n",
       "      <td>The purpose of this pilot study is to develop...</td>\n",
       "      <td>Developing a Intervention to Enhance Motivatio...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2014</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389557</th>\n",
       "      <td>NCT02432690</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>This is an open label, single-arm, phase II s...</td>\n",
       "      <td>A Study of BBI503 in Asymptomatic Recurrent Ov...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389559</th>\n",
       "      <td>NCT02432105</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Otitis Media Recurrent</td>\n",
       "      <td>The purpose of this study is to evaluate EXE8...</td>\n",
       "      <td>Safety and Efficacy of EXE844 Otic Suspension ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 25, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up, W...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389573</th>\n",
       "      <td>NCT02437890</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Lupus Erythematosus, Systemic</td>\n",
       "      <td>Primary objective:\\r\\r To assess the efficacy...</td>\n",
       "      <td>A Phase II Study to Evaluate Safety and Effica...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Non-compliance to st...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389575</th>\n",
       "      <td>NCT02438787</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Axial Spondyloarthritis</td>\n",
       "      <td>The purpose of this study is to assess the ef...</td>\n",
       "      <td>A Study to Evaluate the Efficacy and Safety of...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 31, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lack ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389579</th>\n",
       "      <td>NCT02430298</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Head and Neck Cancer</td>\n",
       "      <td>The study evaluates the effect of melatonin f...</td>\n",
       "      <td>Topical/Oral Melatonin for Preventing Concurre...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 2013</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389585</th>\n",
       "      <td>NCT02433639</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Biliary Tract Cancer</td>\n",
       "      <td>Biliary tract cancer is relatively rare cance...</td>\n",
       "      <td>Study of TH-302 Monotherapy as Second-line Tre...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389588</th>\n",
       "      <td>NCT02434029</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Eosinophilic Esophagitis</td>\n",
       "      <td>The purpose of this study is to prove the sup...</td>\n",
       "      <td>Budesonide Orodispersible Tablet vs. Placebo i...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>November 11, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389589</th>\n",
       "      <td>NCT02435862</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Non-Proliferative Diabetic Retinopathy</td>\n",
       "      <td>A Phase 2, Randomized, Double-masked, Placebo...</td>\n",
       "      <td>A Clinical Trial Designed to Evaluate the Safe...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 1, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389590</th>\n",
       "      <td>NCT02431468</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alzheimer's Disease</td>\n",
       "      <td>This is a randomized double-blind placebo-con...</td>\n",
       "      <td>A Study Assessing Bryostatin in the Treatment ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>November 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389591</th>\n",
       "      <td>NCT02432365</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cervical Cancer</td>\n",
       "      <td>The purpose was to establish a quick (7-day) ...</td>\n",
       "      <td>Study of Weekly Paclitaxel and Cisplatin in FI...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>February 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389599</th>\n",
       "      <td>NCT02430974</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>Epidermal growth factor receptor (EGFR) mutat...</td>\n",
       "      <td>Chemotherapy of NSCLC With or Without Icotinib</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2011</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389601</th>\n",
       "      <td>NCT02430909</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Rheumatoid Arthritis</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Multiple Dose Study of UCB4940 as add-on to Ce...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>79020 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             Nct_id    Phase                                  Condition  \\\n",
       "3       NCT00461123  Phase 2              Prostatic Hypertrophy, Benign   \n",
       "5       NCT00462202  Phase 3                       Diabetic Nephropathy   \n",
       "6       NCT00462735  Phase 2                  Cancer of the Oral Cavity   \n",
       "7       NCT00468286  Phase 2                            Prostate Cancer   \n",
       "13      NCT00466856  Phase 2                           Pheochromocytoma   \n",
       "21      NCT00462709  Phase 3                      Hereditary Angioedema   \n",
       "25      NCT00461058  Phase 2                   Diabetes Mellitus Type 2   \n",
       "29      NCT00463437  Phase 3          Streptococcus Pneumoniae Vaccines   \n",
       "30      NCT00464763  Phase 3                                   Delirium   \n",
       "31      NCT00460746  Phase 3                                        HIV   \n",
       "33      NCT00467493  Phase 2                     Menstruation Disorders   \n",
       "34      NCT00465205  Phase 3              Sexually Transmitted Diseases   \n",
       "37      NCT00467077  Phase 2                              Kidney Cancer   \n",
       "43      NCT00464425  Phase 3                        Postoperative Ileus   \n",
       "44      NCT00466089  Phase 2             Carcinoma, Non-Small-Cell Lung   \n",
       "47      NCT00463346  Phase 3                              Schizophrenia   \n",
       "53      NCT00462540  Phase 3      Chronic Obstructive Pulmonary Disease   \n",
       "54      NCT00466440  Phase 2                            Prostate Cancer   \n",
       "63      NCT00460317  Phase 3                 Non-Small Cell Lung Cancer   \n",
       "66      NCT00464347  Phase 2           Age-Related Macular Degeneration   \n",
       "69      NCT00469885  Phase 2                       Tobacco Use Disorder   \n",
       "71      NCT00462384  Phase 3                                     Anemia   \n",
       "74      NCT00461773  Phase 2                              Breast Cancer   \n",
       "75      NCT00462267  Phase 2                                 Overweight   \n",
       "79      NCT00468611  Phase 3  Multiple Sclerosis, Secondary Progressive   \n",
       "80      NCT00467519  Phase 3                                  Pertussis   \n",
       "83      NCT00467844  Phase 2                                   Cachexia   \n",
       "94      NCT00464165  Phase 3                          Smoking Cessation   \n",
       "95      NCT00468247  Phase 2                             Intensive Care   \n",
       "96      NCT00469326  Phase 3                    Coronary Artery Disease   \n",
       "...             ...      ...                                        ...   \n",
       "389454  NCT02435108  Phase 2              c-MET Positive Gastric Cancer   \n",
       "389455  NCT02433522  Phase 3               ANCA-associated Vasculitides   \n",
       "389460  NCT02435121  Phase 2                         Neoplasm Malignant   \n",
       "389466  NCT02432534  Phase 2                                   Vitiligo   \n",
       "389472  NCT02435914  Phase 2                          Dry Eye Syndromes   \n",
       "389490  NCT02439034  Phase 2        Upper Aerodigestive Tract Neoplasms   \n",
       "389493  NCT02437812  Phase 2               Epithelial Ovarian Carcinoma   \n",
       "389502  NCT02433236  Phase 2                            IGA Nephropathy   \n",
       "389513  NCT02431611  Phase 2                                  Pregnancy   \n",
       "389515  NCT02438852  Phase 3                        Post-operative Pain   \n",
       "389516  NCT02432846  Phase 2           Renal Cell Carcinoma, Metastatic   \n",
       "389520  NCT02431052  Phase 2                              Acne Vulgaris   \n",
       "389522  NCT02432209  Phase 3                        Infertility, Female   \n",
       "389541  NCT02436512  Phase 3            Pulmonary Arterial Hypertension   \n",
       "389546  NCT02433340  Phase 2                       Rheumatoid Arthritis   \n",
       "389550  NCT02430077  Phase 2             Familial Partial Lipodystrophy   \n",
       "389551  NCT02439320  Phase 3                             Acute Migraine   \n",
       "389553  NCT02433249  Phase 2                        Sedentary Lifestyle   \n",
       "389557  NCT02432690  Phase 2                             Ovarian Cancer   \n",
       "389559  NCT02432105  Phase 3                     Otitis Media Recurrent   \n",
       "389573  NCT02437890  Phase 2              Lupus Erythematosus, Systemic   \n",
       "389575  NCT02438787  Phase 3                    Axial Spondyloarthritis   \n",
       "389579  NCT02430298  Phase 2                       Head and Neck Cancer   \n",
       "389585  NCT02433639  Phase 2                       Biliary Tract Cancer   \n",
       "389588  NCT02434029  Phase 3                   Eosinophilic Esophagitis   \n",
       "389589  NCT02435862  Phase 2     Non-Proliferative Diabetic Retinopathy   \n",
       "389590  NCT02431468  Phase 2                        Alzheimer's Disease   \n",
       "389591  NCT02432365  Phase 2                            Cervical Cancer   \n",
       "389599  NCT02430974  Phase 2             Carcinoma, Non-Small-Cell Lung   \n",
       "389601  NCT02430909  Phase 2                       Rheumatoid Arthritis   \n",
       "\n",
       "                                                  Summary  \\\n",
       "3        The greenlight laser has an absorption maximu...   \n",
       "5        The purpose of this study is to assess the to...   \n",
       "6        For advanced head and neck cancer, combined r...   \n",
       "7        The study will have two treatment groups, eva...   \n",
       "13       RATIONALE: Specialized radiation therapy that...   \n",
       "21       The study objective was to evaluate the safet...   \n",
       "25       This 2 arm study will compare the safety, tol...   \n",
       "29       The purpose of this study is to assess the sa...   \n",
       "30       The purpose of this study is to evaluate the ...   \n",
       "31       The purpose of this study is to examine the s...   \n",
       "33       Aromatase inhibitors have been approved for u...   \n",
       "34       Over 80% of HIV-1 infected persons are also s...   \n",
       "37       RATIONALE: Gefitinib may stop the growth of k...   \n",
       "43       Postoperative ileus remains a significant med...   \n",
       "44       A phase II, multicenter, randomized trial of ...   \n",
       "47       The aim of this study is to evaluate the safe...   \n",
       "53       The purpose of this study is to compare the e...   \n",
       "54       The purpose of the study is to compare the re...   \n",
       "63       To determine if treatment with AMG 706 (motes...   \n",
       "66       VERTACL will investigate whether a triple the...   \n",
       "69       This study evaluates the effect of smoking re...   \n",
       "71       This single arm study will assess the efficac...   \n",
       "74       The purpose of this study is to evaluate the ...   \n",
       "75       This project will examine the effectiveness o...   \n",
       "79       This study will assess the efficacy and safet...   \n",
       "80       Currently, there is no 5-component acellular ...   \n",
       "83       The purpose of this study is to assess if Gtx...   \n",
       "94       The primary objective is to assess the effica...   \n",
       "95       A multicentre, open, RCT to assess the safety...   \n",
       "96       This study investigates potential protective ...   \n",
       "...                                                   ...   \n",
       "389454   This is a pilot study of crizotinib in patien...   \n",
       "389455   MAINRITSAN study compared Rituximab and azath...   \n",
       "389460   Primary Objective:\\r\\r To determine objective...   \n",
       "389466   Condition:\\r\\r Non segmental and active vitil...   \n",
       "389472   This study will evaluate the safety, efficacy...   \n",
       "389490   The results of the study will permit to set u...   \n",
       "389493   Initially, the prospect of metformin as a neo...   \n",
       "389502   Phase 2, multi-center, open label extension s...   \n",
       "389513                   Phase 3 Pilot Clinical Trial.\\r    \n",
       "389515   This randomized phase IV trial studies how we...   \n",
       "389516   The purpose of this study is to compare tumor...   \n",
       "389520   The objectives of this study are to assess th...   \n",
       "389522   A two-arm, multicenter, prospective, randomiz...   \n",
       "389541   The EAGLE study is a Phase 3, open-label, mul...   \n",
       "389546   This is a Phase 2, multicenter, 24-week OLE s...   \n",
       "389550   Lipodystrophies are rare disorders characteri...   \n",
       "389551   This is a prospective randomized, double-blin...   \n",
       "389553   The purpose of this pilot study is to develop...   \n",
       "389557   This is an open label, single-arm, phase II s...   \n",
       "389559   The purpose of this study is to evaluate EXE8...   \n",
       "389573   Primary objective:\\r\\r To assess the efficacy...   \n",
       "389575   The purpose of this study is to assess the ef...   \n",
       "389579   The study evaluates the effect of melatonin f...   \n",
       "389585   Biliary tract cancer is relatively rare cance...   \n",
       "389588   The purpose of this study is to prove the sup...   \n",
       "389589   A Phase 2, Randomized, Double-masked, Placebo...   \n",
       "389590   This is a randomized double-blind placebo-con...   \n",
       "389591   The purpose was to establish a quick (7-day) ...   \n",
       "389599   Epidermal growth factor receptor (EGFR) mutat...   \n",
       "389601   The purpose of this study is to evaluate the ...   \n",
       "\n",
       "                                                    Title  \\\n",
       "3       Vardenafil in Greenlight(TM) Laser Surgery of ...   \n",
       "5       Open Label Tolerability and Safety Study of KR...   \n",
       "6       Fluorouracil, Hydroxyurea, Cetuximab and Twice...   \n",
       "7       Investigating Efficacy and Safety of Two Degar...   \n",
       "13      Internal Radiation Therapy in Treating Patient...   \n",
       "21      Open-Label C1 Esterase Inhibitor (C1INH-nf) fo...   \n",
       "25      A Comparative Study of Aleglitazar and Actos i...   \n",
       "29      Pneumococcal Vaccine Booster Study in Healthy ...   \n",
       "30      A Research Study to Evaluate the Effectiveness...   \n",
       "31      Enfuvirtide/Current Protease Inhibitor Switch ...   \n",
       "33      Partial Double-Blind, Placebo-Controlled Study...   \n",
       "34      HSV-2 Suppression to Reduce HIV-1 Levels in HI...   \n",
       "37      Gefitinib and PEG-Interferon Alfa-2b in Treati...   \n",
       "43      Electroacupuncture for Postoperative Ileus Aft...   \n",
       "44      Study of 3D Radiotherapy With or Without Erlot...   \n",
       "47      Treatment With Acamprosate in Patients With Sc...   \n",
       "53      A Crossover Study in the Treatment of Patients...   \n",
       "54      A Phase 2 Study With Enzastaurin Plus Chemothe...   \n",
       "63      MONET1-MOtesanib NSCLC Efficacy and Tolerabili...   \n",
       "66      TAC-PF, Avastin® in Combination With Photodyna...   \n",
       "69       Reduction of Smoking in Cardiac Disease Patients   \n",
       "71      A Study of Subcutaneous Mircera for the Treatm...   \n",
       "74      Randomized Phase II Study of Preoperative Letr...   \n",
       "75      Examining the Feasibility of Collaborative Car...   \n",
       "79      Efficacy and Safety of MBP8298 in Subjects Wit...   \n",
       "80      Safety and Immunogenicity of Tdap Vaccine Comp...   \n",
       "83      Study of GTx-024 on Muscle Wasting (Cachexia) ...   \n",
       "94      Comparison of Efficacy and Safety of Rimonaban...   \n",
       "95      Registration Enabling Study of the Safety and ...   \n",
       "96      Atorvastatin Pre-Treatment Influences the Risk...   \n",
       "...                                                   ...   \n",
       "389454  A Pilot Study of Crizotinib in Patients With c...   \n",
       "389455  Comparison Between a Long Term and a Conventio...   \n",
       "389460  A Study Assessing Efficacy and Safety of SAR12...   \n",
       "389466                    Atorvastatin in Active Vitiligo   \n",
       "389472  Safety, Efficacy, Tolerability and Pharmacokin...   \n",
       "389490  Paracetamol With or Without Ketoprofen in the ...   \n",
       "389493  Study of Paclitaxel, Carboplatin and Oral Metf...   \n",
       "389502  Open Label Study of Fostamatinib in the Treatm...   \n",
       "389513  Biomarker Feedback to Motivate Cessation in Pr...   \n",
       "389515  Continuous Infusion of Ropivacaine Hydrochlori...   \n",
       "389516  Intratumoral Vaccination With Intuvax Pre-neph...   \n",
       "389520  A Dose-ranging Study of DRM01 in Subjects With...   \n",
       "389522  Improving Reproductive Fitness Through Pretrea...   \n",
       "389541  Study to Assess Acute Vasodilation Response of...   \n",
       "389546  Phase 2, Multicenter, Open-Label Extension Stu...   \n",
       "389550  Phase 2 Study of Obeticholic Acid for Lipodyst...   \n",
       "389551  Lasmiditan Compared to Placebo in the Acute Tr...   \n",
       "389553  Developing a Intervention to Enhance Motivatio...   \n",
       "389557  A Study of BBI503 in Asymptomatic Recurrent Ov...   \n",
       "389559  Safety and Efficacy of EXE844 Otic Suspension ...   \n",
       "389573  A Phase II Study to Evaluate Safety and Effica...   \n",
       "389575  A Study to Evaluate the Efficacy and Safety of...   \n",
       "389579  Topical/Oral Melatonin for Preventing Concurre...   \n",
       "389585  Study of TH-302 Monotherapy as Second-line Tre...   \n",
       "389588  Budesonide Orodispersible Tablet vs. Placebo i...   \n",
       "389589  A Clinical Trial Designed to Evaluate the Safe...   \n",
       "389590  A Study Assessing Bryostatin in the Treatment ...   \n",
       "389591  Study of Weekly Paclitaxel and Cisplatin in FI...   \n",
       "389599     Chemotherapy of NSCLC With or Without Icotinib   \n",
       "389601  Multiple Dose Study of UCB4940 as add-on to Ce...   \n",
       "\n",
       "                          Model               Date  \\\n",
       "3           Parallel Assignment         March 2007   \n",
       "5       Single Group Assignment         April 2007   \n",
       "6       Single Group Assignment      February 2007   \n",
       "7           Parallel Assignment           May 2007   \n",
       "13      Single Group Assignment      December 2003   \n",
       "21      Single Group Assignment      June 27, 2006   \n",
       "25          Parallel Assignment           May 2007   \n",
       "29          Parallel Assignment     April 25, 2007   \n",
       "30          Parallel Assignment         April 2007   \n",
       "31      Single Group Assignment           May 2007   \n",
       "33          Parallel Assignment         March 2007   \n",
       "34         Crossover Assignment       January 2005   \n",
       "37      Single Group Assignment     September 2004   \n",
       "43          Parallel Assignment       October 2008   \n",
       "44          Parallel Assignment         March 2006   \n",
       "47          Parallel Assignment     September 2006   \n",
       "53         Crossover Assignment           May 2007   \n",
       "54          Parallel Assignment          June 2007   \n",
       "63          Parallel Assignment          July 2007   \n",
       "66          Parallel Assignment       January 2007   \n",
       "69          Parallel Assignment       January 2001   \n",
       "71      Single Group Assignment      February 2008   \n",
       "74          Parallel Assignment         March 2007   \n",
       "75          Parallel Assignment       January 2005   \n",
       "79          Parallel Assignment          June 2007   \n",
       "80          Parallel Assignment         April 2007   \n",
       "83          Parallel Assignment           May 2007   \n",
       "94          Parallel Assignment      November 2002   \n",
       "95          Parallel Assignment         March 2007   \n",
       "96          Parallel Assignment         April 2005   \n",
       "...                         ...                ...   \n",
       "389454  Single Group Assignment       May 15, 2014   \n",
       "389455      Parallel Assignment     March 31, 2015   \n",
       "389460  Single Group Assignment      November 2015   \n",
       "389466      Parallel Assignment           May 2015   \n",
       "389472      Parallel Assignment          June 2015   \n",
       "389490      Parallel Assignment      February 2015   \n",
       "389493  Single Group Assignment       January 2014   \n",
       "389502  Single Group Assignment     September 2015   \n",
       "389513      Parallel Assignment         March 2015   \n",
       "389515      Parallel Assignment  February 25, 2019   \n",
       "389516      Parallel Assignment         April 2015   \n",
       "389520      Parallel Assignment         April 2015   \n",
       "389522      Parallel Assignment        August 2015   \n",
       "389541  Single Group Assignment          June 2015   \n",
       "389546  Single Group Assignment         April 2015   \n",
       "389550     Crossover Assignment          June 2016   \n",
       "389551      Parallel Assignment         April 2015   \n",
       "389553      Parallel Assignment         April 2014   \n",
       "389557  Single Group Assignment          June 2015   \n",
       "389559      Parallel Assignment      June 25, 2015   \n",
       "389573      Parallel Assignment          July 2015   \n",
       "389575      Parallel Assignment      July 31, 2015   \n",
       "389579      Parallel Assignment          July 2013   \n",
       "389585  Single Group Assignment         April 2015   \n",
       "389588      Parallel Assignment  November 11, 2015   \n",
       "389589      Parallel Assignment   February 1, 2015   \n",
       "389590      Parallel Assignment      November 2015   \n",
       "389591  Single Group Assignment      February 2015   \n",
       "389599      Parallel Assignment       January 2011   \n",
       "389601      Parallel Assignment         April 2015   \n",
       "\n",
       "                                                   reason  \n",
       "3       NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "5                                NOT COMPLETED BECAUSE OF  \n",
       "6                                NOT COMPLETED BECAUSE OF  \n",
       "7       NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  \n",
       "13                               NOT COMPLETED BECAUSE OF  \n",
       "21      NOT COMPLETED BECAUSE OF, Transitioned to comm...  \n",
       "25                               NOT COMPLETED BECAUSE OF  \n",
       "29                               NOT COMPLETED BECAUSE OF  \n",
       "30                               NOT COMPLETED BECAUSE OF  \n",
       "31      NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "33                               NOT COMPLETED BECAUSE OF  \n",
       "34                               NOT COMPLETED BECAUSE OF  \n",
       "37                               NOT COMPLETED BECAUSE OF  \n",
       "43                               NOT COMPLETED BECAUSE OF  \n",
       "44                               NOT COMPLETED BECAUSE OF  \n",
       "47        NOT COMPLETED BECAUSE OF, Withdrawal by Subject  \n",
       "53                               NOT COMPLETED BECAUSE OF  \n",
       "54      NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "63                               NOT COMPLETED BECAUSE OF  \n",
       "66                               NOT COMPLETED BECAUSE OF  \n",
       "69                               NOT COMPLETED BECAUSE OF  \n",
       "71      NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "74                               NOT COMPLETED BECAUSE OF  \n",
       "75                               NOT COMPLETED BECAUSE OF  \n",
       "79                               NOT COMPLETED BECAUSE OF  \n",
       "80      NOT COMPLETED BECAUSE OF, Protocol Violation, ...  \n",
       "83                               NOT COMPLETED BECAUSE OF  \n",
       "94                               NOT COMPLETED BECAUSE OF  \n",
       "95                               NOT COMPLETED BECAUSE OF  \n",
       "96                               NOT COMPLETED BECAUSE OF  \n",
       "...                                                   ...  \n",
       "389454                           NOT COMPLETED BECAUSE OF  \n",
       "389455                           NOT COMPLETED BECAUSE OF  \n",
       "389460                           NOT COMPLETED BECAUSE OF  \n",
       "389466                           NOT COMPLETED BECAUSE OF  \n",
       "389472  NOT COMPLETED BECAUSE OF, Ocular Adverse Event...  \n",
       "389490                           NOT COMPLETED BECAUSE OF  \n",
       "389493                           NOT COMPLETED BECAUSE OF  \n",
       "389502                           NOT COMPLETED BECAUSE OF  \n",
       "389513                           NOT COMPLETED BECAUSE OF  \n",
       "389515                           NOT COMPLETED BECAUSE OF  \n",
       "389516                           NOT COMPLETED BECAUSE OF  \n",
       "389520                           NOT COMPLETED BECAUSE OF  \n",
       "389522                           NOT COMPLETED BECAUSE OF  \n",
       "389541                           NOT COMPLETED BECAUSE OF  \n",
       "389546  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "389550                           NOT COMPLETED BECAUSE OF  \n",
       "389551  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "389553                           NOT COMPLETED BECAUSE OF  \n",
       "389557                           NOT COMPLETED BECAUSE OF  \n",
       "389559  NOT COMPLETED BECAUSE OF, Lost to Follow-up, W...  \n",
       "389573  NOT COMPLETED BECAUSE OF, Non-compliance to st...  \n",
       "389575  NOT COMPLETED BECAUSE OF, Adverse Event, Lack ...  \n",
       "389579                           NOT COMPLETED BECAUSE OF  \n",
       "389585                           NOT COMPLETED BECAUSE OF  \n",
       "389588                           NOT COMPLETED BECAUSE OF  \n",
       "389589                           NOT COMPLETED BECAUSE OF  \n",
       "389590  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "389591                           NOT COMPLETED BECAUSE OF  \n",
       "389599                           NOT COMPLETED BECAUSE OF  \n",
       "389601                           NOT COMPLETED BECAUSE OF  \n",
       "\n",
       "[79020 rows x 8 columns]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_clinical_trials_na_removed=all_clinical_trials.dropna()\n",
    "all_clinical_trials_na_removed.columns =  ['Nct_id', 'Phase' , 'Condition' , 'Summary', 'Title', \"Model\" , 'Date' , 'reason']\n",
    "all_clinical_trials_na_removed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Nct_id</th>\n",
       "      <th>Phase</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Title</th>\n",
       "      <th>Model</th>\n",
       "      <th>Date</th>\n",
       "      <th>reason</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00461123</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prostatic Hypertrophy, Benign</td>\n",
       "      <td>The greenlight laser has an absorption maximu...</td>\n",
       "      <td>Vardenafil in Greenlight(TM) Laser Surgery of ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT00462202</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetic Nephropathy</td>\n",
       "      <td>The purpose of this study is to assess the to...</td>\n",
       "      <td>Open Label Tolerability and Safety Study of KR...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>April 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00462735</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cancer of the Oral Cavity</td>\n",
       "      <td>For advanced head and neck cancer, combined r...</td>\n",
       "      <td>Fluorouracil, Hydroxyurea, Cetuximab and Twice...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>February 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00468286</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prostate Cancer</td>\n",
       "      <td>The study will have two treatment groups, eva...</td>\n",
       "      <td>Investigating Efficacy and Safety of Two Degar...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT00466856</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Pheochromocytoma</td>\n",
       "      <td>RATIONALE: Specialized radiation therapy that...</td>\n",
       "      <td>Internal Radiation Therapy in Treating Patient...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>December 2003</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NCT00462709</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hereditary Angioedema</td>\n",
       "      <td>The study objective was to evaluate the safet...</td>\n",
       "      <td>Open-Label C1 Esterase Inhibitor (C1INH-nf) fo...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 27, 2006</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Transitioned to comm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>NCT00461058</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Diabetes Mellitus Type 2</td>\n",
       "      <td>This 2 arm study will compare the safety, tol...</td>\n",
       "      <td>A Comparative Study of Aleglitazar and Actos i...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NCT00463437</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Streptococcus Pneumoniae Vaccines</td>\n",
       "      <td>The purpose of this study is to assess the sa...</td>\n",
       "      <td>Pneumococcal Vaccine Booster Study in Healthy ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 25, 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>NCT00464763</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Delirium</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>A Research Study to Evaluate the Effectiveness...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>NCT00460746</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>HIV</td>\n",
       "      <td>The purpose of this study is to examine the s...</td>\n",
       "      <td>Enfuvirtide/Current Protease Inhibitor Switch ...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>NCT00467493</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Menstruation Disorders</td>\n",
       "      <td>Aromatase inhibitors have been approved for u...</td>\n",
       "      <td>Partial Double-Blind, Placebo-Controlled Study...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>NCT00465205</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Sexually Transmitted Diseases</td>\n",
       "      <td>Over 80% of HIV-1 infected persons are also s...</td>\n",
       "      <td>HSV-2 Suppression to Reduce HIV-1 Levels in HI...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>January 2005</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>NCT00467077</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Kidney Cancer</td>\n",
       "      <td>RATIONALE: Gefitinib may stop the growth of k...</td>\n",
       "      <td>Gefitinib and PEG-Interferon Alfa-2b in Treati...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>September 2004</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>NCT00464425</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Postoperative Ileus</td>\n",
       "      <td>Postoperative ileus remains a significant med...</td>\n",
       "      <td>Electroacupuncture for Postoperative Ileus Aft...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 2008</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>NCT00466089</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>A phase II, multicenter, randomized trial of ...</td>\n",
       "      <td>Study of 3D Radiotherapy With or Without Erlot...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2006</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>NCT00463346</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>The aim of this study is to evaluate the safe...</td>\n",
       "      <td>Treatment With Acamprosate in Patients With Sc...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>September 2006</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subject</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>NCT00462540</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Chronic Obstructive Pulmonary Disease</td>\n",
       "      <td>The purpose of this study is to compare the e...</td>\n",
       "      <td>A Crossover Study in the Treatment of Patients...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>NCT00466440</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prostate Cancer</td>\n",
       "      <td>The purpose of the study is to compare the re...</td>\n",
       "      <td>A Phase 2 Study With Enzastaurin Plus Chemothe...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>NCT00460317</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>To determine if treatment with AMG 706 (motes...</td>\n",
       "      <td>MONET1-MOtesanib NSCLC Efficacy and Tolerabili...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>NCT00464347</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Age-Related Macular Degeneration</td>\n",
       "      <td>VERTACL will investigate whether a triple the...</td>\n",
       "      <td>TAC-PF, Avastin® in Combination With Photodyna...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>NCT00469885</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Tobacco Use Disorder</td>\n",
       "      <td>This study evaluates the effect of smoking re...</td>\n",
       "      <td>Reduction of Smoking in Cardiac Disease Patients</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2001</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>NCT00462384</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Anemia</td>\n",
       "      <td>This single arm study will assess the efficac...</td>\n",
       "      <td>A Study of Subcutaneous Mircera for the Treatm...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>February 2008</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>NCT00461773</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Randomized Phase II Study of Preoperative Letr...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>NCT00462267</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Overweight</td>\n",
       "      <td>This project will examine the effectiveness o...</td>\n",
       "      <td>Examining the Feasibility of Collaborative Car...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2005</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>NCT00468611</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Multiple Sclerosis, Secondary Progressive</td>\n",
       "      <td>This study will assess the efficacy and safet...</td>\n",
       "      <td>Efficacy and Safety of MBP8298 in Subjects Wit...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>NCT00467519</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Pertussis</td>\n",
       "      <td>Currently, there is no 5-component acellular ...</td>\n",
       "      <td>Safety and Immunogenicity of Tdap Vaccine Comp...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Protocol Violation, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>NCT00467844</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cachexia</td>\n",
       "      <td>The purpose of this study is to assess if Gtx...</td>\n",
       "      <td>Study of GTx-024 on Muscle Wasting (Cachexia) ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>NCT00464165</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Smoking Cessation</td>\n",
       "      <td>The primary objective is to assess the effica...</td>\n",
       "      <td>Comparison of Efficacy and Safety of Rimonaban...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>November 2002</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>NCT00468247</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Intensive Care</td>\n",
       "      <td>A multicentre, open, RCT to assess the safety...</td>\n",
       "      <td>Registration Enabling Study of the Safety and ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2007</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>NCT00469326</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Coronary Artery Disease</td>\n",
       "      <td>This study investigates potential protective ...</td>\n",
       "      <td>Atorvastatin Pre-Treatment Influences the Risk...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2005</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389454</th>\n",
       "      <td>NCT02435108</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>c-MET Positive Gastric Cancer</td>\n",
       "      <td>This is a pilot study of crizotinib in patien...</td>\n",
       "      <td>A Pilot Study of Crizotinib in Patients With c...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>May 15, 2014</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389455</th>\n",
       "      <td>NCT02433522</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>ANCA-associated Vasculitides</td>\n",
       "      <td>MAINRITSAN study compared Rituximab and azath...</td>\n",
       "      <td>Comparison Between a Long Term and a Conventio...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 31, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389460</th>\n",
       "      <td>NCT02435121</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Neoplasm Malignant</td>\n",
       "      <td>Primary Objective:\\r\\r To determine objective...</td>\n",
       "      <td>A Study Assessing Efficacy and Safety of SAR12...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>November 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389466</th>\n",
       "      <td>NCT02432534</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Vitiligo</td>\n",
       "      <td>Condition:\\r\\r Non segmental and active vitil...</td>\n",
       "      <td>Atorvastatin in Active Vitiligo</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389472</th>\n",
       "      <td>NCT02435914</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Dry Eye Syndromes</td>\n",
       "      <td>This study will evaluate the safety, efficacy...</td>\n",
       "      <td>Safety, Efficacy, Tolerability and Pharmacokin...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Ocular Adverse Event...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389490</th>\n",
       "      <td>NCT02439034</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Upper Aerodigestive Tract Neoplasms</td>\n",
       "      <td>The results of the study will permit to set u...</td>\n",
       "      <td>Paracetamol With or Without Ketoprofen in the ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389493</th>\n",
       "      <td>NCT02437812</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Epithelial Ovarian Carcinoma</td>\n",
       "      <td>Initially, the prospect of metformin as a neo...</td>\n",
       "      <td>Study of Paclitaxel, Carboplatin and Oral Metf...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>January 2014</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389502</th>\n",
       "      <td>NCT02433236</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>IGA Nephropathy</td>\n",
       "      <td>Phase 2, multi-center, open label extension s...</td>\n",
       "      <td>Open Label Study of Fostamatinib in the Treatm...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>September 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389513</th>\n",
       "      <td>NCT02431611</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Pregnancy</td>\n",
       "      <td>Phase 3 Pilot Clinical Trial.\\r</td>\n",
       "      <td>Biomarker Feedback to Motivate Cessation in Pr...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389515</th>\n",
       "      <td>NCT02438852</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Post-operative Pain</td>\n",
       "      <td>This randomized phase IV trial studies how we...</td>\n",
       "      <td>Continuous Infusion of Ropivacaine Hydrochlori...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 25, 2019</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389516</th>\n",
       "      <td>NCT02432846</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Renal Cell Carcinoma, Metastatic</td>\n",
       "      <td>The purpose of this study is to compare tumor...</td>\n",
       "      <td>Intratumoral Vaccination With Intuvax Pre-neph...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389520</th>\n",
       "      <td>NCT02431052</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Acne Vulgaris</td>\n",
       "      <td>The objectives of this study are to assess th...</td>\n",
       "      <td>A Dose-ranging Study of DRM01 in Subjects With...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389522</th>\n",
       "      <td>NCT02432209</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Infertility, Female</td>\n",
       "      <td>A two-arm, multicenter, prospective, randomiz...</td>\n",
       "      <td>Improving Reproductive Fitness Through Pretrea...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>August 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389541</th>\n",
       "      <td>NCT02436512</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Pulmonary Arterial Hypertension</td>\n",
       "      <td>The EAGLE study is a Phase 3, open-label, mul...</td>\n",
       "      <td>Study to Assess Acute Vasodilation Response of...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389546</th>\n",
       "      <td>NCT02433340</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Rheumatoid Arthritis</td>\n",
       "      <td>This is a Phase 2, multicenter, 24-week OLE s...</td>\n",
       "      <td>Phase 2, Multicenter, Open-Label Extension Stu...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389550</th>\n",
       "      <td>NCT02430077</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Familial Partial Lipodystrophy</td>\n",
       "      <td>Lipodystrophies are rare disorders characteri...</td>\n",
       "      <td>Phase 2 Study of Obeticholic Acid for Lipodyst...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>June 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389551</th>\n",
       "      <td>NCT02439320</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Acute Migraine</td>\n",
       "      <td>This is a prospective randomized, double-blin...</td>\n",
       "      <td>Lasmiditan Compared to Placebo in the Acute Tr...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389553</th>\n",
       "      <td>NCT02433249</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Sedentary Lifestyle</td>\n",
       "      <td>The purpose of this pilot study is to develop...</td>\n",
       "      <td>Developing a Intervention to Enhance Motivatio...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2014</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389557</th>\n",
       "      <td>NCT02432690</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>This is an open label, single-arm, phase II s...</td>\n",
       "      <td>A Study of BBI503 in Asymptomatic Recurrent Ov...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389559</th>\n",
       "      <td>NCT02432105</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Otitis Media Recurrent</td>\n",
       "      <td>The purpose of this study is to evaluate EXE8...</td>\n",
       "      <td>Safety and Efficacy of EXE844 Otic Suspension ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 25, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up, W...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389573</th>\n",
       "      <td>NCT02437890</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Lupus Erythematosus, Systemic</td>\n",
       "      <td>Primary objective:\\r\\r To assess the efficacy...</td>\n",
       "      <td>A Phase II Study to Evaluate Safety and Effica...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Non-compliance to st...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389575</th>\n",
       "      <td>NCT02438787</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Axial Spondyloarthritis</td>\n",
       "      <td>The purpose of this study is to assess the ef...</td>\n",
       "      <td>A Study to Evaluate the Efficacy and Safety of...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 31, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lack ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389579</th>\n",
       "      <td>NCT02430298</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Head and Neck Cancer</td>\n",
       "      <td>The study evaluates the effect of melatonin f...</td>\n",
       "      <td>Topical/Oral Melatonin for Preventing Concurre...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 2013</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389585</th>\n",
       "      <td>NCT02433639</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Biliary Tract Cancer</td>\n",
       "      <td>Biliary tract cancer is relatively rare cance...</td>\n",
       "      <td>Study of TH-302 Monotherapy as Second-line Tre...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389588</th>\n",
       "      <td>NCT02434029</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Eosinophilic Esophagitis</td>\n",
       "      <td>The purpose of this study is to prove the sup...</td>\n",
       "      <td>Budesonide Orodispersible Tablet vs. Placebo i...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>November 11, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389589</th>\n",
       "      <td>NCT02435862</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Non-Proliferative Diabetic Retinopathy</td>\n",
       "      <td>A Phase 2, Randomized, Double-masked, Placebo...</td>\n",
       "      <td>A Clinical Trial Designed to Evaluate the Safe...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 1, 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389590</th>\n",
       "      <td>NCT02431468</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alzheimer's Disease</td>\n",
       "      <td>This is a randomized double-blind placebo-con...</td>\n",
       "      <td>A Study Assessing Bryostatin in the Treatment ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>November 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389591</th>\n",
       "      <td>NCT02432365</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cervical Cancer</td>\n",
       "      <td>The purpose was to establish a quick (7-day) ...</td>\n",
       "      <td>Study of Weekly Paclitaxel and Cisplatin in FI...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>February 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389599</th>\n",
       "      <td>NCT02430974</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>Epidermal growth factor receptor (EGFR) mutat...</td>\n",
       "      <td>Chemotherapy of NSCLC With or Without Icotinib</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2011</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>389601</th>\n",
       "      <td>NCT02430909</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Rheumatoid Arthritis</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Multiple Dose Study of UCB4940 as add-on to Ce...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2015</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>79020 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             Nct_id    Phase                                  Condition  \\\n",
       "3       NCT00461123  Phase 2              Prostatic Hypertrophy, Benign   \n",
       "5       NCT00462202  Phase 3                       Diabetic Nephropathy   \n",
       "6       NCT00462735  Phase 2                  Cancer of the Oral Cavity   \n",
       "7       NCT00468286  Phase 2                            Prostate Cancer   \n",
       "13      NCT00466856  Phase 2                           Pheochromocytoma   \n",
       "21      NCT00462709  Phase 3                      Hereditary Angioedema   \n",
       "25      NCT00461058  Phase 2                   Diabetes Mellitus Type 2   \n",
       "29      NCT00463437  Phase 3          Streptococcus Pneumoniae Vaccines   \n",
       "30      NCT00464763  Phase 3                                   Delirium   \n",
       "31      NCT00460746  Phase 3                                        HIV   \n",
       "33      NCT00467493  Phase 2                     Menstruation Disorders   \n",
       "34      NCT00465205  Phase 3              Sexually Transmitted Diseases   \n",
       "37      NCT00467077  Phase 2                              Kidney Cancer   \n",
       "43      NCT00464425  Phase 3                        Postoperative Ileus   \n",
       "44      NCT00466089  Phase 2             Carcinoma, Non-Small-Cell Lung   \n",
       "47      NCT00463346  Phase 3                              Schizophrenia   \n",
       "53      NCT00462540  Phase 3      Chronic Obstructive Pulmonary Disease   \n",
       "54      NCT00466440  Phase 2                            Prostate Cancer   \n",
       "63      NCT00460317  Phase 3                 Non-Small Cell Lung Cancer   \n",
       "66      NCT00464347  Phase 2           Age-Related Macular Degeneration   \n",
       "69      NCT00469885  Phase 2                       Tobacco Use Disorder   \n",
       "71      NCT00462384  Phase 3                                     Anemia   \n",
       "74      NCT00461773  Phase 2                              Breast Cancer   \n",
       "75      NCT00462267  Phase 2                                 Overweight   \n",
       "79      NCT00468611  Phase 3  Multiple Sclerosis, Secondary Progressive   \n",
       "80      NCT00467519  Phase 3                                  Pertussis   \n",
       "83      NCT00467844  Phase 2                                   Cachexia   \n",
       "94      NCT00464165  Phase 3                          Smoking Cessation   \n",
       "95      NCT00468247  Phase 2                             Intensive Care   \n",
       "96      NCT00469326  Phase 3                    Coronary Artery Disease   \n",
       "...             ...      ...                                        ...   \n",
       "389454  NCT02435108  Phase 2              c-MET Positive Gastric Cancer   \n",
       "389455  NCT02433522  Phase 3               ANCA-associated Vasculitides   \n",
       "389460  NCT02435121  Phase 2                         Neoplasm Malignant   \n",
       "389466  NCT02432534  Phase 2                                   Vitiligo   \n",
       "389472  NCT02435914  Phase 2                          Dry Eye Syndromes   \n",
       "389490  NCT02439034  Phase 2        Upper Aerodigestive Tract Neoplasms   \n",
       "389493  NCT02437812  Phase 2               Epithelial Ovarian Carcinoma   \n",
       "389502  NCT02433236  Phase 2                            IGA Nephropathy   \n",
       "389513  NCT02431611  Phase 2                                  Pregnancy   \n",
       "389515  NCT02438852  Phase 3                        Post-operative Pain   \n",
       "389516  NCT02432846  Phase 2           Renal Cell Carcinoma, Metastatic   \n",
       "389520  NCT02431052  Phase 2                              Acne Vulgaris   \n",
       "389522  NCT02432209  Phase 3                        Infertility, Female   \n",
       "389541  NCT02436512  Phase 3            Pulmonary Arterial Hypertension   \n",
       "389546  NCT02433340  Phase 2                       Rheumatoid Arthritis   \n",
       "389550  NCT02430077  Phase 2             Familial Partial Lipodystrophy   \n",
       "389551  NCT02439320  Phase 3                             Acute Migraine   \n",
       "389553  NCT02433249  Phase 2                        Sedentary Lifestyle   \n",
       "389557  NCT02432690  Phase 2                             Ovarian Cancer   \n",
       "389559  NCT02432105  Phase 3                     Otitis Media Recurrent   \n",
       "389573  NCT02437890  Phase 2              Lupus Erythematosus, Systemic   \n",
       "389575  NCT02438787  Phase 3                    Axial Spondyloarthritis   \n",
       "389579  NCT02430298  Phase 2                       Head and Neck Cancer   \n",
       "389585  NCT02433639  Phase 2                       Biliary Tract Cancer   \n",
       "389588  NCT02434029  Phase 3                   Eosinophilic Esophagitis   \n",
       "389589  NCT02435862  Phase 2     Non-Proliferative Diabetic Retinopathy   \n",
       "389590  NCT02431468  Phase 2                        Alzheimer's Disease   \n",
       "389591  NCT02432365  Phase 2                            Cervical Cancer   \n",
       "389599  NCT02430974  Phase 2             Carcinoma, Non-Small-Cell Lung   \n",
       "389601  NCT02430909  Phase 2                       Rheumatoid Arthritis   \n",
       "\n",
       "                                                  Summary  \\\n",
       "3        The greenlight laser has an absorption maximu...   \n",
       "5        The purpose of this study is to assess the to...   \n",
       "6        For advanced head and neck cancer, combined r...   \n",
       "7        The study will have two treatment groups, eva...   \n",
       "13       RATIONALE: Specialized radiation therapy that...   \n",
       "21       The study objective was to evaluate the safet...   \n",
       "25       This 2 arm study will compare the safety, tol...   \n",
       "29       The purpose of this study is to assess the sa...   \n",
       "30       The purpose of this study is to evaluate the ...   \n",
       "31       The purpose of this study is to examine the s...   \n",
       "33       Aromatase inhibitors have been approved for u...   \n",
       "34       Over 80% of HIV-1 infected persons are also s...   \n",
       "37       RATIONALE: Gefitinib may stop the growth of k...   \n",
       "43       Postoperative ileus remains a significant med...   \n",
       "44       A phase II, multicenter, randomized trial of ...   \n",
       "47       The aim of this study is to evaluate the safe...   \n",
       "53       The purpose of this study is to compare the e...   \n",
       "54       The purpose of the study is to compare the re...   \n",
       "63       To determine if treatment with AMG 706 (motes...   \n",
       "66       VERTACL will investigate whether a triple the...   \n",
       "69       This study evaluates the effect of smoking re...   \n",
       "71       This single arm study will assess the efficac...   \n",
       "74       The purpose of this study is to evaluate the ...   \n",
       "75       This project will examine the effectiveness o...   \n",
       "79       This study will assess the efficacy and safet...   \n",
       "80       Currently, there is no 5-component acellular ...   \n",
       "83       The purpose of this study is to assess if Gtx...   \n",
       "94       The primary objective is to assess the effica...   \n",
       "95       A multicentre, open, RCT to assess the safety...   \n",
       "96       This study investigates potential protective ...   \n",
       "...                                                   ...   \n",
       "389454   This is a pilot study of crizotinib in patien...   \n",
       "389455   MAINRITSAN study compared Rituximab and azath...   \n",
       "389460   Primary Objective:\\r\\r To determine objective...   \n",
       "389466   Condition:\\r\\r Non segmental and active vitil...   \n",
       "389472   This study will evaluate the safety, efficacy...   \n",
       "389490   The results of the study will permit to set u...   \n",
       "389493   Initially, the prospect of metformin as a neo...   \n",
       "389502   Phase 2, multi-center, open label extension s...   \n",
       "389513                   Phase 3 Pilot Clinical Trial.\\r    \n",
       "389515   This randomized phase IV trial studies how we...   \n",
       "389516   The purpose of this study is to compare tumor...   \n",
       "389520   The objectives of this study are to assess th...   \n",
       "389522   A two-arm, multicenter, prospective, randomiz...   \n",
       "389541   The EAGLE study is a Phase 3, open-label, mul...   \n",
       "389546   This is a Phase 2, multicenter, 24-week OLE s...   \n",
       "389550   Lipodystrophies are rare disorders characteri...   \n",
       "389551   This is a prospective randomized, double-blin...   \n",
       "389553   The purpose of this pilot study is to develop...   \n",
       "389557   This is an open label, single-arm, phase II s...   \n",
       "389559   The purpose of this study is to evaluate EXE8...   \n",
       "389573   Primary objective:\\r\\r To assess the efficacy...   \n",
       "389575   The purpose of this study is to assess the ef...   \n",
       "389579   The study evaluates the effect of melatonin f...   \n",
       "389585   Biliary tract cancer is relatively rare cance...   \n",
       "389588   The purpose of this study is to prove the sup...   \n",
       "389589   A Phase 2, Randomized, Double-masked, Placebo...   \n",
       "389590   This is a randomized double-blind placebo-con...   \n",
       "389591   The purpose was to establish a quick (7-day) ...   \n",
       "389599   Epidermal growth factor receptor (EGFR) mutat...   \n",
       "389601   The purpose of this study is to evaluate the ...   \n",
       "\n",
       "                                                    Title  \\\n",
       "3       Vardenafil in Greenlight(TM) Laser Surgery of ...   \n",
       "5       Open Label Tolerability and Safety Study of KR...   \n",
       "6       Fluorouracil, Hydroxyurea, Cetuximab and Twice...   \n",
       "7       Investigating Efficacy and Safety of Two Degar...   \n",
       "13      Internal Radiation Therapy in Treating Patient...   \n",
       "21      Open-Label C1 Esterase Inhibitor (C1INH-nf) fo...   \n",
       "25      A Comparative Study of Aleglitazar and Actos i...   \n",
       "29      Pneumococcal Vaccine Booster Study in Healthy ...   \n",
       "30      A Research Study to Evaluate the Effectiveness...   \n",
       "31      Enfuvirtide/Current Protease Inhibitor Switch ...   \n",
       "33      Partial Double-Blind, Placebo-Controlled Study...   \n",
       "34      HSV-2 Suppression to Reduce HIV-1 Levels in HI...   \n",
       "37      Gefitinib and PEG-Interferon Alfa-2b in Treati...   \n",
       "43      Electroacupuncture for Postoperative Ileus Aft...   \n",
       "44      Study of 3D Radiotherapy With or Without Erlot...   \n",
       "47      Treatment With Acamprosate in Patients With Sc...   \n",
       "53      A Crossover Study in the Treatment of Patients...   \n",
       "54      A Phase 2 Study With Enzastaurin Plus Chemothe...   \n",
       "63      MONET1-MOtesanib NSCLC Efficacy and Tolerabili...   \n",
       "66      TAC-PF, Avastin® in Combination With Photodyna...   \n",
       "69       Reduction of Smoking in Cardiac Disease Patients   \n",
       "71      A Study of Subcutaneous Mircera for the Treatm...   \n",
       "74      Randomized Phase II Study of Preoperative Letr...   \n",
       "75      Examining the Feasibility of Collaborative Car...   \n",
       "79      Efficacy and Safety of MBP8298 in Subjects Wit...   \n",
       "80      Safety and Immunogenicity of Tdap Vaccine Comp...   \n",
       "83      Study of GTx-024 on Muscle Wasting (Cachexia) ...   \n",
       "94      Comparison of Efficacy and Safety of Rimonaban...   \n",
       "95      Registration Enabling Study of the Safety and ...   \n",
       "96      Atorvastatin Pre-Treatment Influences the Risk...   \n",
       "...                                                   ...   \n",
       "389454  A Pilot Study of Crizotinib in Patients With c...   \n",
       "389455  Comparison Between a Long Term and a Conventio...   \n",
       "389460  A Study Assessing Efficacy and Safety of SAR12...   \n",
       "389466                    Atorvastatin in Active Vitiligo   \n",
       "389472  Safety, Efficacy, Tolerability and Pharmacokin...   \n",
       "389490  Paracetamol With or Without Ketoprofen in the ...   \n",
       "389493  Study of Paclitaxel, Carboplatin and Oral Metf...   \n",
       "389502  Open Label Study of Fostamatinib in the Treatm...   \n",
       "389513  Biomarker Feedback to Motivate Cessation in Pr...   \n",
       "389515  Continuous Infusion of Ropivacaine Hydrochlori...   \n",
       "389516  Intratumoral Vaccination With Intuvax Pre-neph...   \n",
       "389520  A Dose-ranging Study of DRM01 in Subjects With...   \n",
       "389522  Improving Reproductive Fitness Through Pretrea...   \n",
       "389541  Study to Assess Acute Vasodilation Response of...   \n",
       "389546  Phase 2, Multicenter, Open-Label Extension Stu...   \n",
       "389550  Phase 2 Study of Obeticholic Acid for Lipodyst...   \n",
       "389551  Lasmiditan Compared to Placebo in the Acute Tr...   \n",
       "389553  Developing a Intervention to Enhance Motivatio...   \n",
       "389557  A Study of BBI503 in Asymptomatic Recurrent Ov...   \n",
       "389559  Safety and Efficacy of EXE844 Otic Suspension ...   \n",
       "389573  A Phase II Study to Evaluate Safety and Effica...   \n",
       "389575  A Study to Evaluate the Efficacy and Safety of...   \n",
       "389579  Topical/Oral Melatonin for Preventing Concurre...   \n",
       "389585  Study of TH-302 Monotherapy as Second-line Tre...   \n",
       "389588  Budesonide Orodispersible Tablet vs. Placebo i...   \n",
       "389589  A Clinical Trial Designed to Evaluate the Safe...   \n",
       "389590  A Study Assessing Bryostatin in the Treatment ...   \n",
       "389591  Study of Weekly Paclitaxel and Cisplatin in FI...   \n",
       "389599     Chemotherapy of NSCLC With or Without Icotinib   \n",
       "389601  Multiple Dose Study of UCB4940 as add-on to Ce...   \n",
       "\n",
       "                          Model               Date  \\\n",
       "3           Parallel Assignment         March 2007   \n",
       "5       Single Group Assignment         April 2007   \n",
       "6       Single Group Assignment      February 2007   \n",
       "7           Parallel Assignment           May 2007   \n",
       "13      Single Group Assignment      December 2003   \n",
       "21      Single Group Assignment      June 27, 2006   \n",
       "25          Parallel Assignment           May 2007   \n",
       "29          Parallel Assignment     April 25, 2007   \n",
       "30          Parallel Assignment         April 2007   \n",
       "31      Single Group Assignment           May 2007   \n",
       "33          Parallel Assignment         March 2007   \n",
       "34         Crossover Assignment       January 2005   \n",
       "37      Single Group Assignment     September 2004   \n",
       "43          Parallel Assignment       October 2008   \n",
       "44          Parallel Assignment         March 2006   \n",
       "47          Parallel Assignment     September 2006   \n",
       "53         Crossover Assignment           May 2007   \n",
       "54          Parallel Assignment          June 2007   \n",
       "63          Parallel Assignment          July 2007   \n",
       "66          Parallel Assignment       January 2007   \n",
       "69          Parallel Assignment       January 2001   \n",
       "71      Single Group Assignment      February 2008   \n",
       "74          Parallel Assignment         March 2007   \n",
       "75          Parallel Assignment       January 2005   \n",
       "79          Parallel Assignment          June 2007   \n",
       "80          Parallel Assignment         April 2007   \n",
       "83          Parallel Assignment           May 2007   \n",
       "94          Parallel Assignment      November 2002   \n",
       "95          Parallel Assignment         March 2007   \n",
       "96          Parallel Assignment         April 2005   \n",
       "...                         ...                ...   \n",
       "389454  Single Group Assignment       May 15, 2014   \n",
       "389455      Parallel Assignment     March 31, 2015   \n",
       "389460  Single Group Assignment      November 2015   \n",
       "389466      Parallel Assignment           May 2015   \n",
       "389472      Parallel Assignment          June 2015   \n",
       "389490      Parallel Assignment      February 2015   \n",
       "389493  Single Group Assignment       January 2014   \n",
       "389502  Single Group Assignment     September 2015   \n",
       "389513      Parallel Assignment         March 2015   \n",
       "389515      Parallel Assignment  February 25, 2019   \n",
       "389516      Parallel Assignment         April 2015   \n",
       "389520      Parallel Assignment         April 2015   \n",
       "389522      Parallel Assignment        August 2015   \n",
       "389541  Single Group Assignment          June 2015   \n",
       "389546  Single Group Assignment         April 2015   \n",
       "389550     Crossover Assignment          June 2016   \n",
       "389551      Parallel Assignment         April 2015   \n",
       "389553      Parallel Assignment         April 2014   \n",
       "389557  Single Group Assignment          June 2015   \n",
       "389559      Parallel Assignment      June 25, 2015   \n",
       "389573      Parallel Assignment          July 2015   \n",
       "389575      Parallel Assignment      July 31, 2015   \n",
       "389579      Parallel Assignment          July 2013   \n",
       "389585  Single Group Assignment         April 2015   \n",
       "389588      Parallel Assignment  November 11, 2015   \n",
       "389589      Parallel Assignment   February 1, 2015   \n",
       "389590      Parallel Assignment      November 2015   \n",
       "389591  Single Group Assignment      February 2015   \n",
       "389599      Parallel Assignment       January 2011   \n",
       "389601      Parallel Assignment         April 2015   \n",
       "\n",
       "                                                   reason  \n",
       "3       NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "5                                NOT COMPLETED BECAUSE OF  \n",
       "6                                NOT COMPLETED BECAUSE OF  \n",
       "7       NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  \n",
       "13                               NOT COMPLETED BECAUSE OF  \n",
       "21      NOT COMPLETED BECAUSE OF, Transitioned to comm...  \n",
       "25                               NOT COMPLETED BECAUSE OF  \n",
       "29                               NOT COMPLETED BECAUSE OF  \n",
       "30                               NOT COMPLETED BECAUSE OF  \n",
       "31      NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "33                               NOT COMPLETED BECAUSE OF  \n",
       "34                               NOT COMPLETED BECAUSE OF  \n",
       "37                               NOT COMPLETED BECAUSE OF  \n",
       "43                               NOT COMPLETED BECAUSE OF  \n",
       "44                               NOT COMPLETED BECAUSE OF  \n",
       "47        NOT COMPLETED BECAUSE OF, Withdrawal by Subject  \n",
       "53                               NOT COMPLETED BECAUSE OF  \n",
       "54      NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "63                               NOT COMPLETED BECAUSE OF  \n",
       "66                               NOT COMPLETED BECAUSE OF  \n",
       "69                               NOT COMPLETED BECAUSE OF  \n",
       "71      NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "74                               NOT COMPLETED BECAUSE OF  \n",
       "75                               NOT COMPLETED BECAUSE OF  \n",
       "79                               NOT COMPLETED BECAUSE OF  \n",
       "80      NOT COMPLETED BECAUSE OF, Protocol Violation, ...  \n",
       "83                               NOT COMPLETED BECAUSE OF  \n",
       "94                               NOT COMPLETED BECAUSE OF  \n",
       "95                               NOT COMPLETED BECAUSE OF  \n",
       "96                               NOT COMPLETED BECAUSE OF  \n",
       "...                                                   ...  \n",
       "389454                           NOT COMPLETED BECAUSE OF  \n",
       "389455                           NOT COMPLETED BECAUSE OF  \n",
       "389460                           NOT COMPLETED BECAUSE OF  \n",
       "389466                           NOT COMPLETED BECAUSE OF  \n",
       "389472  NOT COMPLETED BECAUSE OF, Ocular Adverse Event...  \n",
       "389490                           NOT COMPLETED BECAUSE OF  \n",
       "389493                           NOT COMPLETED BECAUSE OF  \n",
       "389502                           NOT COMPLETED BECAUSE OF  \n",
       "389513                           NOT COMPLETED BECAUSE OF  \n",
       "389515                           NOT COMPLETED BECAUSE OF  \n",
       "389516                           NOT COMPLETED BECAUSE OF  \n",
       "389520                           NOT COMPLETED BECAUSE OF  \n",
       "389522                           NOT COMPLETED BECAUSE OF  \n",
       "389541                           NOT COMPLETED BECAUSE OF  \n",
       "389546  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "389550                           NOT COMPLETED BECAUSE OF  \n",
       "389551  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "389553                           NOT COMPLETED BECAUSE OF  \n",
       "389557                           NOT COMPLETED BECAUSE OF  \n",
       "389559  NOT COMPLETED BECAUSE OF, Lost to Follow-up, W...  \n",
       "389573  NOT COMPLETED BECAUSE OF, Non-compliance to st...  \n",
       "389575  NOT COMPLETED BECAUSE OF, Adverse Event, Lack ...  \n",
       "389579                           NOT COMPLETED BECAUSE OF  \n",
       "389585                           NOT COMPLETED BECAUSE OF  \n",
       "389588                           NOT COMPLETED BECAUSE OF  \n",
       "389589                           NOT COMPLETED BECAUSE OF  \n",
       "389590  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "389591                           NOT COMPLETED BECAUSE OF  \n",
       "389599                           NOT COMPLETED BECAUSE OF  \n",
       "389601                           NOT COMPLETED BECAUSE OF  \n",
       "\n",
       "[79020 rows x 8 columns]"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df=all_clinical_trials_na_removed\n",
    "df\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "16468"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = df[df.reason.str.len() > 26]\n",
    "len(df)\n",
    "#df.to_csv('filtered_clinical_trials.csv',index=False, encoding='utf-8', quoting=csv.QUOTE_NONNUMERIC)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "# to_drop = ['July']\n",
    "# df[~df['Date'].isin(to_drop)]\n",
    "# len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "# searchfor = ['2016','2017','2018','2019','2020']\n",
    "# for index, row in df.iterrows():\n",
    "#     for i in searchfor: \n",
    "#         if i not in str(row['Date']):\n",
    "#             df.drop(index)\n",
    "# display(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Nct_id</th>\n",
       "      <th>Phase</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Title</th>\n",
       "      <th>Model</th>\n",
       "      <th>Date</th>\n",
       "      <th>reason</th>\n",
       "      <th>date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>4274</th>\n",
       "      <td>NCT04249336</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Dentin Hypersensitivity</td>\n",
       "      <td>This will be multi-centered, triple blinded, ...</td>\n",
       "      <td>Clinical Efficacy Of BioMin F, Colgate Sensiti...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>September 27, 2019</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6097</th>\n",
       "      <td>NCT03118739</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>The purpose of this clinical research study i...</td>\n",
       "      <td>Intensive Uric Acid Lowering With Verinurad an...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 18, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Physician Decision, ...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6104</th>\n",
       "      <td>NCT03111732</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Gallbladder Cancer</td>\n",
       "      <td>Background:\\r\\r Biliary tract cancers are rar...</td>\n",
       "      <td>Pembrolizumab, a Monoclonal Antibody Against P...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 14, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Enrolled in differen...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6125</th>\n",
       "      <td>NCT03117361</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>This is a multi-center, open-label, single ar...</td>\n",
       "      <td>Trial of Plitidepsin (Aplidin®) in Combination...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>May 8, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Progressive disease,...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6136</th>\n",
       "      <td>NCT03118765</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Mild to Moderate Chronic Obstructive Pulmonary...</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rang...</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rangi...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 24, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6162</th>\n",
       "      <td>NCT03118297</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Bleeding</td>\n",
       "      <td>The subdermal etonogestrel (ENG) implant, a l...</td>\n",
       "      <td>Intervention to End Recurrent Unscheduled Blee...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 1, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6353</th>\n",
       "      <td>NCT03114657</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alzheimer's Disease</td>\n",
       "      <td>This randomized, double-blind, placebo-contro...</td>\n",
       "      <td>A Study of Crenezumab Versus Placebo to Evalua...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 29, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6466</th>\n",
       "      <td>NCT03110770</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>RNA Virus Infections</td>\n",
       "      <td>This was a multicenter, randomized study to e...</td>\n",
       "      <td>VRC 705: A Zika Virus DNA Vaccine in Healthy A...</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>March 29, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Enrolled but ...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6655</th>\n",
       "      <td>NCT03118947</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Agitation and Aggression in Alzheimer's Disease</td>\n",
       "      <td>To evaluate the safety and tolerability of pi...</td>\n",
       "      <td>A Study of Pimavanserin for the Treatment of A...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>February 23, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6656</th>\n",
       "      <td>NCT03110380</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>HIV-1-infection</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Switching to a Fixed Dose Combination of Bicte...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 12, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Randomized and Never...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6702</th>\n",
       "      <td>NCT03115112</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Type 2 Diabetes Mellitus</td>\n",
       "      <td>The purpose of this study is to investigate t...</td>\n",
       "      <td>Safety and Efficacy of Bexagliflozin Compared ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 12, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6809</th>\n",
       "      <td>NCT03115476</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Squamous Cell Carcinoma</td>\n",
       "      <td>One of the main reasons for treating actinic ...</td>\n",
       "      <td>A Trial to Compare the Incidence of Squamous C...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 16, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Trial termina...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6814</th>\n",
       "      <td>NCT03110562</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>This Phase 3, 2-arm, randomized, active compa...</td>\n",
       "      <td>Bortezomib, Selinexor, and Dexamethasone in Pa...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>May 24, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6815</th>\n",
       "      <td>NCT03119701</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Multi Organ Failure</td>\n",
       "      <td>A study to assess effectiveness and safety of...</td>\n",
       "      <td>Efficacy and Safety of FP-1201-lyo (Interferon...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 18, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Adverse Event...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6834</th>\n",
       "      <td>NCT03116152</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Esophageal Squamous Cell Carcinoma</td>\n",
       "      <td>Efficacy and safety evaluation of IBI308 vers...</td>\n",
       "      <td>Study of IBI308 With Advanced/Metastatic Esoph...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 10, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Disease Progression,...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6910</th>\n",
       "      <td>NCT03181503</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prurigo Nodularis</td>\n",
       "      <td>The aim of this study is to assess the safety...</td>\n",
       "      <td>Safety and Efficacy of Nemolizumab in PN</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 2, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6947</th>\n",
       "      <td>NCT03189745</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Meningococcal ACWY Disease</td>\n",
       "      <td>This study will evaluate the immunogenicity, ...</td>\n",
       "      <td>A Study To Evaluate A Booster Dose Of Menacwy-...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>August 1, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Conflict in work sch...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7051</th>\n",
       "      <td>NCT03186378</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Molluscum Contagiosum</td>\n",
       "      <td>The primary objective of the study is to dete...</td>\n",
       "      <td>Evaluation of Systemic Exposure to VP-102 in S...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 8, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7187</th>\n",
       "      <td>NCT03189719</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Esophageal Neoplasms</td>\n",
       "      <td>The purpose of this trial is to evaluate effi...</td>\n",
       "      <td>First-line Esophageal Carcinoma Study With Che...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 25, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Withdrawal by...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7228</th>\n",
       "      <td>NCT03180801</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Influenza</td>\n",
       "      <td>FLU-v is a broad spectrum influenza vaccine t...</td>\n",
       "      <td>Efficacy of FLU-v in an H1N1 Influenza Human C...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>August 18, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Physician Decision, ...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7242</th>\n",
       "      <td>NCT03187262</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Waldenström Macroglobulinemia</td>\n",
       "      <td>This research study is studying Daratumumab a...</td>\n",
       "      <td>A Study of Daratumumab in Patients With Relaps...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>November 27, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lack of Efficacy, Pr...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7319</th>\n",
       "      <td>NCT03180528</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Skin Basal Cell Carcinoma</td>\n",
       "      <td>This phase 2 trial studies how well remetinos...</td>\n",
       "      <td>Topical Remetinostat in Treating Patient With ...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>July 7, 2018</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7347</th>\n",
       "      <td>NCT03188991</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Pancreatic Mucinous-Cystic Neoplasm</td>\n",
       "      <td>This study will evaluate intracystic NanoPac®...</td>\n",
       "      <td>Intracystic Injection of NanoPac® in Subjects ...</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>September 29, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subject</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7469</th>\n",
       "      <td>NCT03187301</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Off Episodes of Parkinson Disease</td>\n",
       "      <td>A cardiac safety study of an investigational ...</td>\n",
       "      <td>A Cardiac Safety Study of an Investigational D...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>August 3, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7477</th>\n",
       "      <td>NCT03187756</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hematopoietic Malignancies</td>\n",
       "      <td>This is an open label phase II single arm stu...</td>\n",
       "      <td>Study of Nonmyeloablative Peripheral Blood Ste...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 2, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Termination of study</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7488</th>\n",
       "      <td>NCT03188185</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Major Depressive Disorder</td>\n",
       "      <td>This study will evaluate the efficacy, safety...</td>\n",
       "      <td>A Study of ALKS 5461 for Treatment Refractory ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 12, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lack ...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7585</th>\n",
       "      <td>NCT03185481</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Parkinson's Disease With Motor Fluctuations</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Safety and Tolerability of PF-06649751 in Park...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 6, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7598</th>\n",
       "      <td>NCT03184987</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Despite availability of treatments and publis...</td>\n",
       "      <td>A Long-term Safety Study of Fixed Dose Combina...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 22, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7602</th>\n",
       "      <td>NCT03180619</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Chronic Hepatitis B</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Study to Evaluate the Safety and Efficacy of S...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 29, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrew Consent, De...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7619</th>\n",
       "      <td>NCT03189446</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Clear Cell Endometrial Cancer</td>\n",
       "      <td>The purpose of this study is to determine the...</td>\n",
       "      <td>Vaginal Cuff Brachytherapy Followed by Chemoth...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>October 2, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382555</th>\n",
       "      <td>NCT02576938</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Atopic Dermatitis</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>A Study of Baricitinib (LY3009104) in Particip...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382580</th>\n",
       "      <td>NCT02574455</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>The primary objective of this study is to com...</td>\n",
       "      <td>Trial of Sacituzumab Govitecan in Participants...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>November 7, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Withdrawal by...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385813</th>\n",
       "      <td>NCT02580877</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Type 1 Diabetes</td>\n",
       "      <td>The study is a 2 arm, multi-center, randomize...</td>\n",
       "      <td>Immune Effects of Oral Insulin in Relatives at...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385849</th>\n",
       "      <td>NCT02586805</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hereditary Angioedema (HAE)</td>\n",
       "      <td>This is a phase 3, multicenter, randomized, d...</td>\n",
       "      <td>Efficacy and Safety Study of DX-2930 to Preven...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 3, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385932</th>\n",
       "      <td>NCT02586025</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>This is an Asia-Pacific regional, randomized,...</td>\n",
       "      <td>Study in Participants With Early-Stage or Loca...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 14, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Did Not Receive Stud...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385962</th>\n",
       "      <td>NCT02582866</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Epilepsy</td>\n",
       "      <td>Study is conducted to evaluate the long-term ...</td>\n",
       "      <td>A Clinical Study to Investigate the Long-term ...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>January 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Lack of Effic...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385993</th>\n",
       "      <td>NCT02581930</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Stage IV Cutaneous Melanoma AJCC v6 and v7</td>\n",
       "      <td>This phase II trial studies how well ibrutini...</td>\n",
       "      <td>Ibrutinib in Treating Patients With Refractory...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>August 17, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386006</th>\n",
       "      <td>NCT02588261</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Non-small Cell Lung Cancer (NSCLC)</td>\n",
       "      <td>The purpose of the study was to evaluate the ...</td>\n",
       "      <td>A Study of ASP8273 vs. Erlotinib or Gefitinib ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 11, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Study Terminated by ...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386008</th>\n",
       "      <td>NCT02583256</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Influenza</td>\n",
       "      <td>Safety, Immunogenicity of an Adjuvanted Quadr...</td>\n",
       "      <td>Clinical Study to Evaluate Safety, Immunogenic...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 29, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386245</th>\n",
       "      <td>NCT02582749</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prostate Neoplasms</td>\n",
       "      <td>Newly diagnosed metastatic prostate cancer su...</td>\n",
       "      <td>Androgen Deprivation Therapy +/- Radium-223 Di...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Study terminated by ...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386271</th>\n",
       "      <td>NCT02588339</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>GVHD</td>\n",
       "      <td>This study will test PANO in combination with...</td>\n",
       "      <td>Panobinostat (LBH589): Acute Graft Versus Host...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>March 4, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386430</th>\n",
       "      <td>NCT02583048</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>HIV Infections</td>\n",
       "      <td>This study evaluated the safety, tolerability...</td>\n",
       "      <td>Evaluating the Safety, Tolerability, and Pharm...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>August 15, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386542</th>\n",
       "      <td>NCT02587221</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Influenza</td>\n",
       "      <td>A Phase III, Randomized, Observer-Blind, Cont...</td>\n",
       "      <td>Clinical Study to Evaluate the Efficacy, Safet...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>September 30, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386549</th>\n",
       "      <td>NCT02584257</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Mild Persistent Asthma</td>\n",
       "      <td>The purpose of this study is to demonstrate t...</td>\n",
       "      <td>Pharmacodynamic Bioequivalence of Metered Dose...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>April 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386620</th>\n",
       "      <td>NCT03150589</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Age-Related Macular Degeneration</td>\n",
       "      <td>This is a randomised, double-masked, parallel...</td>\n",
       "      <td>A Study to Compare SB11 (Proposed Ranibizumab ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 14, 2018</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386652</th>\n",
       "      <td>NCT03155178</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Bacterial Recovery of Skin Flora Post-product ...</td>\n",
       "      <td>Evaluate persistent antimicrobial effectivene...</td>\n",
       "      <td>In Vivo Preoperative Skin Preparation Persiste...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>December 5, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Did not meet treatme...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386667</th>\n",
       "      <td>NCT03152019</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hemorrhagic Hereditary Telangiectasia (HHT)</td>\n",
       "      <td>The recognized manifestations of HHT are all ...</td>\n",
       "      <td>Efficacy and Safety of a 0.1% Tacrolimus Nasal...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 22, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386713</th>\n",
       "      <td>NCT03155997</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Endocrine Therapy With or Without Abemaciclib ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 12, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386893</th>\n",
       "      <td>NCT03154047</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>AL Amyloidosis</td>\n",
       "      <td>The objective of this study is to evaluate th...</td>\n",
       "      <td>Study in Subjects With Light Chain (AL) Amyloi...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 14, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Study termina...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386925</th>\n",
       "      <td>NCT03158285</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Arthritis, Psoriatic</td>\n",
       "      <td>The primary purpose of this study is to evalu...</td>\n",
       "      <td>A Study Evaluating the Efficacy and Safety of ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 12, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lack ...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387022</th>\n",
       "      <td>NCT03150719</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>Study VX16-661-114 (Study 114) is a Phase 3b,...</td>\n",
       "      <td>A Study to Evaluate Safety, Efficacy, and Tole...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 24, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387038</th>\n",
       "      <td>NCT03159611</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Sequelae of Perinatal Brain Injury</td>\n",
       "      <td>Purpose of the study:\\r\\r - To assess the cli...</td>\n",
       "      <td>Efficacy and Safety Clinical Trial of Tenoten ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 19, 2016</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Did Not Meet Inclusi...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387042</th>\n",
       "      <td>NCT03158220</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Human Papillomavirus Infection</td>\n",
       "      <td>This study will assess the safety and immunog...</td>\n",
       "      <td>Immunogenicity and Tolerability of Broad Spect...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>September 20, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Screen Failure, With...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387054</th>\n",
       "      <td>NCT03157089</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>The main objective is to assess the efficacy ...</td>\n",
       "      <td>Testing Afatinib in Combination With Pembroliz...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>November 2, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Treated only with pe...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387133</th>\n",
       "      <td>NCT03158311</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>The purpose of this trial was to demonstrate ...</td>\n",
       "      <td>Study to Compare QVM149 and Free Triple Combin...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 5, 2018</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Subject/Guardian Dec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387199</th>\n",
       "      <td>NCT03154476</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Congenital Heart Disease</td>\n",
       "      <td>The purpose of this study is to determine if ...</td>\n",
       "      <td>Role of Sildenafil for Fontan Associated Liver...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 5, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387225</th>\n",
       "      <td>NCT03156621</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Homozygous Familial Hypercholesterolemia</td>\n",
       "      <td>The primary objective of the study is to demo...</td>\n",
       "      <td>Study in Participants With Homozygous Familial...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 3, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387280</th>\n",
       "      <td>NCT03158688</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Refractory Multiple Myeloma</td>\n",
       "      <td>Compare carfizomib, dexamethasone, and daratu...</td>\n",
       "      <td>Study of Carfilzomib, Daratumumab and Dexameth...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 13, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Continuing in study,...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387300</th>\n",
       "      <td>NCT03152552</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Diabetes Mellitus and Heart Failure</td>\n",
       "      <td>This was a dose-finding study to evaluate the...</td>\n",
       "      <td>A Dose Finding Study to Assess the Effect of L...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 25, 2017</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Protocol devi...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387803</th>\n",
       "      <td>NCT04161144</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Nicotine Dependence</td>\n",
       "      <td>The purpose of this study is to examine the e...</td>\n",
       "      <td>Enhancing Self Regulation Among Smokers</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 1, 2018</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2120 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             Nct_id    Phase  \\\n",
       "4274    NCT04249336  Phase 3   \n",
       "6097    NCT03118739  Phase 2   \n",
       "6104    NCT03111732  Phase 2   \n",
       "6125    NCT03117361  Phase 2   \n",
       "6136    NCT03118765  Phase 2   \n",
       "6162    NCT03118297  Phase 3   \n",
       "6353    NCT03114657  Phase 3   \n",
       "6466    NCT03110770  Phase 2   \n",
       "6655    NCT03118947  Phase 2   \n",
       "6656    NCT03110380  Phase 3   \n",
       "6702    NCT03115112  Phase 3   \n",
       "6809    NCT03115476  Phase 3   \n",
       "6814    NCT03110562  Phase 3   \n",
       "6815    NCT03119701  Phase 2   \n",
       "6834    NCT03116152  Phase 2   \n",
       "6910    NCT03181503  Phase 2   \n",
       "6947    NCT03189745  Phase 3   \n",
       "7051    NCT03186378  Phase 2   \n",
       "7187    NCT03189719  Phase 3   \n",
       "7228    NCT03180801  Phase 2   \n",
       "7242    NCT03187262  Phase 2   \n",
       "7319    NCT03180528  Phase 2   \n",
       "7347    NCT03188991  Phase 2   \n",
       "7469    NCT03187301  Phase 2   \n",
       "7477    NCT03187756  Phase 2   \n",
       "7488    NCT03188185  Phase 3   \n",
       "7585    NCT03185481  Phase 2   \n",
       "7598    NCT03184987  Phase 3   \n",
       "7602    NCT03180619  Phase 2   \n",
       "7619    NCT03189446  Phase 2   \n",
       "...             ...      ...   \n",
       "382555  NCT02576938  Phase 2   \n",
       "382580  NCT02574455  Phase 3   \n",
       "385813  NCT02580877  Phase 2   \n",
       "385849  NCT02586805  Phase 3   \n",
       "385932  NCT02586025  Phase 3   \n",
       "385962  NCT02582866  Phase 3   \n",
       "385993  NCT02581930  Phase 2   \n",
       "386006  NCT02588261  Phase 3   \n",
       "386008  NCT02583256  Phase 3   \n",
       "386245  NCT02582749  Phase 2   \n",
       "386271  NCT02588339  Phase 2   \n",
       "386430  NCT02583048  Phase 2   \n",
       "386542  NCT02587221  Phase 3   \n",
       "386549  NCT02584257  Phase 3   \n",
       "386620  NCT03150589  Phase 3   \n",
       "386652  NCT03155178  Phase 2   \n",
       "386667  NCT03152019  Phase 2   \n",
       "386713  NCT03155997  Phase 3   \n",
       "386893  NCT03154047  Phase 2   \n",
       "386925  NCT03158285  Phase 3   \n",
       "387022  NCT03150719  Phase 3   \n",
       "387038  NCT03159611  Phase 3   \n",
       "387042  NCT03158220  Phase 3   \n",
       "387054  NCT03157089  Phase 2   \n",
       "387133  NCT03158311  Phase 3   \n",
       "387199  NCT03154476  Phase 3   \n",
       "387225  NCT03156621  Phase 3   \n",
       "387280  NCT03158688  Phase 3   \n",
       "387300  NCT03152552  Phase 2   \n",
       "387803  NCT04161144  Phase 2   \n",
       "\n",
       "                                                Condition  \\\n",
       "4274                              Dentin Hypersensitivity   \n",
       "6097                                      Type 2 Diabetes   \n",
       "6104                                   Gallbladder Cancer   \n",
       "6125                                     Multiple Myeloma   \n",
       "6136    Mild to Moderate Chronic Obstructive Pulmonary...   \n",
       "6162                                             Bleeding   \n",
       "6353                                  Alzheimer's Disease   \n",
       "6466                                 RNA Virus Infections   \n",
       "6655      Agitation and Aggression in Alzheimer's Disease   \n",
       "6656                                      HIV-1-infection   \n",
       "6702                             Type 2 Diabetes Mellitus   \n",
       "6809                              Squamous Cell Carcinoma   \n",
       "6814                                     Multiple Myeloma   \n",
       "6815                                  Multi Organ Failure   \n",
       "6834                   Esophageal Squamous Cell Carcinoma   \n",
       "6910                                    Prurigo Nodularis   \n",
       "6947                           Meningococcal ACWY Disease   \n",
       "7051                                Molluscum Contagiosum   \n",
       "7187                                 Esophageal Neoplasms   \n",
       "7228                                            Influenza   \n",
       "7242                        Waldenström Macroglobulinemia   \n",
       "7319                            Skin Basal Cell Carcinoma   \n",
       "7347                  Pancreatic Mucinous-Cystic Neoplasm   \n",
       "7469                    Off Episodes of Parkinson Disease   \n",
       "7477                           Hematopoietic Malignancies   \n",
       "7488                            Major Depressive Disorder   \n",
       "7585          Parkinson's Disease With Motor Fluctuations   \n",
       "7598                                               Asthma   \n",
       "7602                                  Chronic Hepatitis B   \n",
       "7619                        Clear Cell Endometrial Cancer   \n",
       "...                                                   ...   \n",
       "382555                                  Atopic Dermatitis   \n",
       "382580                                      Breast Cancer   \n",
       "385813                                    Type 1 Diabetes   \n",
       "385849                        Hereditary Angioedema (HAE)   \n",
       "385932                                      Breast Cancer   \n",
       "385962                                           Epilepsy   \n",
       "385993         Stage IV Cutaneous Melanoma AJCC v6 and v7   \n",
       "386006                 Non-small Cell Lung Cancer (NSCLC)   \n",
       "386008                                          Influenza   \n",
       "386245                                 Prostate Neoplasms   \n",
       "386271                                               GVHD   \n",
       "386430                                     HIV Infections   \n",
       "386542                                          Influenza   \n",
       "386549                             Mild Persistent Asthma   \n",
       "386620                   Age-Related Macular Degeneration   \n",
       "386652  Bacterial Recovery of Skin Flora Post-product ...   \n",
       "386667        Hemorrhagic Hereditary Telangiectasia (HHT)   \n",
       "386713                                      Breast Cancer   \n",
       "386893                                     AL Amyloidosis   \n",
       "386925                               Arthritis, Psoriatic   \n",
       "387022                                    Cystic Fibrosis   \n",
       "387038                 Sequelae of Perinatal Brain Injury   \n",
       "387042                     Human Papillomavirus Infection   \n",
       "387054                     Carcinoma, Non-Small-Cell Lung   \n",
       "387133                                             Asthma   \n",
       "387199                           Congenital Heart Disease   \n",
       "387225           Homozygous Familial Hypercholesterolemia   \n",
       "387280                        Refractory Multiple Myeloma   \n",
       "387300                Diabetes Mellitus and Heart Failure   \n",
       "387803                                Nicotine Dependence   \n",
       "\n",
       "                                                  Summary  \\\n",
       "4274     This will be multi-centered, triple blinded, ...   \n",
       "6097     The purpose of this clinical research study i...   \n",
       "6104     Background:\\r\\r Biliary tract cancers are rar...   \n",
       "6125     This is a multi-center, open-label, single ar...   \n",
       "6136     Pharmacodynamic and Pharmacokinetic Dose Rang...   \n",
       "6162     The subdermal etonogestrel (ENG) implant, a l...   \n",
       "6353     This randomized, double-blind, placebo-contro...   \n",
       "6466     This was a multicenter, randomized study to e...   \n",
       "6655     To evaluate the safety and tolerability of pi...   \n",
       "6656     The primary objective of this study is to eva...   \n",
       "6702     The purpose of this study is to investigate t...   \n",
       "6809     One of the main reasons for treating actinic ...   \n",
       "6814     This Phase 3, 2-arm, randomized, active compa...   \n",
       "6815     A study to assess effectiveness and safety of...   \n",
       "6834     Efficacy and safety evaluation of IBI308 vers...   \n",
       "6910     The aim of this study is to assess the safety...   \n",
       "6947     This study will evaluate the immunogenicity, ...   \n",
       "7051     The primary objective of the study is to dete...   \n",
       "7187     The purpose of this trial is to evaluate effi...   \n",
       "7228     FLU-v is a broad spectrum influenza vaccine t...   \n",
       "7242     This research study is studying Daratumumab a...   \n",
       "7319     This phase 2 trial studies how well remetinos...   \n",
       "7347     This study will evaluate intracystic NanoPac®...   \n",
       "7469     A cardiac safety study of an investigational ...   \n",
       "7477     This is an open label phase II single arm stu...   \n",
       "7488     This study will evaluate the efficacy, safety...   \n",
       "7585     The purpose of this study is to evaluate the ...   \n",
       "7598     Despite availability of treatments and publis...   \n",
       "7602     The primary objective of this study is to eva...   \n",
       "7619     The purpose of this study is to determine the...   \n",
       "...                                                   ...   \n",
       "382555   The purpose of this study is to evaluate the ...   \n",
       "382580   The primary objective of this study is to com...   \n",
       "385813   The study is a 2 arm, multi-center, randomize...   \n",
       "385849   This is a phase 3, multicenter, randomized, d...   \n",
       "385932   This is an Asia-Pacific regional, randomized,...   \n",
       "385962   Study is conducted to evaluate the long-term ...   \n",
       "385993   This phase II trial studies how well ibrutini...   \n",
       "386006   The purpose of the study was to evaluate the ...   \n",
       "386008   Safety, Immunogenicity of an Adjuvanted Quadr...   \n",
       "386245   Newly diagnosed metastatic prostate cancer su...   \n",
       "386271   This study will test PANO in combination with...   \n",
       "386430   This study evaluated the safety, tolerability...   \n",
       "386542   A Phase III, Randomized, Observer-Blind, Cont...   \n",
       "386549   The purpose of this study is to demonstrate t...   \n",
       "386620   This is a randomised, double-masked, parallel...   \n",
       "386652   Evaluate persistent antimicrobial effectivene...   \n",
       "386667   The recognized manifestations of HHT are all ...   \n",
       "386713   The purpose of this study is to evaluate the ...   \n",
       "386893   The objective of this study is to evaluate th...   \n",
       "386925   The primary purpose of this study is to evalu...   \n",
       "387022   Study VX16-661-114 (Study 114) is a Phase 3b,...   \n",
       "387038   Purpose of the study:\\r\\r - To assess the cli...   \n",
       "387042   This study will assess the safety and immunog...   \n",
       "387054   The main objective is to assess the efficacy ...   \n",
       "387133   The purpose of this trial was to demonstrate ...   \n",
       "387199   The purpose of this study is to determine if ...   \n",
       "387225   The primary objective of the study is to demo...   \n",
       "387280   Compare carfizomib, dexamethasone, and daratu...   \n",
       "387300   This was a dose-finding study to evaluate the...   \n",
       "387803   The purpose of this study is to examine the e...   \n",
       "\n",
       "                                                    Title  \\\n",
       "4274    Clinical Efficacy Of BioMin F, Colgate Sensiti...   \n",
       "6097    Intensive Uric Acid Lowering With Verinurad an...   \n",
       "6104    Pembrolizumab, a Monoclonal Antibody Against P...   \n",
       "6125    Trial of Plitidepsin (Aplidin®) in Combination...   \n",
       "6136    Pharmacodynamic and Pharmacokinetic Dose Rangi...   \n",
       "6162    Intervention to End Recurrent Unscheduled Blee...   \n",
       "6353    A Study of Crenezumab Versus Placebo to Evalua...   \n",
       "6466    VRC 705: A Zika Virus DNA Vaccine in Healthy A...   \n",
       "6655    A Study of Pimavanserin for the Treatment of A...   \n",
       "6656    Switching to a Fixed Dose Combination of Bicte...   \n",
       "6702    Safety and Efficacy of Bexagliflozin Compared ...   \n",
       "6809    A Trial to Compare the Incidence of Squamous C...   \n",
       "6814    Bortezomib, Selinexor, and Dexamethasone in Pa...   \n",
       "6815    Efficacy and Safety of FP-1201-lyo (Interferon...   \n",
       "6834    Study of IBI308 With Advanced/Metastatic Esoph...   \n",
       "6910             Safety and Efficacy of Nemolizumab in PN   \n",
       "6947    A Study To Evaluate A Booster Dose Of Menacwy-...   \n",
       "7051    Evaluation of Systemic Exposure to VP-102 in S...   \n",
       "7187    First-line Esophageal Carcinoma Study With Che...   \n",
       "7228    Efficacy of FLU-v in an H1N1 Influenza Human C...   \n",
       "7242    A Study of Daratumumab in Patients With Relaps...   \n",
       "7319    Topical Remetinostat in Treating Patient With ...   \n",
       "7347    Intracystic Injection of NanoPac® in Subjects ...   \n",
       "7469    A Cardiac Safety Study of an Investigational D...   \n",
       "7477    Study of Nonmyeloablative Peripheral Blood Ste...   \n",
       "7488    A Study of ALKS 5461 for Treatment Refractory ...   \n",
       "7585    Safety and Tolerability of PF-06649751 in Park...   \n",
       "7598    A Long-term Safety Study of Fixed Dose Combina...   \n",
       "7602    Study to Evaluate the Safety and Efficacy of S...   \n",
       "7619    Vaginal Cuff Brachytherapy Followed by Chemoth...   \n",
       "...                                                   ...   \n",
       "382555  A Study of Baricitinib (LY3009104) in Particip...   \n",
       "382580  Trial of Sacituzumab Govitecan in Participants...   \n",
       "385813  Immune Effects of Oral Insulin in Relatives at...   \n",
       "385849  Efficacy and Safety Study of DX-2930 to Preven...   \n",
       "385932  Study in Participants With Early-Stage or Loca...   \n",
       "385962  A Clinical Study to Investigate the Long-term ...   \n",
       "385993  Ibrutinib in Treating Patients With Refractory...   \n",
       "386006  A Study of ASP8273 vs. Erlotinib or Gefitinib ...   \n",
       "386008  Clinical Study to Evaluate Safety, Immunogenic...   \n",
       "386245  Androgen Deprivation Therapy +/- Radium-223 Di...   \n",
       "386271  Panobinostat (LBH589): Acute Graft Versus Host...   \n",
       "386430  Evaluating the Safety, Tolerability, and Pharm...   \n",
       "386542  Clinical Study to Evaluate the Efficacy, Safet...   \n",
       "386549  Pharmacodynamic Bioequivalence of Metered Dose...   \n",
       "386620  A Study to Compare SB11 (Proposed Ranibizumab ...   \n",
       "386652  In Vivo Preoperative Skin Preparation Persiste...   \n",
       "386667  Efficacy and Safety of a 0.1% Tacrolimus Nasal...   \n",
       "386713  Endocrine Therapy With or Without Abemaciclib ...   \n",
       "386893  Study in Subjects With Light Chain (AL) Amyloi...   \n",
       "386925  A Study Evaluating the Efficacy and Safety of ...   \n",
       "387022  A Study to Evaluate Safety, Efficacy, and Tole...   \n",
       "387038  Efficacy and Safety Clinical Trial of Tenoten ...   \n",
       "387042  Immunogenicity and Tolerability of Broad Spect...   \n",
       "387054  Testing Afatinib in Combination With Pembroliz...   \n",
       "387133  Study to Compare QVM149 and Free Triple Combin...   \n",
       "387199  Role of Sildenafil for Fontan Associated Liver...   \n",
       "387225  Study in Participants With Homozygous Familial...   \n",
       "387280  Study of Carfilzomib, Daratumumab and Dexameth...   \n",
       "387300  A Dose Finding Study to Assess the Effect of L...   \n",
       "387803            Enhancing Self Regulation Among Smokers   \n",
       "\n",
       "                          Model                Date  \\\n",
       "4274        Parallel Assignment  September 27, 2019   \n",
       "6097        Parallel Assignment        May 18, 2017   \n",
       "6104    Single Group Assignment       June 14, 2017   \n",
       "6125    Single Group Assignment         May 8, 2017   \n",
       "6136        Parallel Assignment      March 24, 2017   \n",
       "6162        Parallel Assignment         May 1, 2017   \n",
       "6353        Parallel Assignment      March 29, 2017   \n",
       "6466      Sequential Assignment      March 29, 2017   \n",
       "6655    Single Group Assignment   February 23, 2017   \n",
       "6656        Parallel Assignment       June 12, 2017   \n",
       "6702        Parallel Assignment    October 12, 2017   \n",
       "6809        Parallel Assignment       June 16, 2017   \n",
       "6814       Crossover Assignment        May 24, 2017   \n",
       "6815        Parallel Assignment   February 18, 2017   \n",
       "6834        Parallel Assignment        May 10, 2017   \n",
       "6910        Parallel Assignment     October 2, 2017   \n",
       "6947        Parallel Assignment      August 1, 2017   \n",
       "7051    Single Group Assignment        June 8, 2017   \n",
       "7187        Parallel Assignment       July 25, 2017   \n",
       "7228        Parallel Assignment     August 18, 2016   \n",
       "7242    Single Group Assignment   November 27, 2017   \n",
       "7319    Single Group Assignment        July 7, 2018   \n",
       "7347      Sequential Assignment  September 29, 2017   \n",
       "7469       Crossover Assignment      August 3, 2017   \n",
       "7477    Single Group Assignment        June 2, 2017   \n",
       "7488        Parallel Assignment       June 12, 2017   \n",
       "7585        Parallel Assignment        July 6, 2017   \n",
       "7598        Parallel Assignment       June 22, 2017   \n",
       "7602        Parallel Assignment       June 29, 2017   \n",
       "7619    Single Group Assignment     October 2, 2017   \n",
       "...                         ...                 ...   \n",
       "382555      Parallel Assignment       February 2016   \n",
       "382580      Parallel Assignment    November 7, 2017   \n",
       "385813      Parallel Assignment        January 2016   \n",
       "385849      Parallel Assignment       March 3, 2016   \n",
       "385932      Parallel Assignment      March 14, 2016   \n",
       "385962  Single Group Assignment        January 2016   \n",
       "385993  Single Group Assignment     August 17, 2016   \n",
       "386006      Parallel Assignment   February 11, 2016   \n",
       "386008      Parallel Assignment    January 29, 2016   \n",
       "386245      Parallel Assignment          April 2016   \n",
       "386271  Single Group Assignment       March 4, 2016   \n",
       "386430      Parallel Assignment     August 15, 2016   \n",
       "386542      Parallel Assignment  September 30, 2016   \n",
       "386549     Crossover Assignment          April 2016   \n",
       "386620      Parallel Assignment      March 14, 2018   \n",
       "386652      Parallel Assignment    December 5, 2016   \n",
       "386667      Parallel Assignment        May 22, 2017   \n",
       "386713      Parallel Assignment       July 12, 2017   \n",
       "386893  Single Group Assignment       June 14, 2017   \n",
       "386925      Parallel Assignment       July 12, 2017   \n",
       "387022      Parallel Assignment        May 24, 2017   \n",
       "387038      Parallel Assignment   February 19, 2016   \n",
       "387042      Parallel Assignment  September 20, 2017   \n",
       "387054  Single Group Assignment    November 2, 2017   \n",
       "387133      Parallel Assignment    February 5, 2018   \n",
       "387199      Parallel Assignment        July 5, 2017   \n",
       "387225      Parallel Assignment     October 3, 2017   \n",
       "387280      Parallel Assignment       June 13, 2017   \n",
       "387300      Parallel Assignment       July 25, 2017   \n",
       "387803      Parallel Assignment     October 1, 2018   \n",
       "\n",
       "                                                   reason  date  \n",
       "4274          NOT COMPLETED BECAUSE OF, Lost to Follow-up  True  \n",
       "6097    NOT COMPLETED BECAUSE OF, Physician Decision, ...  True  \n",
       "6104    NOT COMPLETED BECAUSE OF, Enrolled in differen...  True  \n",
       "6125    NOT COMPLETED BECAUSE OF, Progressive disease,...  True  \n",
       "6136    NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "6162          NOT COMPLETED BECAUSE OF, Lost to Follow-up  True  \n",
       "6353    NOT COMPLETED BECAUSE OF, Adverse Event, Death...  True  \n",
       "6466    NOT COMPLETED BECAUSE OF, Death, Enrolled but ...  True  \n",
       "6655    NOT COMPLETED BECAUSE OF, Adverse Event, Death...  True  \n",
       "6656    NOT COMPLETED BECAUSE OF, Randomized and Never...  True  \n",
       "6702    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  True  \n",
       "6809    NOT COMPLETED BECAUSE OF, Death, Trial termina...  True  \n",
       "6814    NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "6815    NOT COMPLETED BECAUSE OF, Death, Adverse Event...  True  \n",
       "6834    NOT COMPLETED BECAUSE OF, Disease Progression,...  True  \n",
       "6910    NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  True  \n",
       "6947    NOT COMPLETED BECAUSE OF, Conflict in work sch...  True  \n",
       "7051          NOT COMPLETED BECAUSE OF, Lost to Follow-up  True  \n",
       "7187    NOT COMPLETED BECAUSE OF, Death, Withdrawal by...  True  \n",
       "7228    NOT COMPLETED BECAUSE OF, Physician Decision, ...  True  \n",
       "7242    NOT COMPLETED BECAUSE OF, Lack of Efficacy, Pr...  True  \n",
       "7319    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  True  \n",
       "7347      NOT COMPLETED BECAUSE OF, Withdrawal by Subject  True  \n",
       "7469    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  True  \n",
       "7477       NOT COMPLETED BECAUSE OF, Termination of study  True  \n",
       "7488    NOT COMPLETED BECAUSE OF, Adverse Event, Lack ...  True  \n",
       "7585    NOT COMPLETED BECAUSE OF, Adverse Event, Study...  True  \n",
       "7598    NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "7602    NOT COMPLETED BECAUSE OF, Withdrew Consent, De...  True  \n",
       "7619    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  True  \n",
       "...                                                   ...   ...  \n",
       "382555  NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  True  \n",
       "382580  NOT COMPLETED BECAUSE OF, Death, Withdrawal by...  True  \n",
       "385813  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "385849  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "385932  NOT COMPLETED BECAUSE OF, Did Not Receive Stud...  True  \n",
       "385962  NOT COMPLETED BECAUSE OF, Death, Lack of Effic...  True  \n",
       "385993  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "386006  NOT COMPLETED BECAUSE OF, Study Terminated by ...  True  \n",
       "386008  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "386245  NOT COMPLETED BECAUSE OF, Study terminated by ...  True  \n",
       "386271  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "386430  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "386542  NOT COMPLETED BECAUSE OF, Adverse Event, Death...  True  \n",
       "386549  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "386620  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "386652  NOT COMPLETED BECAUSE OF, Did not meet treatme...  True  \n",
       "386667            NOT COMPLETED BECAUSE OF, Adverse Event  True  \n",
       "386713  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "386893  NOT COMPLETED BECAUSE OF, Death, Study termina...  True  \n",
       "386925  NOT COMPLETED BECAUSE OF, Adverse Event, Lack ...  True  \n",
       "387022  NOT COMPLETED BECAUSE OF, Adverse Event, Death...  True  \n",
       "387038  NOT COMPLETED BECAUSE OF, Did Not Meet Inclusi...  True  \n",
       "387042  NOT COMPLETED BECAUSE OF, Screen Failure, With...  True  \n",
       "387054  NOT COMPLETED BECAUSE OF, Treated only with pe...  True  \n",
       "387133  NOT COMPLETED BECAUSE OF, Subject/Guardian Dec...  True  \n",
       "387199        NOT COMPLETED BECAUSE OF, Lost to Follow-up  True  \n",
       "387225  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  True  \n",
       "387280  NOT COMPLETED BECAUSE OF, Continuing in study,...  True  \n",
       "387300  NOT COMPLETED BECAUSE OF, Death, Protocol devi...  True  \n",
       "387803  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  True  \n",
       "\n",
       "[2120 rows x 9 columns]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "searchfor = ['2016','2017','2018','2019','2020']\n",
    "df['date'] = df['Date'].apply(lambda date: date.split(' ')[-1] in searchfor)\n",
    "df_with_chosen_dates = df[df.date]\n",
    "display(df_with_chosen_dates)\n",
    "#df_with_chosen_dates.to_csv('filtered_clinical_trials.csv',index=False, encoding='utf-8', quoting=csv.QUOTE_NONNUMERIC)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2120"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df=df_with_chosen_dates\n",
    "len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Nct_id</th>\n",
       "      <th>Phase</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Title</th>\n",
       "      <th>Model</th>\n",
       "      <th>Date</th>\n",
       "      <th>reason</th>\n",
       "      <th>date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>6097</th>\n",
       "      <td>NCT03118739</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>The purpose of this clinical research study i...</td>\n",
       "      <td>Intensive Uric Acid Lowering With Verinurad an...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 18, 2017</td>\n",
       "      <td>Withdrawal by Subject</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6104</th>\n",
       "      <td>NCT03111732</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Gallbladder Cancer</td>\n",
       "      <td>Background:\\r\\r Biliary tract cancers are rar...</td>\n",
       "      <td>Pembrolizumab, a Monoclonal Antibody Against P...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 14, 2017</td>\n",
       "      <td>Lack of efficacy</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6125</th>\n",
       "      <td>NCT03117361</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>This is a multi-center, open-label, single ar...</td>\n",
       "      <td>Trial of Plitidepsin (Aplidin®) in Combination...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>May 8, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6136</th>\n",
       "      <td>NCT03118765</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Mild to Moderate Chronic Obstructive Pulmonary...</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rang...</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rangi...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 24, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6353</th>\n",
       "      <td>NCT03114657</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alzheimer's Disease</td>\n",
       "      <td>This randomized, double-blind, placebo-contro...</td>\n",
       "      <td>A Study of Crenezumab Versus Placebo to Evalua...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 29, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6466</th>\n",
       "      <td>NCT03110770</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>RNA Virus Infections</td>\n",
       "      <td>This was a multicenter, randomized study to e...</td>\n",
       "      <td>VRC 705: A Zika Virus DNA Vaccine in Healthy A...</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>March 29, 2017</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6655</th>\n",
       "      <td>NCT03118947</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Agitation and Aggression in Alzheimer's Disease</td>\n",
       "      <td>To evaluate the safety and tolerability of pi...</td>\n",
       "      <td>A Study of Pimavanserin for the Treatment of A...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>February 23, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6656</th>\n",
       "      <td>NCT03110380</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>HIV-1-infection</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Switching to a Fixed Dose Combination of Bicte...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 12, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6702</th>\n",
       "      <td>NCT03115112</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Type 2 Diabetes Mellitus</td>\n",
       "      <td>The purpose of this study is to investigate t...</td>\n",
       "      <td>Safety and Efficacy of Bexagliflozin Compared ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 12, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6809</th>\n",
       "      <td>NCT03115476</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Squamous Cell Carcinoma</td>\n",
       "      <td>One of the main reasons for treating actinic ...</td>\n",
       "      <td>A Trial to Compare the Incidence of Squamous C...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 16, 2017</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6814</th>\n",
       "      <td>NCT03110562</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>This Phase 3, 2-arm, randomized, active compa...</td>\n",
       "      <td>Bortezomib, Selinexor, and Dexamethasone in Pa...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>May 24, 2017</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6815</th>\n",
       "      <td>NCT03119701</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Multi Organ Failure</td>\n",
       "      <td>A study to assess effectiveness and safety of...</td>\n",
       "      <td>Efficacy and Safety of FP-1201-lyo (Interferon...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 18, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6834</th>\n",
       "      <td>NCT03116152</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Esophageal Squamous Cell Carcinoma</td>\n",
       "      <td>Efficacy and safety evaluation of IBI308 vers...</td>\n",
       "      <td>Study of IBI308 With Advanced/Metastatic Esoph...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 10, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6910</th>\n",
       "      <td>NCT03181503</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prurigo Nodularis</td>\n",
       "      <td>The aim of this study is to assess the safety...</td>\n",
       "      <td>Safety and Efficacy of Nemolizumab in PN</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 2, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7187</th>\n",
       "      <td>NCT03189719</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Esophageal Neoplasms</td>\n",
       "      <td>The purpose of this trial is to evaluate effi...</td>\n",
       "      <td>First-line Esophageal Carcinoma Study With Che...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 25, 2017</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7228</th>\n",
       "      <td>NCT03180801</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Influenza</td>\n",
       "      <td>FLU-v is a broad spectrum influenza vaccine t...</td>\n",
       "      <td>Efficacy of FLU-v in an H1N1 Influenza Human C...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>August 18, 2016</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7242</th>\n",
       "      <td>NCT03187262</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Waldenström Macroglobulinemia</td>\n",
       "      <td>This research study is studying Daratumumab a...</td>\n",
       "      <td>A Study of Daratumumab in Patients With Relaps...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>November 27, 2017</td>\n",
       "      <td>Lack of efficacy</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7319</th>\n",
       "      <td>NCT03180528</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Skin Basal Cell Carcinoma</td>\n",
       "      <td>This phase 2 trial studies how well remetinos...</td>\n",
       "      <td>Topical Remetinostat in Treating Patient With ...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>July 7, 2018</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7347</th>\n",
       "      <td>NCT03188991</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Pancreatic Mucinous-Cystic Neoplasm</td>\n",
       "      <td>This study will evaluate intracystic NanoPac®...</td>\n",
       "      <td>Intracystic Injection of NanoPac® in Subjects ...</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>September 29, 2017</td>\n",
       "      <td>Withdrawal by Subject</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7469</th>\n",
       "      <td>NCT03187301</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Off Episodes of Parkinson Disease</td>\n",
       "      <td>A cardiac safety study of an investigational ...</td>\n",
       "      <td>A Cardiac Safety Study of an Investigational D...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>August 3, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7488</th>\n",
       "      <td>NCT03188185</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Major Depressive Disorder</td>\n",
       "      <td>This study will evaluate the efficacy, safety...</td>\n",
       "      <td>A Study of ALKS 5461 for Treatment Refractory ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 12, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7585</th>\n",
       "      <td>NCT03185481</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Parkinson's Disease With Motor Fluctuations</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Safety and Tolerability of PF-06649751 in Park...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 6, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7598</th>\n",
       "      <td>NCT03184987</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Despite availability of treatments and publis...</td>\n",
       "      <td>A Long-term Safety Study of Fixed Dose Combina...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 22, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7602</th>\n",
       "      <td>NCT03180619</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Chronic Hepatitis B</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Study to Evaluate the Safety and Efficacy of S...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 29, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7619</th>\n",
       "      <td>NCT03189446</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Clear Cell Endometrial Cancer</td>\n",
       "      <td>The purpose of this study is to determine the...</td>\n",
       "      <td>Vaginal Cuff Brachytherapy Followed by Chemoth...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>October 2, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7799</th>\n",
       "      <td>NCT03722576</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Primary Sclerosing Cholangitis</td>\n",
       "      <td>To examine the safety, tolerability, and effi...</td>\n",
       "      <td>Vidofludimus Calcium for Primary Sclerosing Ch...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 17, 2019</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7866</th>\n",
       "      <td>NCT03725722</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Atopic Dermatitis</td>\n",
       "      <td>This is a double-blind, multi-centre, randomi...</td>\n",
       "      <td>Dose-ranging Trial to Evaluate Delgocitinib Cr...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>December 28, 2018</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7941</th>\n",
       "      <td>NCT03720470</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Immune System Diseases</td>\n",
       "      <td>B7451029 is a Phase 3 study to investigate PF...</td>\n",
       "      <td>Study Evaluating Efficacy and Safety of PF-049...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 29, 2018</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8151</th>\n",
       "      <td>NCT03723915</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Stage IV Pancreatic Cancer AJCC v8</td>\n",
       "      <td>This phase II trial studies the side effects ...</td>\n",
       "      <td>Pembrolizumab and Pelareorep in Treating Patie...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>November 14, 2018</td>\n",
       "      <td>Lack of efficacy</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8230</th>\n",
       "      <td>NCT03725852</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Idiopathic Pulmonary Fibrosis</td>\n",
       "      <td>This is a randomized, double-blind, parallel-...</td>\n",
       "      <td>A Clinical Study to Test How Effective and Saf...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>September 27, 2018</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382289</th>\n",
       "      <td>NCT02575950</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Acne Vulgaris</td>\n",
       "      <td>An exploratory Phase 2, single, centre, prosp...</td>\n",
       "      <td>Explorative Trial Evaluating the Efficacy and ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 2016</td>\n",
       "      <td>Withdrawal by Subject</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382555</th>\n",
       "      <td>NCT02576938</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Atopic Dermatitis</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>A Study of Baricitinib (LY3009104) in Particip...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 2016</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>382580</th>\n",
       "      <td>NCT02574455</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>The primary objective of this study is to com...</td>\n",
       "      <td>Trial of Sacituzumab Govitecan in Participants...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>November 7, 2017</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385813</th>\n",
       "      <td>NCT02580877</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Type 1 Diabetes</td>\n",
       "      <td>The study is a 2 arm, multi-center, randomize...</td>\n",
       "      <td>Immune Effects of Oral Insulin in Relatives at...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 2016</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385849</th>\n",
       "      <td>NCT02586805</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hereditary Angioedema (HAE)</td>\n",
       "      <td>This is a phase 3, multicenter, randomized, d...</td>\n",
       "      <td>Efficacy and Safety Study of DX-2930 to Preven...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 3, 2016</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385932</th>\n",
       "      <td>NCT02586025</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>This is an Asia-Pacific regional, randomized,...</td>\n",
       "      <td>Study in Participants With Early-Stage or Loca...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 14, 2016</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385962</th>\n",
       "      <td>NCT02582866</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Epilepsy</td>\n",
       "      <td>Study is conducted to evaluate the long-term ...</td>\n",
       "      <td>A Clinical Study to Investigate the Long-term ...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>January 2016</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>385993</th>\n",
       "      <td>NCT02581930</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Stage IV Cutaneous Melanoma AJCC v6 and v7</td>\n",
       "      <td>This phase II trial studies how well ibrutini...</td>\n",
       "      <td>Ibrutinib in Treating Patients With Refractory...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>August 17, 2016</td>\n",
       "      <td>Lack of efficacy</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386006</th>\n",
       "      <td>NCT02588261</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Non-small Cell Lung Cancer (NSCLC)</td>\n",
       "      <td>The purpose of the study was to evaluate the ...</td>\n",
       "      <td>A Study of ASP8273 vs. Erlotinib or Gefitinib ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 11, 2016</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386008</th>\n",
       "      <td>NCT02583256</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Influenza</td>\n",
       "      <td>Safety, Immunogenicity of an Adjuvanted Quadr...</td>\n",
       "      <td>Clinical Study to Evaluate Safety, Immunogenic...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>January 29, 2016</td>\n",
       "      <td>Withdrawal by Subject</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386245</th>\n",
       "      <td>NCT02582749</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prostate Neoplasms</td>\n",
       "      <td>Newly diagnosed metastatic prostate cancer su...</td>\n",
       "      <td>Androgen Deprivation Therapy +/- Radium-223 Di...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>April 2016</td>\n",
       "      <td>Sponsor/physician terminated</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386271</th>\n",
       "      <td>NCT02588339</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>GVHD</td>\n",
       "      <td>This study will test PANO in combination with...</td>\n",
       "      <td>Panobinostat (LBH589): Acute Graft Versus Host...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>March 4, 2016</td>\n",
       "      <td>Lack of efficacy</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386430</th>\n",
       "      <td>NCT02583048</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>HIV Infections</td>\n",
       "      <td>This study evaluated the safety, tolerability...</td>\n",
       "      <td>Evaluating the Safety, Tolerability, and Pharm...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>August 15, 2016</td>\n",
       "      <td>Withdrawal by Subject</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386542</th>\n",
       "      <td>NCT02587221</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Influenza</td>\n",
       "      <td>A Phase III, Randomized, Observer-Blind, Cont...</td>\n",
       "      <td>Clinical Study to Evaluate the Efficacy, Safet...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>September 30, 2016</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386549</th>\n",
       "      <td>NCT02584257</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Mild Persistent Asthma</td>\n",
       "      <td>The purpose of this study is to demonstrate t...</td>\n",
       "      <td>Pharmacodynamic Bioequivalence of Metered Dose...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>April 2016</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386620</th>\n",
       "      <td>NCT03150589</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Age-Related Macular Degeneration</td>\n",
       "      <td>This is a randomised, double-masked, parallel...</td>\n",
       "      <td>A Study to Compare SB11 (Proposed Ranibizumab ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>March 14, 2018</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386652</th>\n",
       "      <td>NCT03155178</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Bacterial Recovery of Skin Flora Post-product ...</td>\n",
       "      <td>Evaluate persistent antimicrobial effectivene...</td>\n",
       "      <td>In Vivo Preoperative Skin Preparation Persiste...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>December 5, 2016</td>\n",
       "      <td>Lack of efficacy</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386667</th>\n",
       "      <td>NCT03152019</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hemorrhagic Hereditary Telangiectasia (HHT)</td>\n",
       "      <td>The recognized manifestations of HHT are all ...</td>\n",
       "      <td>Efficacy and Safety of a 0.1% Tacrolimus Nasal...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 22, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386713</th>\n",
       "      <td>NCT03155997</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Endocrine Therapy With or Without Abemaciclib ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 12, 2017</td>\n",
       "      <td>Lack of efficacy</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386893</th>\n",
       "      <td>NCT03154047</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>AL Amyloidosis</td>\n",
       "      <td>The objective of this study is to evaluate th...</td>\n",
       "      <td>Study in Subjects With Light Chain (AL) Amyloi...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>June 14, 2017</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>386925</th>\n",
       "      <td>NCT03158285</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Arthritis, Psoriatic</td>\n",
       "      <td>The primary purpose of this study is to evalu...</td>\n",
       "      <td>A Study Evaluating the Efficacy and Safety of ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 12, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387022</th>\n",
       "      <td>NCT03150719</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>Study VX16-661-114 (Study 114) is a Phase 3b,...</td>\n",
       "      <td>A Study to Evaluate Safety, Efficacy, and Tole...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>May 24, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387038</th>\n",
       "      <td>NCT03159611</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Sequelae of Perinatal Brain Injury</td>\n",
       "      <td>Purpose of the study:\\r\\r - To assess the cli...</td>\n",
       "      <td>Efficacy and Safety Clinical Trial of Tenoten ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 19, 2016</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387042</th>\n",
       "      <td>NCT03158220</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Human Papillomavirus Infection</td>\n",
       "      <td>This study will assess the safety and immunog...</td>\n",
       "      <td>Immunogenicity and Tolerability of Broad Spect...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>September 20, 2017</td>\n",
       "      <td>Withdrawal by Subject</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387054</th>\n",
       "      <td>NCT03157089</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>The main objective is to assess the efficacy ...</td>\n",
       "      <td>Testing Afatinib in Combination With Pembroliz...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>November 2, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387133</th>\n",
       "      <td>NCT03158311</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>The purpose of this trial was to demonstrate ...</td>\n",
       "      <td>Study to Compare QVM149 and Free Triple Combin...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>February 5, 2018</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387225</th>\n",
       "      <td>NCT03156621</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Homozygous Familial Hypercholesterolemia</td>\n",
       "      <td>The primary objective of the study is to demo...</td>\n",
       "      <td>Study in Participants With Homozygous Familial...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 3, 2017</td>\n",
       "      <td>Adverse reaction(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387280</th>\n",
       "      <td>NCT03158688</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Refractory Multiple Myeloma</td>\n",
       "      <td>Compare carfizomib, dexamethasone, and daratu...</td>\n",
       "      <td>Study of Carfilzomib, Daratumumab and Dexameth...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>June 13, 2017</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387300</th>\n",
       "      <td>NCT03152552</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Diabetes Mellitus and Heart Failure</td>\n",
       "      <td>This was a dose-finding study to evaluate the...</td>\n",
       "      <td>A Dose Finding Study to Assess the Effect of L...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>July 25, 2017</td>\n",
       "      <td>Death of participant(s)</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>387803</th>\n",
       "      <td>NCT04161144</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Nicotine Dependence</td>\n",
       "      <td>The purpose of this study is to examine the e...</td>\n",
       "      <td>Enhancing Self Regulation Among Smokers</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>October 1, 2018</td>\n",
       "      <td>Withdrawal by Subject</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1891 rows × 9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             Nct_id    Phase  \\\n",
       "6097    NCT03118739  Phase 2   \n",
       "6104    NCT03111732  Phase 2   \n",
       "6125    NCT03117361  Phase 2   \n",
       "6136    NCT03118765  Phase 2   \n",
       "6353    NCT03114657  Phase 3   \n",
       "6466    NCT03110770  Phase 2   \n",
       "6655    NCT03118947  Phase 2   \n",
       "6656    NCT03110380  Phase 3   \n",
       "6702    NCT03115112  Phase 3   \n",
       "6809    NCT03115476  Phase 3   \n",
       "6814    NCT03110562  Phase 3   \n",
       "6815    NCT03119701  Phase 2   \n",
       "6834    NCT03116152  Phase 2   \n",
       "6910    NCT03181503  Phase 2   \n",
       "7187    NCT03189719  Phase 3   \n",
       "7228    NCT03180801  Phase 2   \n",
       "7242    NCT03187262  Phase 2   \n",
       "7319    NCT03180528  Phase 2   \n",
       "7347    NCT03188991  Phase 2   \n",
       "7469    NCT03187301  Phase 2   \n",
       "7488    NCT03188185  Phase 3   \n",
       "7585    NCT03185481  Phase 2   \n",
       "7598    NCT03184987  Phase 3   \n",
       "7602    NCT03180619  Phase 2   \n",
       "7619    NCT03189446  Phase 2   \n",
       "7799    NCT03722576  Phase 2   \n",
       "7866    NCT03725722  Phase 2   \n",
       "7941    NCT03720470  Phase 3   \n",
       "8151    NCT03723915  Phase 2   \n",
       "8230    NCT03725852  Phase 2   \n",
       "...             ...      ...   \n",
       "382289  NCT02575950  Phase 2   \n",
       "382555  NCT02576938  Phase 2   \n",
       "382580  NCT02574455  Phase 3   \n",
       "385813  NCT02580877  Phase 2   \n",
       "385849  NCT02586805  Phase 3   \n",
       "385932  NCT02586025  Phase 3   \n",
       "385962  NCT02582866  Phase 3   \n",
       "385993  NCT02581930  Phase 2   \n",
       "386006  NCT02588261  Phase 3   \n",
       "386008  NCT02583256  Phase 3   \n",
       "386245  NCT02582749  Phase 2   \n",
       "386271  NCT02588339  Phase 2   \n",
       "386430  NCT02583048  Phase 2   \n",
       "386542  NCT02587221  Phase 3   \n",
       "386549  NCT02584257  Phase 3   \n",
       "386620  NCT03150589  Phase 3   \n",
       "386652  NCT03155178  Phase 2   \n",
       "386667  NCT03152019  Phase 2   \n",
       "386713  NCT03155997  Phase 3   \n",
       "386893  NCT03154047  Phase 2   \n",
       "386925  NCT03158285  Phase 3   \n",
       "387022  NCT03150719  Phase 3   \n",
       "387038  NCT03159611  Phase 3   \n",
       "387042  NCT03158220  Phase 3   \n",
       "387054  NCT03157089  Phase 2   \n",
       "387133  NCT03158311  Phase 3   \n",
       "387225  NCT03156621  Phase 3   \n",
       "387280  NCT03158688  Phase 3   \n",
       "387300  NCT03152552  Phase 2   \n",
       "387803  NCT04161144  Phase 2   \n",
       "\n",
       "                                                Condition  \\\n",
       "6097                                      Type 2 Diabetes   \n",
       "6104                                   Gallbladder Cancer   \n",
       "6125                                     Multiple Myeloma   \n",
       "6136    Mild to Moderate Chronic Obstructive Pulmonary...   \n",
       "6353                                  Alzheimer's Disease   \n",
       "6466                                 RNA Virus Infections   \n",
       "6655      Agitation and Aggression in Alzheimer's Disease   \n",
       "6656                                      HIV-1-infection   \n",
       "6702                             Type 2 Diabetes Mellitus   \n",
       "6809                              Squamous Cell Carcinoma   \n",
       "6814                                     Multiple Myeloma   \n",
       "6815                                  Multi Organ Failure   \n",
       "6834                   Esophageal Squamous Cell Carcinoma   \n",
       "6910                                    Prurigo Nodularis   \n",
       "7187                                 Esophageal Neoplasms   \n",
       "7228                                            Influenza   \n",
       "7242                        Waldenström Macroglobulinemia   \n",
       "7319                            Skin Basal Cell Carcinoma   \n",
       "7347                  Pancreatic Mucinous-Cystic Neoplasm   \n",
       "7469                    Off Episodes of Parkinson Disease   \n",
       "7488                            Major Depressive Disorder   \n",
       "7585          Parkinson's Disease With Motor Fluctuations   \n",
       "7598                                               Asthma   \n",
       "7602                                  Chronic Hepatitis B   \n",
       "7619                        Clear Cell Endometrial Cancer   \n",
       "7799                       Primary Sclerosing Cholangitis   \n",
       "7866                                    Atopic Dermatitis   \n",
       "7941                               Immune System Diseases   \n",
       "8151                   Stage IV Pancreatic Cancer AJCC v8   \n",
       "8230                        Idiopathic Pulmonary Fibrosis   \n",
       "...                                                   ...   \n",
       "382289                                      Acne Vulgaris   \n",
       "382555                                  Atopic Dermatitis   \n",
       "382580                                      Breast Cancer   \n",
       "385813                                    Type 1 Diabetes   \n",
       "385849                        Hereditary Angioedema (HAE)   \n",
       "385932                                      Breast Cancer   \n",
       "385962                                           Epilepsy   \n",
       "385993         Stage IV Cutaneous Melanoma AJCC v6 and v7   \n",
       "386006                 Non-small Cell Lung Cancer (NSCLC)   \n",
       "386008                                          Influenza   \n",
       "386245                                 Prostate Neoplasms   \n",
       "386271                                               GVHD   \n",
       "386430                                     HIV Infections   \n",
       "386542                                          Influenza   \n",
       "386549                             Mild Persistent Asthma   \n",
       "386620                   Age-Related Macular Degeneration   \n",
       "386652  Bacterial Recovery of Skin Flora Post-product ...   \n",
       "386667        Hemorrhagic Hereditary Telangiectasia (HHT)   \n",
       "386713                                      Breast Cancer   \n",
       "386893                                     AL Amyloidosis   \n",
       "386925                               Arthritis, Psoriatic   \n",
       "387022                                    Cystic Fibrosis   \n",
       "387038                 Sequelae of Perinatal Brain Injury   \n",
       "387042                     Human Papillomavirus Infection   \n",
       "387054                     Carcinoma, Non-Small-Cell Lung   \n",
       "387133                                             Asthma   \n",
       "387225           Homozygous Familial Hypercholesterolemia   \n",
       "387280                        Refractory Multiple Myeloma   \n",
       "387300                Diabetes Mellitus and Heart Failure   \n",
       "387803                                Nicotine Dependence   \n",
       "\n",
       "                                                  Summary  \\\n",
       "6097     The purpose of this clinical research study i...   \n",
       "6104     Background:\\r\\r Biliary tract cancers are rar...   \n",
       "6125     This is a multi-center, open-label, single ar...   \n",
       "6136     Pharmacodynamic and Pharmacokinetic Dose Rang...   \n",
       "6353     This randomized, double-blind, placebo-contro...   \n",
       "6466     This was a multicenter, randomized study to e...   \n",
       "6655     To evaluate the safety and tolerability of pi...   \n",
       "6656     The primary objective of this study is to eva...   \n",
       "6702     The purpose of this study is to investigate t...   \n",
       "6809     One of the main reasons for treating actinic ...   \n",
       "6814     This Phase 3, 2-arm, randomized, active compa...   \n",
       "6815     A study to assess effectiveness and safety of...   \n",
       "6834     Efficacy and safety evaluation of IBI308 vers...   \n",
       "6910     The aim of this study is to assess the safety...   \n",
       "7187     The purpose of this trial is to evaluate effi...   \n",
       "7228     FLU-v is a broad spectrum influenza vaccine t...   \n",
       "7242     This research study is studying Daratumumab a...   \n",
       "7319     This phase 2 trial studies how well remetinos...   \n",
       "7347     This study will evaluate intracystic NanoPac®...   \n",
       "7469     A cardiac safety study of an investigational ...   \n",
       "7488     This study will evaluate the efficacy, safety...   \n",
       "7585     The purpose of this study is to evaluate the ...   \n",
       "7598     Despite availability of treatments and publis...   \n",
       "7602     The primary objective of this study is to eva...   \n",
       "7619     The purpose of this study is to determine the...   \n",
       "7799     To examine the safety, tolerability, and effi...   \n",
       "7866     This is a double-blind, multi-centre, randomi...   \n",
       "7941     B7451029 is a Phase 3 study to investigate PF...   \n",
       "8151     This phase II trial studies the side effects ...   \n",
       "8230     This is a randomized, double-blind, parallel-...   \n",
       "...                                                   ...   \n",
       "382289   An exploratory Phase 2, single, centre, prosp...   \n",
       "382555   The purpose of this study is to evaluate the ...   \n",
       "382580   The primary objective of this study is to com...   \n",
       "385813   The study is a 2 arm, multi-center, randomize...   \n",
       "385849   This is a phase 3, multicenter, randomized, d...   \n",
       "385932   This is an Asia-Pacific regional, randomized,...   \n",
       "385962   Study is conducted to evaluate the long-term ...   \n",
       "385993   This phase II trial studies how well ibrutini...   \n",
       "386006   The purpose of the study was to evaluate the ...   \n",
       "386008   Safety, Immunogenicity of an Adjuvanted Quadr...   \n",
       "386245   Newly diagnosed metastatic prostate cancer su...   \n",
       "386271   This study will test PANO in combination with...   \n",
       "386430   This study evaluated the safety, tolerability...   \n",
       "386542   A Phase III, Randomized, Observer-Blind, Cont...   \n",
       "386549   The purpose of this study is to demonstrate t...   \n",
       "386620   This is a randomised, double-masked, parallel...   \n",
       "386652   Evaluate persistent antimicrobial effectivene...   \n",
       "386667   The recognized manifestations of HHT are all ...   \n",
       "386713   The purpose of this study is to evaluate the ...   \n",
       "386893   The objective of this study is to evaluate th...   \n",
       "386925   The primary purpose of this study is to evalu...   \n",
       "387022   Study VX16-661-114 (Study 114) is a Phase 3b,...   \n",
       "387038   Purpose of the study:\\r\\r - To assess the cli...   \n",
       "387042   This study will assess the safety and immunog...   \n",
       "387054   The main objective is to assess the efficacy ...   \n",
       "387133   The purpose of this trial was to demonstrate ...   \n",
       "387225   The primary objective of the study is to demo...   \n",
       "387280   Compare carfizomib, dexamethasone, and daratu...   \n",
       "387300   This was a dose-finding study to evaluate the...   \n",
       "387803   The purpose of this study is to examine the e...   \n",
       "\n",
       "                                                    Title  \\\n",
       "6097    Intensive Uric Acid Lowering With Verinurad an...   \n",
       "6104    Pembrolizumab, a Monoclonal Antibody Against P...   \n",
       "6125    Trial of Plitidepsin (Aplidin®) in Combination...   \n",
       "6136    Pharmacodynamic and Pharmacokinetic Dose Rangi...   \n",
       "6353    A Study of Crenezumab Versus Placebo to Evalua...   \n",
       "6466    VRC 705: A Zika Virus DNA Vaccine in Healthy A...   \n",
       "6655    A Study of Pimavanserin for the Treatment of A...   \n",
       "6656    Switching to a Fixed Dose Combination of Bicte...   \n",
       "6702    Safety and Efficacy of Bexagliflozin Compared ...   \n",
       "6809    A Trial to Compare the Incidence of Squamous C...   \n",
       "6814    Bortezomib, Selinexor, and Dexamethasone in Pa...   \n",
       "6815    Efficacy and Safety of FP-1201-lyo (Interferon...   \n",
       "6834    Study of IBI308 With Advanced/Metastatic Esoph...   \n",
       "6910             Safety and Efficacy of Nemolizumab in PN   \n",
       "7187    First-line Esophageal Carcinoma Study With Che...   \n",
       "7228    Efficacy of FLU-v in an H1N1 Influenza Human C...   \n",
       "7242    A Study of Daratumumab in Patients With Relaps...   \n",
       "7319    Topical Remetinostat in Treating Patient With ...   \n",
       "7347    Intracystic Injection of NanoPac® in Subjects ...   \n",
       "7469    A Cardiac Safety Study of an Investigational D...   \n",
       "7488    A Study of ALKS 5461 for Treatment Refractory ...   \n",
       "7585    Safety and Tolerability of PF-06649751 in Park...   \n",
       "7598    A Long-term Safety Study of Fixed Dose Combina...   \n",
       "7602    Study to Evaluate the Safety and Efficacy of S...   \n",
       "7619    Vaginal Cuff Brachytherapy Followed by Chemoth...   \n",
       "7799    Vidofludimus Calcium for Primary Sclerosing Ch...   \n",
       "7866    Dose-ranging Trial to Evaluate Delgocitinib Cr...   \n",
       "7941    Study Evaluating Efficacy and Safety of PF-049...   \n",
       "8151    Pembrolizumab and Pelareorep in Treating Patie...   \n",
       "8230    A Clinical Study to Test How Effective and Saf...   \n",
       "...                                                   ...   \n",
       "382289  Explorative Trial Evaluating the Efficacy and ...   \n",
       "382555  A Study of Baricitinib (LY3009104) in Particip...   \n",
       "382580  Trial of Sacituzumab Govitecan in Participants...   \n",
       "385813  Immune Effects of Oral Insulin in Relatives at...   \n",
       "385849  Efficacy and Safety Study of DX-2930 to Preven...   \n",
       "385932  Study in Participants With Early-Stage or Loca...   \n",
       "385962  A Clinical Study to Investigate the Long-term ...   \n",
       "385993  Ibrutinib in Treating Patients With Refractory...   \n",
       "386006  A Study of ASP8273 vs. Erlotinib or Gefitinib ...   \n",
       "386008  Clinical Study to Evaluate Safety, Immunogenic...   \n",
       "386245  Androgen Deprivation Therapy +/- Radium-223 Di...   \n",
       "386271  Panobinostat (LBH589): Acute Graft Versus Host...   \n",
       "386430  Evaluating the Safety, Tolerability, and Pharm...   \n",
       "386542  Clinical Study to Evaluate the Efficacy, Safet...   \n",
       "386549  Pharmacodynamic Bioequivalence of Metered Dose...   \n",
       "386620  A Study to Compare SB11 (Proposed Ranibizumab ...   \n",
       "386652  In Vivo Preoperative Skin Preparation Persiste...   \n",
       "386667  Efficacy and Safety of a 0.1% Tacrolimus Nasal...   \n",
       "386713  Endocrine Therapy With or Without Abemaciclib ...   \n",
       "386893  Study in Subjects With Light Chain (AL) Amyloi...   \n",
       "386925  A Study Evaluating the Efficacy and Safety of ...   \n",
       "387022  A Study to Evaluate Safety, Efficacy, and Tole...   \n",
       "387038  Efficacy and Safety Clinical Trial of Tenoten ...   \n",
       "387042  Immunogenicity and Tolerability of Broad Spect...   \n",
       "387054  Testing Afatinib in Combination With Pembroliz...   \n",
       "387133  Study to Compare QVM149 and Free Triple Combin...   \n",
       "387225  Study in Participants With Homozygous Familial...   \n",
       "387280  Study of Carfilzomib, Daratumumab and Dexameth...   \n",
       "387300  A Dose Finding Study to Assess the Effect of L...   \n",
       "387803            Enhancing Self Regulation Among Smokers   \n",
       "\n",
       "                          Model                Date  \\\n",
       "6097        Parallel Assignment        May 18, 2017   \n",
       "6104    Single Group Assignment       June 14, 2017   \n",
       "6125    Single Group Assignment         May 8, 2017   \n",
       "6136        Parallel Assignment      March 24, 2017   \n",
       "6353        Parallel Assignment      March 29, 2017   \n",
       "6466      Sequential Assignment      March 29, 2017   \n",
       "6655    Single Group Assignment   February 23, 2017   \n",
       "6656        Parallel Assignment       June 12, 2017   \n",
       "6702        Parallel Assignment    October 12, 2017   \n",
       "6809        Parallel Assignment       June 16, 2017   \n",
       "6814       Crossover Assignment        May 24, 2017   \n",
       "6815        Parallel Assignment   February 18, 2017   \n",
       "6834        Parallel Assignment        May 10, 2017   \n",
       "6910        Parallel Assignment     October 2, 2017   \n",
       "7187        Parallel Assignment       July 25, 2017   \n",
       "7228        Parallel Assignment     August 18, 2016   \n",
       "7242    Single Group Assignment   November 27, 2017   \n",
       "7319    Single Group Assignment        July 7, 2018   \n",
       "7347      Sequential Assignment  September 29, 2017   \n",
       "7469       Crossover Assignment      August 3, 2017   \n",
       "7488        Parallel Assignment       June 12, 2017   \n",
       "7585        Parallel Assignment        July 6, 2017   \n",
       "7598        Parallel Assignment       June 22, 2017   \n",
       "7602        Parallel Assignment       June 29, 2017   \n",
       "7619    Single Group Assignment     October 2, 2017   \n",
       "7799    Single Group Assignment       June 17, 2019   \n",
       "7866        Parallel Assignment   December 28, 2018   \n",
       "7941        Parallel Assignment    October 29, 2018   \n",
       "8151    Single Group Assignment   November 14, 2018   \n",
       "8230        Parallel Assignment  September 27, 2018   \n",
       "...                         ...                 ...   \n",
       "382289      Parallel Assignment           June 2016   \n",
       "382555      Parallel Assignment       February 2016   \n",
       "382580      Parallel Assignment    November 7, 2017   \n",
       "385813      Parallel Assignment        January 2016   \n",
       "385849      Parallel Assignment       March 3, 2016   \n",
       "385932      Parallel Assignment      March 14, 2016   \n",
       "385962  Single Group Assignment        January 2016   \n",
       "385993  Single Group Assignment     August 17, 2016   \n",
       "386006      Parallel Assignment   February 11, 2016   \n",
       "386008      Parallel Assignment    January 29, 2016   \n",
       "386245      Parallel Assignment          April 2016   \n",
       "386271  Single Group Assignment       March 4, 2016   \n",
       "386430      Parallel Assignment     August 15, 2016   \n",
       "386542      Parallel Assignment  September 30, 2016   \n",
       "386549     Crossover Assignment          April 2016   \n",
       "386620      Parallel Assignment      March 14, 2018   \n",
       "386652      Parallel Assignment    December 5, 2016   \n",
       "386667      Parallel Assignment        May 22, 2017   \n",
       "386713      Parallel Assignment       July 12, 2017   \n",
       "386893  Single Group Assignment       June 14, 2017   \n",
       "386925      Parallel Assignment       July 12, 2017   \n",
       "387022      Parallel Assignment        May 24, 2017   \n",
       "387038      Parallel Assignment   February 19, 2016   \n",
       "387042      Parallel Assignment  September 20, 2017   \n",
       "387054  Single Group Assignment    November 2, 2017   \n",
       "387133      Parallel Assignment    February 5, 2018   \n",
       "387225      Parallel Assignment     October 3, 2017   \n",
       "387280      Parallel Assignment       June 13, 2017   \n",
       "387300      Parallel Assignment       July 25, 2017   \n",
       "387803      Parallel Assignment     October 1, 2018   \n",
       "\n",
       "                              reason  date  \n",
       "6097           Withdrawal by Subject  True  \n",
       "6104                Lack of efficacy  True  \n",
       "6125             Adverse reaction(s)  True  \n",
       "6136             Adverse reaction(s)  True  \n",
       "6353             Adverse reaction(s)  True  \n",
       "6466         Death of participant(s)  True  \n",
       "6655             Adverse reaction(s)  True  \n",
       "6656             Adverse reaction(s)  True  \n",
       "6702             Adverse reaction(s)  True  \n",
       "6809         Death of participant(s)  True  \n",
       "6814         Death of participant(s)  True  \n",
       "6815             Adverse reaction(s)  True  \n",
       "6834             Adverse reaction(s)  True  \n",
       "6910             Adverse reaction(s)  True  \n",
       "7187         Death of participant(s)  True  \n",
       "7228             Adverse reaction(s)  True  \n",
       "7242                Lack of efficacy  True  \n",
       "7319             Adverse reaction(s)  True  \n",
       "7347           Withdrawal by Subject  True  \n",
       "7469             Adverse reaction(s)  True  \n",
       "7488             Adverse reaction(s)  True  \n",
       "7585             Adverse reaction(s)  True  \n",
       "7598             Adverse reaction(s)  True  \n",
       "7602             Adverse reaction(s)  True  \n",
       "7619             Adverse reaction(s)  True  \n",
       "7799             Adverse reaction(s)  True  \n",
       "7866             Adverse reaction(s)  True  \n",
       "7941             Adverse reaction(s)  True  \n",
       "8151                Lack of efficacy  True  \n",
       "8230         Death of participant(s)  True  \n",
       "...                              ...   ...  \n",
       "382289         Withdrawal by Subject  True  \n",
       "382555           Adverse reaction(s)  True  \n",
       "382580       Death of participant(s)  True  \n",
       "385813           Adverse reaction(s)  True  \n",
       "385849           Adverse reaction(s)  True  \n",
       "385932           Adverse reaction(s)  True  \n",
       "385962       Death of participant(s)  True  \n",
       "385993              Lack of efficacy  True  \n",
       "386006           Adverse reaction(s)  True  \n",
       "386008         Withdrawal by Subject  True  \n",
       "386245  Sponsor/physician terminated  True  \n",
       "386271              Lack of efficacy  True  \n",
       "386430         Withdrawal by Subject  True  \n",
       "386542           Adverse reaction(s)  True  \n",
       "386549           Adverse reaction(s)  True  \n",
       "386620           Adverse reaction(s)  True  \n",
       "386652              Lack of efficacy  True  \n",
       "386667           Adverse reaction(s)  True  \n",
       "386713              Lack of efficacy  True  \n",
       "386893       Death of participant(s)  True  \n",
       "386925           Adverse reaction(s)  True  \n",
       "387022           Adverse reaction(s)  True  \n",
       "387038           Adverse reaction(s)  True  \n",
       "387042         Withdrawal by Subject  True  \n",
       "387054           Adverse reaction(s)  True  \n",
       "387133           Adverse reaction(s)  True  \n",
       "387225           Adverse reaction(s)  True  \n",
       "387280       Death of participant(s)  True  \n",
       "387300       Death of participant(s)  True  \n",
       "387803         Withdrawal by Subject  True  \n",
       "\n",
       "[1891 rows x 9 columns]"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "\n",
    "df.loc[df.reason.str.contains('Adverse'), 'reason'] = 'Adverse reaction(s)'\n",
    "df.loc[df.reason.str.contains('adverse'), 'reason'] = 'Adverse reaction(s)'\n",
    "\n",
    "df.loc[df.reason.str.contains('Death'), 'reason'] = 'Death of participant(s)'\n",
    "df.loc[df.reason.str.contains('death'), 'reason'] = 'Death of participant(s)'\n",
    "\n",
    "df.loc[df.reason.str.contains('Progression'), 'reason'] = 'Lack of efficacy'\n",
    "df.loc[df.reason.str.contains('progression'), 'reason'] = 'Lack of efficacy'\n",
    "\n",
    "df.loc[df.reason.str.contains('Progressive'), 'reason'] = 'Lack of efficacy'\n",
    "df.loc[df.reason.str.contains('progressive'), 'reason'] = 'Lack of efficacy'\n",
    "\n",
    "df.loc[df.reason.str.contains('treatment'), 'reason'] = 'Lack of efficacy'\n",
    "df.loc[df.reason.str.contains('Treatment'), 'reason'] = 'Lack of efficacy'\n",
    "\n",
    "df.loc[df.reason.str.contains('Compliance'), 'reason'] = 'Non-compliance'\n",
    "df.loc[df.reason.str.contains('compliance'), 'reason'] = 'Non-compliance'\n",
    "\n",
    "df.loc[df.reason.str.contains('Deviation'), 'reason'] = 'Non-compliance'\n",
    "df.loc[df.reason.str.contains('deviation'), 'reason'] = 'Non-compliance'\n",
    "\n",
    "df.loc[df.reason.str.contains('Terminate'), 'reason'] = 'Sponsor/physician terminated'\n",
    "df.loc[df.reason.str.contains('terminate'), 'reason'] = 'Sponsor/physician terminated'\n",
    "\n",
    "df.loc[df.reason.str.contains('Sponsor'), 'reason'] = 'Sponsor/physician terminated'\n",
    "df.loc[df.reason.str.contains('sponsor'), 'reason'] = 'Sponsor/physician terminated'\n",
    "\n",
    "df.loc[df.reason.str.contains('Withdrawal'), 'reason'] = 'Withdrawal by Subject'\n",
    "df.loc[df.reason.str.contains('withdrawal'), 'reason'] = 'Withdrawal by Subject'\n",
    "\n",
    "df=df[~df.reason.str.contains(\"NOT COMPLETED BEC\")]\n",
    "\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "\n",
    "import seaborn as sns\n",
    "sns.set(style=\"whitegrid\", color_codes=True)\n",
    "ax1 = sns.countplot(x=\"reason\",data=df, order = df['reason'].value_counts().index)\n",
    "ax1.set_title(\"Reason of Clinical trial Failure\")\n",
    "plt.ylabel(\"Number of Clinical Trials\")\n",
    "plt.xlabel(\"Failure Reason\")\n",
    "for item in ax1.get_xticklabels():\n",
    "    item.set_rotation(90)\n",
    "    \n",
    "plt.savefig('2016+_failure_reason.png', dpi=300, bbox_inches='tight')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import seaborn as sns\n",
    "sns.set(style=\"darkgrid\")\n",
    "ax1 = sns.countplot(x=\"reason\", data=df, order = df['reason'].value_counts().index)\n",
    "ax1.set_title(\"Reason of clinical trial failure\")\n",
    "for item in ax1.get_xticklabels():\n",
    "    item.set_rotation(90)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Nct_id</th>\n",
       "      <th>Phase</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Title</th>\n",
       "      <th>Model</th>\n",
       "      <th>Date</th>\n",
       "      <th>reason</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03118765</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Mild to Moderate Chronic Obstructive Pulmonary...</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rang...</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rangi...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>24-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03114657</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Alzheimer's Disease</td>\n",
       "      <td>This randomized, double-blind, placebo-contro...</td>\n",
       "      <td>A Study of Crenezumab Versus Placebo to Evalua...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03110380</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>HIV-1-infection</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Switching to a Fixed Dose Combination of Bicte...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>12-Jun-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Randomized and Never...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT03115112</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Type 2 Diabetes Mellitus</td>\n",
       "      <td>The purpose of this study is to investigate t...</td>\n",
       "      <td>Safety and Efficacy of Bexagliflozin Compared ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>12-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT03119701</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Multi Organ Failure</td>\n",
       "      <td>A study to assess effectiveness and safety of...</td>\n",
       "      <td>Efficacy and Safety of FP-1201-lyo (Interferon...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>18-Feb-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Adverse Event...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT03181503</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Prurigo Nodularis</td>\n",
       "      <td>The aim of this study is to assess the safety...</td>\n",
       "      <td>Safety and Efficacy of Nemolizumab in PN</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>2-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT03180801</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Influenza</td>\n",
       "      <td>FLU-v is a broad spectrum influenza vaccine t...</td>\n",
       "      <td>Efficacy of FLU-v in an H1N1 Influenza Human C...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>18-Aug-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Physician Decision, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT03180528</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Skin Basal Cell Carcinoma</td>\n",
       "      <td>This phase 2 trial studies how well remetinos...</td>\n",
       "      <td>Topical Remetinostat in Treating Patient With ...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>7-Jul-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT03187301</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Off Episodes of Parkinson Disease</td>\n",
       "      <td>A cardiac safety study of an investigational ...</td>\n",
       "      <td>A Cardiac Safety Study of an Investigational D...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>3-Aug-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT03185481</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Parkinson's Disease With Motor Fluctuations</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Safety and Tolerability of PF-06649751 in Park...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>6-Jul-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NCT03184987</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Despite availability of treatments and publis...</td>\n",
       "      <td>A Long-term Safety Study of Fixed Dose Combina...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>22-Jun-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>NCT03180619</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Chronic Hepatitis B</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Study to Evaluate the Safety and Efficacy of S...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Jun-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrew Consent, De...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NCT03189446</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Clear Cell Endometrial Cancer</td>\n",
       "      <td>The purpose of this study is to determine the...</td>\n",
       "      <td>Vaginal Cuff Brachytherapy Followed by Chemoth...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>2-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT03722576</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Primary Sclerosing Cholangitis</td>\n",
       "      <td>To examine the safety, tolerability, and effi...</td>\n",
       "      <td>Vidofludimus Calcium for Primary Sclerosing Ch...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>17-Jun-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NCT03922750</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Diabetes Mellitus, Type 2</td>\n",
       "      <td>This study compares insulin 287 (a possible n...</td>\n",
       "      <td>A Research Study in People With Type 2 Diabete...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>9-May-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Unclassified, Advers...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NCT03686033</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Photosensitive Epilepsy</td>\n",
       "      <td>The primary purpose of the study is to assess...</td>\n",
       "      <td>A Study to Evaluate the Pharmacodynamic Activi...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>31-Oct-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NCT03684044</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Influenza</td>\n",
       "      <td>This study will evaluate the efficacy, safety...</td>\n",
       "      <td>Study to Assess Efficacy and Safety of Baloxav...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>8-Jan-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NCT03682705</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Rheumatoid Arthritis (RA)</td>\n",
       "      <td>This was a phase 2 study to evaluate the safe...</td>\n",
       "      <td>A Study to Investigate the Safety and Efficacy...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>8-Oct-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>NCT04401202</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>SARS-CoV-2</td>\n",
       "      <td>Natural products with immunomodulation and an...</td>\n",
       "      <td>Nigella Sativa in COVID-19</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>21-May-20</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>NCT02942017</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Postpartum Depression</td>\n",
       "      <td>The purpose of this study was to determine if...</td>\n",
       "      <td>A Study to Evaluate Safety and Efficacy of SAG...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Jul-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NCT02945657</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Atopic Dermatitis</td>\n",
       "      <td>The purpose of this study is to assess the ph...</td>\n",
       "      <td>Pharmacokinetics and Safety of MM36 Topical Oi...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NCT02943460</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Primary Sclerosing Cholangitis</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Study to Evaluate the Safety, Tolerability, an...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Nov-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>NCT02942576</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Atrial Fibrillation</td>\n",
       "      <td>There are insufficient data on the safety and...</td>\n",
       "      <td>Edoxaban Treatment Versus Vitamin K Antagonist...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>21-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>NCT02949128</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Atypical Hemolytic Uremic Syndrome (aHUS)</td>\n",
       "      <td>The purpose of the study is to assess the saf...</td>\n",
       "      <td>Study of ALXN1210 in Complement Inhibitor Trea...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>18-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Failed to Meet Eligi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>NCT02943577</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Depressive Disorder, Major</td>\n",
       "      <td>This study will evaluate the efficacy, safety...</td>\n",
       "      <td>A Study of Rapastinel as Adjunctive Therapy in...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>2-Nov-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Protocol Violation, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>NCT03694275</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CDKL5 Deficiency Disease</td>\n",
       "      <td>The purpose of this study is to investigate t...</td>\n",
       "      <td>A Multicenter, Open-label, Pilot Study of Soti...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>10-Sep-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Reaso...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>NCT03697252</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>This is a Phase 2, randomized, double-blinded...</td>\n",
       "      <td>A Study to Assess Safety and Efficacy of KarXT...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>18-Sep-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NCT03693625</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Urticaria</td>\n",
       "      <td>This is a Phase II, multicenter, open-label e...</td>\n",
       "      <td>A Study to Evaluate the Long-term Safety and E...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>27-Sep-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NCT03699124</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Smallpox</td>\n",
       "      <td>This is a Phase 3 multicenter trial to evalua...</td>\n",
       "      <td>Freeze-Dried MVA-BN® Lot Consistency Smallpox ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>19-Jun-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NCT03610048</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Refractory Major Depressive Disorder</td>\n",
       "      <td>This study will assess the long-term safety a...</td>\n",
       "      <td>A Long Term Study of ALKS 5461 in the Treatmen...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>9-Aug-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Study terminated by ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>682</th>\n",
       "      <td>NCT03452189</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>End Stage Renal Disease</td>\n",
       "      <td>The purpose of this study is to determine if ...</td>\n",
       "      <td>The Effect of an Antibiotic on the Production ...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>27-Nov-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, insuf...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>683</th>\n",
       "      <td>NCT02787304</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Non-Alcoholic Steatohepatitis</td>\n",
       "      <td>The purpose of this study is to determine if ...</td>\n",
       "      <td>Volixibat (SHP626) in the Treatment of Adults ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>24-Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>684</th>\n",
       "      <td>NCT02782741</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Glycogen Storage Disease Type II;Pompe's Disease</td>\n",
       "      <td>Primary Objective:\\r\\r To determine the effec...</td>\n",
       "      <td>Study to Compare the Efficacy and Safety of En...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>2-Nov-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Other...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>685</th>\n",
       "      <td>NCT02786901</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Ocular Inflammation</td>\n",
       "      <td>Loteprednol Etabonate Ophthalmic Gel, (BID an...</td>\n",
       "      <td>LE Gel for the Treatment of Ocular Inflammatio...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Jun-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Physi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>686</th>\n",
       "      <td>NCT02788747</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Heart Failure</td>\n",
       "      <td>This was a randomized, double-blinded, placeb...</td>\n",
       "      <td>Effect of Elamipretide on Left Ventricular Fun...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Jun-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>687</th>\n",
       "      <td>NCT02781311</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alopecia</td>\n",
       "      <td>This study will evaluate the safety, tolerabi...</td>\n",
       "      <td>A Safety and Efficacy Study of Setipiprant Tab...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>14-Jul-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>688</th>\n",
       "      <td>NCT02787083</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Cystitis, Interstitial</td>\n",
       "      <td>Bladder pain syndrome/interstitial cystitis (...</td>\n",
       "      <td>A Pilot Study of the Effects of Mirabegron on ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Aug-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>689</th>\n",
       "      <td>NCT02781558</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hepatitis C Virus Infection</td>\n",
       "      <td>The primary objectives of this study are to e...</td>\n",
       "      <td>Efficacy and Safety of Sofosbuvir/Velpatasvir ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Jul-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>690</th>\n",
       "      <td>NCT02784704</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Complicated Appendicitis</td>\n",
       "      <td>This is a Phase 3, randomized, double-blind, ...</td>\n",
       "      <td>Efficacy and Safety Study of Eravacycline Comp...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>13-Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>691</th>\n",
       "      <td>NCT02780115</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Presbyopia</td>\n",
       "      <td>This is a safety, efficacy and pharmacokineti...</td>\n",
       "      <td>A Safety, Efficacy and Pharmacokinetic Study o...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>26-May-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>692</th>\n",
       "      <td>NCT03657095</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Pulmonary Arterial Hypertension</td>\n",
       "      <td>This is a multi-center, open-label study for ...</td>\n",
       "      <td>A Study With BPS-314d-MR-PAH-303 in Participan...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>10-Dec-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>693</th>\n",
       "      <td>NCT03909295</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Heart Failure With Preserved Ejection Fraction...</td>\n",
       "      <td>This study evaluated the safety and tolerabil...</td>\n",
       "      <td>An Open-label Extension Study Evaluating Safet...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>7-May-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>694</th>\n",
       "      <td>NCT03908970</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Atopic Dermatitis</td>\n",
       "      <td>To demonstrate the superiority of IMP (1% OPA...</td>\n",
       "      <td>Comparison Trial of OPA-15406 Ointment in Adul...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>25-Mar-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Physi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>695</th>\n",
       "      <td>NCT02648217</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetes Mellitus, Type 2</td>\n",
       "      <td>This trial is conducted in Africa and Asia. T...</td>\n",
       "      <td>Comparing Efficacy and Safety of Insulin Deglu...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>4-Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>696</th>\n",
       "      <td>NCT02644668</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Spinal Muscular Atrophy</td>\n",
       "      <td>This study will evaluate the pharmacodynamic ...</td>\n",
       "      <td>A Study of CK-2127107 in Patients With Spinal ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>14-Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>697</th>\n",
       "      <td>NCT02649231</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Primary Alcohol Use Disorder</td>\n",
       "      <td>96 recently detoxified alcoholics will be ran...</td>\n",
       "      <td>Ketamine for Reduction of Alcoholic Relapse</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>698</th>\n",
       "      <td>NCT02647866</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Abdominal Pain</td>\n",
       "      <td>The purpose of this study is to determine the...</td>\n",
       "      <td>Study of a Monoclonal Antibody KHK4083 in Mode...</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>Jun-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Disea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>699</th>\n",
       "      <td>NCT02648204</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetes Mellitus, Type 2</td>\n",
       "      <td>This trial is conducted in Asia, Europe and t...</td>\n",
       "      <td>Efficacy and Safety of Semaglutide Versus Dula...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>6-Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>700</th>\n",
       "      <td>NCT02580877</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Type 1 Diabetes</td>\n",
       "      <td>The study is a 2 arm, multi-center, randomize...</td>\n",
       "      <td>Immune Effects of Oral Insulin in Relatives at...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>701</th>\n",
       "      <td>NCT02586805</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hereditary Angioedema (HAE)</td>\n",
       "      <td>This is a phase 3, multicenter, randomized, d...</td>\n",
       "      <td>Efficacy and Safety Study of DX-2930 to Preven...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>3-Mar-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>702</th>\n",
       "      <td>NCT02587221</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Influenza</td>\n",
       "      <td>A Phase III, Randomized, Observer-Blind, Cont...</td>\n",
       "      <td>Clinical Study to Evaluate the Efficacy, Safet...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>30-Sep-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>703</th>\n",
       "      <td>NCT02584257</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Mild Persistent Asthma</td>\n",
       "      <td>The purpose of this study is to demonstrate t...</td>\n",
       "      <td>Pharmacodynamic Bioequivalence of Metered Dose...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>Apr-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>704</th>\n",
       "      <td>NCT03150589</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Age-Related Macular Degeneration</td>\n",
       "      <td>This is a randomised, double-masked, parallel...</td>\n",
       "      <td>A Study to Compare SB11 (Proposed Ranibizumab ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>14-Mar-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>705</th>\n",
       "      <td>NCT03152019</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hemorrhagic Hereditary Telangiectasia (HHT)</td>\n",
       "      <td>The recognized manifestations of HHT are all ...</td>\n",
       "      <td>Efficacy and Safety of a 0.1% Tacrolimus Nasal...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>22-May-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>706</th>\n",
       "      <td>NCT03150719</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Cystic Fibrosis</td>\n",
       "      <td>Study VX16-661-114 (Study 114) is a Phase 3b,...</td>\n",
       "      <td>A Study to Evaluate Safety, Efficacy, and Tole...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>24-May-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>707</th>\n",
       "      <td>NCT03159611</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Sequelae of Perinatal Brain Injury</td>\n",
       "      <td>Purpose of the study:\\r\\r - To assess the cli...</td>\n",
       "      <td>Efficacy and Safety Clinical Trial of Tenoten ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>19-Feb-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Did Not Meet Inclusi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>708</th>\n",
       "      <td>NCT03158311</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>The purpose of this trial was to demonstrate ...</td>\n",
       "      <td>Study to Compare QVM149 and Free Triple Combin...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>5-Feb-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Subject/Guardian Dec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>709</th>\n",
       "      <td>NCT03156621</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Homozygous Familial Hypercholesterolemia</td>\n",
       "      <td>The primary objective of the study is to demo...</td>\n",
       "      <td>Study in Participants With Homozygous Familial...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>3-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>710</th>\n",
       "      <td>NCT03846219</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Relapsing-Remitting Multiple Sclerosis (RRMS)</td>\n",
       "      <td>This is a Phase 2 multicenter, double-blind, ...</td>\n",
       "      <td>MRI Trial to exPlore the efficAcy and Safety o...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>28-Jan-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>711</th>\n",
       "      <td>NCT02635386</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>This is a randomized, single-blind, parallel ...</td>\n",
       "      <td>EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>22-Mar-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Pregnancy, Withdrawa...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>712 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          Nct_id    Phase                                          Condition  \\\n",
       "0    NCT03118765  Phase 2  Mild to Moderate Chronic Obstructive Pulmonary...   \n",
       "1    NCT03114657  Phase 3                                Alzheimer's Disease   \n",
       "2    NCT03110380  Phase 3                                    HIV-1-infection   \n",
       "3    NCT03115112  Phase 3                           Type 2 Diabetes Mellitus   \n",
       "4    NCT03119701  Phase 2                                Multi Organ Failure   \n",
       "5    NCT03181503  Phase 2                                  Prurigo Nodularis   \n",
       "6    NCT03180801  Phase 2                                          Influenza   \n",
       "7    NCT03180528  Phase 2                          Skin Basal Cell Carcinoma   \n",
       "8    NCT03187301  Phase 2                  Off Episodes of Parkinson Disease   \n",
       "9    NCT03185481  Phase 2        Parkinson's Disease With Motor Fluctuations   \n",
       "10   NCT03184987  Phase 3                                             Asthma   \n",
       "11   NCT03180619  Phase 2                                Chronic Hepatitis B   \n",
       "12   NCT03189446  Phase 2                      Clear Cell Endometrial Cancer   \n",
       "13   NCT03722576  Phase 2                     Primary Sclerosing Cholangitis   \n",
       "14   NCT03922750  Phase 2                          Diabetes Mellitus, Type 2   \n",
       "15   NCT03686033  Phase 2                            Photosensitive Epilepsy   \n",
       "16   NCT03684044  Phase 3                                          Influenza   \n",
       "17   NCT03682705  Phase 2                          Rheumatoid Arthritis (RA)   \n",
       "18   NCT04401202  Phase 2                                         SARS-CoV-2   \n",
       "19   NCT02942017  Phase 3                              Postpartum Depression   \n",
       "20   NCT02945657  Phase 2                                  Atopic Dermatitis   \n",
       "21   NCT02943460  Phase 2                     Primary Sclerosing Cholangitis   \n",
       "22   NCT02942576  Phase 3                                Atrial Fibrillation   \n",
       "23   NCT02949128  Phase 3          Atypical Hemolytic Uremic Syndrome (aHUS)   \n",
       "24   NCT02943577  Phase 3                         Depressive Disorder, Major   \n",
       "25   NCT03694275  Phase 2                           CDKL5 Deficiency Disease   \n",
       "26   NCT03697252  Phase 2                                      Schizophrenia   \n",
       "27   NCT03693625  Phase 2                                          Urticaria   \n",
       "28   NCT03699124  Phase 3                                           Smallpox   \n",
       "29   NCT03610048  Phase 3               Refractory Major Depressive Disorder   \n",
       "..           ...      ...                                                ...   \n",
       "682  NCT03452189  Phase 2                            End Stage Renal Disease   \n",
       "683  NCT02787304  Phase 2                      Non-Alcoholic Steatohepatitis   \n",
       "684  NCT02782741  Phase 3   Glycogen Storage Disease Type II;Pompe's Disease   \n",
       "685  NCT02786901  Phase 3                                Ocular Inflammation   \n",
       "686  NCT02788747  Phase 2                                      Heart Failure   \n",
       "687  NCT02781311  Phase 2                                           Alopecia   \n",
       "688  NCT02787083  Phase 3                             Cystitis, Interstitial   \n",
       "689  NCT02781558  Phase 2                        Hepatitis C Virus Infection   \n",
       "690  NCT02784704  Phase 3                           Complicated Appendicitis   \n",
       "691  NCT02780115  Phase 2                                         Presbyopia   \n",
       "692  NCT03657095  Phase 3                    Pulmonary Arterial Hypertension   \n",
       "693  NCT03909295  Phase 3  Heart Failure With Preserved Ejection Fraction...   \n",
       "694  NCT03908970  Phase 3                                  Atopic Dermatitis   \n",
       "695  NCT02648217  Phase 3                          Diabetes Mellitus, Type 2   \n",
       "696  NCT02644668  Phase 2                            Spinal Muscular Atrophy   \n",
       "697  NCT02649231  Phase 2                       Primary Alcohol Use Disorder   \n",
       "698  NCT02647866  Phase 2                                     Abdominal Pain   \n",
       "699  NCT02648204  Phase 3                          Diabetes Mellitus, Type 2   \n",
       "700  NCT02580877  Phase 2                                    Type 1 Diabetes   \n",
       "701  NCT02586805  Phase 3                        Hereditary Angioedema (HAE)   \n",
       "702  NCT02587221  Phase 3                                          Influenza   \n",
       "703  NCT02584257  Phase 3                             Mild Persistent Asthma   \n",
       "704  NCT03150589  Phase 3                   Age-Related Macular Degeneration   \n",
       "705  NCT03152019  Phase 2        Hemorrhagic Hereditary Telangiectasia (HHT)   \n",
       "706  NCT03150719  Phase 3                                    Cystic Fibrosis   \n",
       "707  NCT03159611  Phase 3                 Sequelae of Perinatal Brain Injury   \n",
       "708  NCT03158311  Phase 3                                             Asthma   \n",
       "709  NCT03156621  Phase 3           Homozygous Familial Hypercholesterolemia   \n",
       "710  NCT03846219  Phase 2      Relapsing-Remitting Multiple Sclerosis (RRMS)   \n",
       "711  NCT02635386  Phase 3                                            Obesity   \n",
       "\n",
       "                                               Summary  \\\n",
       "0     Pharmacodynamic and Pharmacokinetic Dose Rang...   \n",
       "1     This randomized, double-blind, placebo-contro...   \n",
       "2     The primary objective of this study is to eva...   \n",
       "3     The purpose of this study is to investigate t...   \n",
       "4     A study to assess effectiveness and safety of...   \n",
       "5     The aim of this study is to assess the safety...   \n",
       "6     FLU-v is a broad spectrum influenza vaccine t...   \n",
       "7     This phase 2 trial studies how well remetinos...   \n",
       "8     A cardiac safety study of an investigational ...   \n",
       "9     The purpose of this study is to evaluate the ...   \n",
       "10    Despite availability of treatments and publis...   \n",
       "11    The primary objective of this study is to eva...   \n",
       "12    The purpose of this study is to determine the...   \n",
       "13    To examine the safety, tolerability, and effi...   \n",
       "14    This study compares insulin 287 (a possible n...   \n",
       "15    The primary purpose of the study is to assess...   \n",
       "16    This study will evaluate the efficacy, safety...   \n",
       "17    This was a phase 2 study to evaluate the safe...   \n",
       "18    Natural products with immunomodulation and an...   \n",
       "19    The purpose of this study was to determine if...   \n",
       "20    The purpose of this study is to assess the ph...   \n",
       "21    The primary objective of this study is to eva...   \n",
       "22    There are insufficient data on the safety and...   \n",
       "23    The purpose of the study is to assess the saf...   \n",
       "24    This study will evaluate the efficacy, safety...   \n",
       "25    The purpose of this study is to investigate t...   \n",
       "26    This is a Phase 2, randomized, double-blinded...   \n",
       "27    This is a Phase II, multicenter, open-label e...   \n",
       "28    This is a Phase 3 multicenter trial to evalua...   \n",
       "29    This study will assess the long-term safety a...   \n",
       "..                                                 ...   \n",
       "682   The purpose of this study is to determine if ...   \n",
       "683   The purpose of this study is to determine if ...   \n",
       "684   Primary Objective:\\r\\r To determine the effec...   \n",
       "685   Loteprednol Etabonate Ophthalmic Gel, (BID an...   \n",
       "686   This was a randomized, double-blinded, placeb...   \n",
       "687   This study will evaluate the safety, tolerabi...   \n",
       "688   Bladder pain syndrome/interstitial cystitis (...   \n",
       "689   The primary objectives of this study are to e...   \n",
       "690   This is a Phase 3, randomized, double-blind, ...   \n",
       "691   This is a safety, efficacy and pharmacokineti...   \n",
       "692   This is a multi-center, open-label study for ...   \n",
       "693   This study evaluated the safety and tolerabil...   \n",
       "694   To demonstrate the superiority of IMP (1% OPA...   \n",
       "695   This trial is conducted in Africa and Asia. T...   \n",
       "696   This study will evaluate the pharmacodynamic ...   \n",
       "697   96 recently detoxified alcoholics will be ran...   \n",
       "698   The purpose of this study is to determine the...   \n",
       "699   This trial is conducted in Asia, Europe and t...   \n",
       "700   The study is a 2 arm, multi-center, randomize...   \n",
       "701   This is a phase 3, multicenter, randomized, d...   \n",
       "702   A Phase III, Randomized, Observer-Blind, Cont...   \n",
       "703   The purpose of this study is to demonstrate t...   \n",
       "704   This is a randomised, double-masked, parallel...   \n",
       "705   The recognized manifestations of HHT are all ...   \n",
       "706   Study VX16-661-114 (Study 114) is a Phase 3b,...   \n",
       "707   Purpose of the study:\\r\\r - To assess the cli...   \n",
       "708   The purpose of this trial was to demonstrate ...   \n",
       "709   The primary objective of the study is to demo...   \n",
       "710   This is a Phase 2 multicenter, double-blind, ...   \n",
       "711   This is a randomized, single-blind, parallel ...   \n",
       "\n",
       "                                                 Title  \\\n",
       "0    Pharmacodynamic and Pharmacokinetic Dose Rangi...   \n",
       "1    A Study of Crenezumab Versus Placebo to Evalua...   \n",
       "2    Switching to a Fixed Dose Combination of Bicte...   \n",
       "3    Safety and Efficacy of Bexagliflozin Compared ...   \n",
       "4    Efficacy and Safety of FP-1201-lyo (Interferon...   \n",
       "5             Safety and Efficacy of Nemolizumab in PN   \n",
       "6    Efficacy of FLU-v in an H1N1 Influenza Human C...   \n",
       "7    Topical Remetinostat in Treating Patient With ...   \n",
       "8    A Cardiac Safety Study of an Investigational D...   \n",
       "9    Safety and Tolerability of PF-06649751 in Park...   \n",
       "10   A Long-term Safety Study of Fixed Dose Combina...   \n",
       "11   Study to Evaluate the Safety and Efficacy of S...   \n",
       "12   Vaginal Cuff Brachytherapy Followed by Chemoth...   \n",
       "13   Vidofludimus Calcium for Primary Sclerosing Ch...   \n",
       "14   A Research Study in People With Type 2 Diabete...   \n",
       "15   A Study to Evaluate the Pharmacodynamic Activi...   \n",
       "16   Study to Assess Efficacy and Safety of Baloxav...   \n",
       "17   A Study to Investigate the Safety and Efficacy...   \n",
       "18                          Nigella Sativa in COVID-19   \n",
       "19   A Study to Evaluate Safety and Efficacy of SAG...   \n",
       "20   Pharmacokinetics and Safety of MM36 Topical Oi...   \n",
       "21   Study to Evaluate the Safety, Tolerability, an...   \n",
       "22   Edoxaban Treatment Versus Vitamin K Antagonist...   \n",
       "23   Study of ALXN1210 in Complement Inhibitor Trea...   \n",
       "24   A Study of Rapastinel as Adjunctive Therapy in...   \n",
       "25   A Multicenter, Open-label, Pilot Study of Soti...   \n",
       "26   A Study to Assess Safety and Efficacy of KarXT...   \n",
       "27   A Study to Evaluate the Long-term Safety and E...   \n",
       "28   Freeze-Dried MVA-BN® Lot Consistency Smallpox ...   \n",
       "29   A Long Term Study of ALKS 5461 in the Treatmen...   \n",
       "..                                                 ...   \n",
       "682  The Effect of an Antibiotic on the Production ...   \n",
       "683  Volixibat (SHP626) in the Treatment of Adults ...   \n",
       "684  Study to Compare the Efficacy and Safety of En...   \n",
       "685  LE Gel for the Treatment of Ocular Inflammatio...   \n",
       "686  Effect of Elamipretide on Left Ventricular Fun...   \n",
       "687  A Safety and Efficacy Study of Setipiprant Tab...   \n",
       "688  A Pilot Study of the Effects of Mirabegron on ...   \n",
       "689  Efficacy and Safety of Sofosbuvir/Velpatasvir ...   \n",
       "690  Efficacy and Safety Study of Eravacycline Comp...   \n",
       "691  A Safety, Efficacy and Pharmacokinetic Study o...   \n",
       "692  A Study With BPS-314d-MR-PAH-303 in Participan...   \n",
       "693  An Open-label Extension Study Evaluating Safet...   \n",
       "694  Comparison Trial of OPA-15406 Ointment in Adul...   \n",
       "695  Comparing Efficacy and Safety of Insulin Deglu...   \n",
       "696  A Study of CK-2127107 in Patients With Spinal ...   \n",
       "697        Ketamine for Reduction of Alcoholic Relapse   \n",
       "698  Study of a Monoclonal Antibody KHK4083 in Mode...   \n",
       "699  Efficacy and Safety of Semaglutide Versus Dula...   \n",
       "700  Immune Effects of Oral Insulin in Relatives at...   \n",
       "701  Efficacy and Safety Study of DX-2930 to Preven...   \n",
       "702  Clinical Study to Evaluate the Efficacy, Safet...   \n",
       "703  Pharmacodynamic Bioequivalence of Metered Dose...   \n",
       "704  A Study to Compare SB11 (Proposed Ranibizumab ...   \n",
       "705  Efficacy and Safety of a 0.1% Tacrolimus Nasal...   \n",
       "706  A Study to Evaluate Safety, Efficacy, and Tole...   \n",
       "707  Efficacy and Safety Clinical Trial of Tenoten ...   \n",
       "708  Study to Compare QVM149 and Free Triple Combin...   \n",
       "709  Study in Participants With Homozygous Familial...   \n",
       "710  MRI Trial to exPlore the efficAcy and Safety o...   \n",
       "711  EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ...   \n",
       "\n",
       "                       Model       Date  \\\n",
       "0        Parallel Assignment  24-Mar-17   \n",
       "1        Parallel Assignment  29-Mar-17   \n",
       "2        Parallel Assignment  12-Jun-17   \n",
       "3        Parallel Assignment  12-Oct-17   \n",
       "4        Parallel Assignment  18-Feb-17   \n",
       "5        Parallel Assignment   2-Oct-17   \n",
       "6        Parallel Assignment  18-Aug-16   \n",
       "7    Single Group Assignment   7-Jul-18   \n",
       "8       Crossover Assignment   3-Aug-17   \n",
       "9        Parallel Assignment   6-Jul-17   \n",
       "10       Parallel Assignment  22-Jun-17   \n",
       "11       Parallel Assignment  29-Jun-17   \n",
       "12   Single Group Assignment   2-Oct-17   \n",
       "13   Single Group Assignment  17-Jun-19   \n",
       "14       Parallel Assignment   9-May-19   \n",
       "15      Crossover Assignment  31-Oct-18   \n",
       "16       Parallel Assignment   8-Jan-19   \n",
       "17       Parallel Assignment   8-Oct-18   \n",
       "18       Parallel Assignment  21-May-20   \n",
       "19       Parallel Assignment     Jul-16   \n",
       "20   Single Group Assignment     Oct-16   \n",
       "21       Parallel Assignment  29-Nov-16   \n",
       "22       Parallel Assignment  21-Mar-17   \n",
       "23   Single Group Assignment  18-Mar-17   \n",
       "24       Parallel Assignment   2-Nov-16   \n",
       "25   Single Group Assignment  10-Sep-18   \n",
       "26       Parallel Assignment  18-Sep-18   \n",
       "27   Single Group Assignment  27-Sep-18   \n",
       "28       Parallel Assignment  19-Jun-19   \n",
       "29   Single Group Assignment   9-Aug-18   \n",
       "..                       ...        ...   \n",
       "682     Crossover Assignment  27-Nov-17   \n",
       "683      Parallel Assignment  24-Oct-16   \n",
       "684      Parallel Assignment   2-Nov-16   \n",
       "685      Parallel Assignment     Jun-16   \n",
       "686      Parallel Assignment     Jun-16   \n",
       "687      Parallel Assignment  14-Jul-16   \n",
       "688      Parallel Assignment     Aug-16   \n",
       "689      Parallel Assignment  29-Jul-16   \n",
       "690      Parallel Assignment  13-Oct-16   \n",
       "691      Parallel Assignment  26-May-16   \n",
       "692      Parallel Assignment  10-Dec-18   \n",
       "693  Single Group Assignment   7-May-19   \n",
       "694      Parallel Assignment  25-Mar-19   \n",
       "695      Parallel Assignment   4-Jan-16   \n",
       "696      Parallel Assignment  14-Jan-16   \n",
       "697      Parallel Assignment     Oct-16   \n",
       "698    Sequential Assignment     Jun-16   \n",
       "699      Parallel Assignment   6-Jan-16   \n",
       "700      Parallel Assignment     Jan-16   \n",
       "701      Parallel Assignment   3-Mar-16   \n",
       "702      Parallel Assignment  30-Sep-16   \n",
       "703     Crossover Assignment     Apr-16   \n",
       "704      Parallel Assignment  14-Mar-18   \n",
       "705      Parallel Assignment  22-May-17   \n",
       "706      Parallel Assignment  24-May-17   \n",
       "707      Parallel Assignment  19-Feb-16   \n",
       "708      Parallel Assignment   5-Feb-18   \n",
       "709      Parallel Assignment   3-Oct-17   \n",
       "710      Parallel Assignment  28-Jan-19   \n",
       "711      Parallel Assignment  22-Mar-16   \n",
       "\n",
       "                                                reason  \n",
       "0    NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "1    NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "2    NOT COMPLETED BECAUSE OF, Randomized and Never...  \n",
       "3    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "4    NOT COMPLETED BECAUSE OF, Death, Adverse Event...  \n",
       "5    NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  \n",
       "6    NOT COMPLETED BECAUSE OF, Physician Decision, ...  \n",
       "7    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "8    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "9    NOT COMPLETED BECAUSE OF, Adverse Event, Study...  \n",
       "10   NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "11   NOT COMPLETED BECAUSE OF, Withdrew Consent, De...  \n",
       "12   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "13   NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "14   NOT COMPLETED BECAUSE OF, Unclassified, Advers...  \n",
       "15             NOT COMPLETED BECAUSE OF, Adverse Event  \n",
       "16   NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "17   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "18   NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...  \n",
       "19   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "20   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "21   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "22   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "23   NOT COMPLETED BECAUSE OF, Failed to Meet Eligi...  \n",
       "24   NOT COMPLETED BECAUSE OF, Protocol Violation, ...  \n",
       "25   NOT COMPLETED BECAUSE OF, Adverse Event, Reaso...  \n",
       "26   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "27   NOT COMPLETED BECAUSE OF, Adverse Event, Study...  \n",
       "28   NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "29   NOT COMPLETED BECAUSE OF, Study terminated by ...  \n",
       "..                                                 ...  \n",
       "682  NOT COMPLETED BECAUSE OF, Adverse Event, insuf...  \n",
       "683  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "684  NOT COMPLETED BECAUSE OF, Adverse Event, Other...  \n",
       "685  NOT COMPLETED BECAUSE OF, Adverse Event, Physi...  \n",
       "686            NOT COMPLETED BECAUSE OF, Adverse Event  \n",
       "687  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "688  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "689  NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...  \n",
       "690  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "691  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "692  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "693  NOT COMPLETED BECAUSE OF, Adverse Event, Study...  \n",
       "694  NOT COMPLETED BECAUSE OF, Adverse Event, Physi...  \n",
       "695  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "696  NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  \n",
       "697  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "698  NOT COMPLETED BECAUSE OF, Adverse Event, Disea...  \n",
       "699  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "700  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "701  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "702  NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "703  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "704  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "705            NOT COMPLETED BECAUSE OF, Adverse Event  \n",
       "706  NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "707  NOT COMPLETED BECAUSE OF, Did Not Meet Inclusi...  \n",
       "708  NOT COMPLETED BECAUSE OF, Subject/Guardian Dec...  \n",
       "709  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "710  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "711  NOT COMPLETED BECAUSE OF, Pregnancy, Withdrawa...  \n",
       "\n",
       "[712 rows x 8 columns]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "adverse_df = pd.read_csv(\"filtered_clinical_trials_adverse_events_only.csv\")\n",
    "display(adverse_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "adverse_df.loc[adverse_df.Condition.str.contains('cancer'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Cancer'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains(r'adeno(?!$)'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains(r'adeno(?!$)'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('cell'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Cell'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('carc'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Carc'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('tumor'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Tumor'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('walden'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Walden'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('fibroid'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Fibroid'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('squamous'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Squamous'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('prostat'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Prostat'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('polyp'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Polyp'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('myeloma'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Myeloma'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('myoma'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Myoma'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('phoma'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Phoma'), 'Condition'] = 'Cancer'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('phomic'), 'Condition'] = 'Cancer'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Phomic'), 'Condition'] = 'Cancer'\n",
    "\n",
    "################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('hemo'), 'Condition'] = 'Blood disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Hemo'), 'Condition'] = 'Blood disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('anem'), 'Condition'] = 'Blood disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Anem'), 'Condition'] = 'Blood disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('willebrand'), 'Condition'] = 'Blood disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Willebrand'), 'Condition'] = 'Blood disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('uremi'), 'Condition'] = 'Blood disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Uremi'), 'Condition'] = 'Blood disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('thromb'), 'Condition'] = 'Blood disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Thromb'), 'Condition'] = 'Blood disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('sickle'), 'Condition'] = 'Blood disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sickle'), 'Condition'] = 'Blood disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('phyria'), 'Condition'] = 'Blood disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Phyria'), 'Condition'] = 'Blood disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('cythemia'), 'Condition'] = 'Blood disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Cythemia'), 'Condition'] = 'Blood disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('clott'), 'Condition'] = 'Blood disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Clott'), 'Condition'] = 'Blood disorder'\n",
    "\n",
    "##################################################################################################################\n",
    "\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('diabet'), 'Condition'] = 'Diabetes'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Diabet'), 'Condition'] = 'Diabetes'\n",
    "\n",
    "\n",
    "########################################################################################################################\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('enceph'), 'Condition'] = 'CNS autoimmune'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Enceph'), 'Condition'] = 'CNS autoimmune'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('dementia'), 'Condition'] = 'CNS autoimmune'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Dementia'), 'Condition'] = 'CNS autoimmune'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('neuro'), 'Condition'] = 'CNS autoimmune'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Neuro'), 'Condition'] = 'CNS autoimmune'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('schiz'), 'Condition'] = 'CNS autoimmune'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Schiz'), 'Condition'] = 'CNS autoimmune'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('MS'), 'Condition'] = 'CNS autoimmune'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('PSP'), 'Condition'] = 'CNS autoimmune'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('parkinson'), 'Condition'] = 'CNS autoimmune'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Parkinson'), 'Condition'] = 'CNS autoimmune'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('spondy'), 'Condition'] = 'CNS autoimmune'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Spondy'), 'Condition'] = 'CNS autoimmune'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('scleros'), 'Condition'] = 'CNS autoimmune'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Scleros'), 'Condition'] = 'CNS autoimmune'\n",
    "\n",
    "#######################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Cereb'), 'Condition'] = 'CNS disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('cereb'), 'Condition'] = 'CNS disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('alzh'), 'Condition'] = 'CNS disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Alzh'), 'Condition'] = 'CNS disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('epilep'), 'Condition'] = 'CNS disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Epilep'), 'Condition'] = 'CNS disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('migraine'), 'Condition'] = 'CNS disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Migraine'), 'Condition'] = 'CNS disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('spin'), 'Condition'] = 'CNS disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Spin'), 'Condition'] = 'CNS disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('seizure'), 'Condition'] = 'CNS disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Seizure'), 'Condition'] = 'CNS disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('stroke'), 'Condition'] = 'CNS disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Stroke'), 'Condition'] = 'CNS disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('spastic'), 'Condition'] = 'CNS disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Spastic'), 'Condition'] = 'CNS disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('seizure'), 'Condition'] = 'CNS disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Seizure'), 'Condition'] = 'CNS disorder'\n",
    "\n",
    "########################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('amyloid'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('amyloid'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('SLE'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sle'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('sjogren'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sjogren'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sjgren'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('sjgren'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('rhin'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Rhin'), 'Condition'] = 'Inflammation/Autoimmune (others)'\n",
    "\n",
    "##########################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('cardio'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Cardio'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('artery'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Artery'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('vascular'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Vascular'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('ventric'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Ventric'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('septa'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Septa'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('aort'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Aort'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('vein'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Vein'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('statin'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Statin'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('cardi'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Cardi'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('pannicul'), 'Condition'] = 'Heart (circulation) condition'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Pannicul'), 'Condition'] = 'Heart (circulation) condition'\n",
    "\n",
    "#########################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('bacter'), 'Condition'] = 'Antibiotics'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Bacter'), 'Condition'] = 'Antibioitcs'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('sonnei'), 'Condition'] = 'Antibiotics'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sonnei'), 'Condition'] = 'Antibioitcs'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('antibiot',regex=False), 'Condition'] = 'Antibiotics'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Antibiot',regex=False), 'Condition'] = 'Antibioitcs'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('shigella'), 'Condition'] = 'Antibiotics'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Shigella'), 'Condition'] = 'Antibioitcs'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('coccal'), 'Condition'] = 'Antibiotics'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Coccal'), 'Condition'] = 'Antibioitcs'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('candid'), 'Condition'] = 'Antibiotics'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Candid'), 'Condition'] = 'Antibioitcs'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('peridon'), 'Condition'] = 'Antibiotics'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Peridon'), 'Condition'] = 'Antibioitcs'\n",
    "\n",
    "#########################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('alopecia'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Alopecia'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('aging'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Aging'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('age'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Age'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('wart'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Wart'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('vitiligo'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Vitiligo'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('pigment'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Pigment'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('stress'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Stress'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('sleep'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sleep'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('traumatic'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Traumatic'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('activity'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Activity'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('active'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Active'), 'Condition'] = 'Hair/Cosmetics/Aging/Stress'\n",
    "\n",
    "\n",
    "##########################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('ART'), 'Condition'] = 'Reproduction'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('partum'), 'Condition'] = 'Reproduction'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Partum'), 'Condition'] = 'Reproduction'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('ovar'), 'Condition'] = 'Reproduction'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Ovar'), 'Condition'] = 'Reproduction'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('natal'), 'Condition'] = 'Reproduction'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Natal'), 'Condition'] = 'Reproduction'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('fertil'), 'Condition'] = 'Reproduction'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Fertil'), 'Condition'] = 'Reproduction'\n",
    "\n",
    "\n",
    "######################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('vira'), 'Condition'] = 'Antiviral'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Vira'), 'Condition'] = 'Antiviral'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('SARS'), 'Condition'] = 'Antiviral'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sars'), 'Condition'] = 'Antiviral'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('cov'), 'Condition'] = 'Antiviral'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Cov'), 'Condition'] = 'Antiviral'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('COV'), 'Condition'] = 'Antiviral'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('CoV'), 'Condition'] = 'Antiviral'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('pox'), 'Condition'] = 'Antiviral'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Pox'), 'Condition'] = 'Antiviral'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('simplex'), 'Condition'] = 'Antiviral'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Simplex'), 'Condition'] = 'Antiviral'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('rabi'), 'Condition'] = 'Antiviral'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Rabi'), 'Condition'] = 'Antiviral'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('herp'), 'Condition'] = 'Antiviral'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Herp'), 'Condition'] = 'Antiviral'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('influenza'), 'Condition'] = 'Antiviral'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Influenza'), 'Condition'] = 'Antiviral'\n",
    "\n",
    "#####################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('ulcer'), 'Condition'] = 'Digestive'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Ulcer'), 'Condition'] = 'Digestive'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('intestin'), 'Condition'] = 'Digestive'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Intestin'), 'Condition'] = 'Digestive'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('digest'), 'Condition'] = 'Digestive'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Digest'), 'Condition'] = 'Digestive'\n",
    "\n",
    "#####################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('bone'), 'Condition'] = 'Bones/Joints Inflammation'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Bone'), 'Condition'] = 'Bones/Joints Inflammation'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('rheum'), 'Condition'] = 'Bones/Joints Inflammation'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Rheum'), 'Condition'] = 'Bones/Joints Inflammation'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('joint'), 'Condition'] = 'Bones/Joints Inflammation'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Joint'), 'Condition'] = 'Bones/Joints Inflammation'\n",
    "\n",
    "########################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('retin'), 'Condition'] = 'Eye Disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Retin'), 'Condition'] = 'Eye Disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('eye'), 'Condition'] = 'Eye Disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Eye'), 'Condition'] = 'Eye Disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Opia'), 'Condition'] = 'Eye Disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('opia'), 'Condition'] = 'Eye Disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Opic'), 'Condition'] = 'Eye Disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('opic'), 'Condition'] = 'Eye Disorder'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('pupil'), 'Condition'] = 'Eye Disorder'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Pupil'), 'Condition'] = 'Eye Disorder'\n",
    "\n",
    "########################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('respir'), 'Condition'] = 'Respiratory'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Respir'), 'Condition'] = 'Respiratory'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('pulmon'), 'Condition'] = 'Respiratory'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Pulmon'), 'Condition'] = 'Respiratory'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('pneumon'), 'Condition'] = 'Respiratory'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Pneumon'), 'Condition'] = 'Respiratory'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('obstructive'), 'Condition'] = 'Respiratory'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Obstructive'), 'Condition'] = 'Respiratory'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('COPD'), 'Condition'] = 'Respiratory'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('copd'), 'Condition'] = 'Respiratory'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Fibrosis'), 'Condition'] = 'Respiratory'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('fibrosis'), 'Condition'] = 'Respiratory'\n",
    "\n",
    "########################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('urin'), 'Condition'] = 'Urinary'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Urin'), 'Condition'] = 'Urinary'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Rena'), 'Condition'] = 'Urinary'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('rena'), 'Condition'] = 'Urinary'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('neph'), 'Condition'] = 'Urinary'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Neph'), 'Condition'] = 'Urinary'\n",
    "\n",
    "########################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Urticaria'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('urticaria'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('histamin'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Histamin'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('allerg'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Allerg'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('telangiect'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Telangiect'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('sclerod'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sclerod'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('derm'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Derm'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('seborrheic'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Seborrheic'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('rosacea'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Rosacea'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('psori'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Psori'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('prurigo'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Prurigo'), 'Condition'] = 'Skin Infection/Allergy'\n",
    "\n",
    "####################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('vaccine'), 'Condition'] = 'Vaccine'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Vaccine'), 'Condition'] = 'Vaccine'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('adjuvant'), 'Condition'] = 'Vaccine'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Adjuvant'), 'Condition'] = 'Vaccine'\n",
    "\n",
    "####################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('transplant'), 'Condition'] = 'Hospital Care'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Transplant'), 'Condition'] = 'Hospital Care'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('transfus'), 'Condition'] = 'Hospital Care'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Transfus'), 'Condition'] = 'Hospital Care'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('sedat'), 'Condition'] = 'Hospital Care'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sedat'), 'Condition'] = 'Hospital Care'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Pediatric'), 'Condition'] = 'Hospital Care'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('pediatric'), 'Condition'] = 'Hospital Care'\n",
    "\n",
    "####################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('clonic'), 'Condition'] = 'Muscle Disorder CNS/Others'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Clonic'), 'Condition'] = 'Muscle Disorder CNS/Others'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('tend'), 'Condition'] = 'Muscle Disorder CNS/Others'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Tend'), 'Condition'] = 'Muscle Disorder CNS/Others'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sarco'), 'Condition'] = 'Muscle Disorder CNS/Others'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('sarco'), 'Condition'] = 'Muscle Disorder CNS/Others'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('CEPS'), 'Condition'] = 'Muscle Disorder CNS/Others'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('motor'), 'Condition'] = 'Muscle Disorder CNS/Others'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Motor'), 'Condition'] = 'Muscle Disorder CNS/Others'\n",
    "\n",
    "####################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('cohol'), 'Condition'] = 'Alcohol/Liver'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Cohol'), 'Condition'] = 'Alcohol/Liver'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('steat'), 'Condition'] = 'Alcohol/Liver'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Steat'), 'Condition'] = 'Alcohol/Liver'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Pancreati'), 'Condition'] = 'Alcohol/Liver'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('pancreati'), 'Condition'] = 'Alcohol/Liver'\n",
    "\n",
    "####################################################################################################################\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('tremor'), 'Condition'] = 'Others'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Tremor'), 'Condition'] = 'Others'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Sequalae'), 'Condition'] = 'Others'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('sequalae'), 'Condition'] = 'Others'\n",
    "\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('Opioid'), 'Condition'] = 'Others'\n",
    "adverse_df.loc[adverse_df.Condition.str.contains('opioid'), 'Condition'] = 'Others'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Nct_id</th>\n",
       "      <th>Phase</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Title</th>\n",
       "      <th>Model</th>\n",
       "      <th>Date</th>\n",
       "      <th>reason</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03118765</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Respiratory</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rang...</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rangi...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>24-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03114657</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>CNS disorder</td>\n",
       "      <td>This randomized, double-blind, placebo-contro...</td>\n",
       "      <td>A Study of Crenezumab Versus Placebo to Evalua...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03110380</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>HIV-1-infection</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Switching to a Fixed Dose Combination of Bicte...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>12-Jun-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Randomized and Never...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT03115112</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>The purpose of this study is to investigate t...</td>\n",
       "      <td>Safety and Efficacy of Bexagliflozin Compared ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>12-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT03119701</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Multi Organ Failure</td>\n",
       "      <td>A study to assess effectiveness and safety of...</td>\n",
       "      <td>Efficacy and Safety of FP-1201-lyo (Interferon...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>18-Feb-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Adverse Event...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT03181503</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Skin Infection/Allergy</td>\n",
       "      <td>The aim of this study is to assess the safety...</td>\n",
       "      <td>Safety and Efficacy of Nemolizumab in PN</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>2-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT03180801</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>FLU-v is a broad spectrum influenza vaccine t...</td>\n",
       "      <td>Efficacy of FLU-v in an H1N1 Influenza Human C...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>18-Aug-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Physician Decision, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT03180528</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>This phase 2 trial studies how well remetinos...</td>\n",
       "      <td>Topical Remetinostat in Treating Patient With ...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>7-Jul-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT03187301</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>A cardiac safety study of an investigational ...</td>\n",
       "      <td>A Cardiac Safety Study of an Investigational D...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>3-Aug-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT03185481</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Safety and Tolerability of PF-06649751 in Park...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>6-Jul-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NCT03184987</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>Despite availability of treatments and publis...</td>\n",
       "      <td>A Long-term Safety Study of Fixed Dose Combina...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>22-Jun-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>NCT03180619</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Chronic Hepatitis B</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Study to Evaluate the Safety and Efficacy of S...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Jun-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrew Consent, De...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NCT03189446</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>The purpose of this study is to determine the...</td>\n",
       "      <td>Vaginal Cuff Brachytherapy Followed by Chemoth...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>2-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT03722576</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>To examine the safety, tolerability, and effi...</td>\n",
       "      <td>Vidofludimus Calcium for Primary Sclerosing Ch...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>17-Jun-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NCT03922750</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>This study compares insulin 287 (a possible n...</td>\n",
       "      <td>A Research Study in People With Type 2 Diabete...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>9-May-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Unclassified, Advers...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NCT03686033</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS disorder</td>\n",
       "      <td>The primary purpose of the study is to assess...</td>\n",
       "      <td>A Study to Evaluate the Pharmacodynamic Activi...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>31-Oct-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NCT03684044</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>This study will evaluate the efficacy, safety...</td>\n",
       "      <td>Study to Assess Efficacy and Safety of Baloxav...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>8-Jan-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NCT03682705</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Bones/Joints Inflammation</td>\n",
       "      <td>This was a phase 2 study to evaluate the safe...</td>\n",
       "      <td>A Study to Investigate the Safety and Efficacy...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>8-Oct-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>NCT04401202</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>Natural products with immunomodulation and an...</td>\n",
       "      <td>Nigella Sativa in COVID-19</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>21-May-20</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>NCT02942017</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Reproduction</td>\n",
       "      <td>The purpose of this study was to determine if...</td>\n",
       "      <td>A Study to Evaluate Safety and Efficacy of SAG...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Jul-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NCT02945657</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Eye Disorder</td>\n",
       "      <td>The purpose of this study is to assess the ph...</td>\n",
       "      <td>Pharmacokinetics and Safety of MM36 Topical Oi...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NCT02943460</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Study to Evaluate the Safety, Tolerability, an...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Nov-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>NCT02942576</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Atrial Fibrillation</td>\n",
       "      <td>There are insufficient data on the safety and...</td>\n",
       "      <td>Edoxaban Treatment Versus Vitamin K Antagonist...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>21-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>NCT02949128</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Blood disorder</td>\n",
       "      <td>The purpose of the study is to assess the saf...</td>\n",
       "      <td>Study of ALXN1210 in Complement Inhibitor Trea...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>18-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Failed to Meet Eligi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>NCT02943577</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Depressive Disorder, Major</td>\n",
       "      <td>This study will evaluate the efficacy, safety...</td>\n",
       "      <td>A Study of Rapastinel as Adjunctive Therapy in...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>2-Nov-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Protocol Violation, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>NCT03694275</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CDKL5 Deficiency Disease</td>\n",
       "      <td>The purpose of this study is to investigate t...</td>\n",
       "      <td>A Multicenter, Open-label, Pilot Study of Soti...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>10-Sep-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Reaso...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>NCT03697252</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>This is a Phase 2, randomized, double-blinded...</td>\n",
       "      <td>A Study to Assess Safety and Efficacy of KarXT...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>18-Sep-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NCT03693625</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Skin Infection/Allergy</td>\n",
       "      <td>This is a Phase II, multicenter, open-label e...</td>\n",
       "      <td>A Study to Evaluate the Long-term Safety and E...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>27-Sep-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NCT03699124</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>This is a Phase 3 multicenter trial to evalua...</td>\n",
       "      <td>Freeze-Dried MVA-BN® Lot Consistency Smallpox ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>19-Jun-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NCT03610048</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Refractory Major Depressive Disorder</td>\n",
       "      <td>This study will assess the long-term safety a...</td>\n",
       "      <td>A Long Term Study of ALKS 5461 in the Treatmen...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>9-Aug-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Study terminated by ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>682</th>\n",
       "      <td>NCT03452189</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress</td>\n",
       "      <td>The purpose of this study is to determine if ...</td>\n",
       "      <td>The Effect of an Antibiotic on the Production ...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>27-Nov-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, insuf...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>683</th>\n",
       "      <td>NCT02787304</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alcohol/Liver</td>\n",
       "      <td>The purpose of this study is to determine if ...</td>\n",
       "      <td>Volixibat (SHP626) in the Treatment of Adults ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>24-Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>684</th>\n",
       "      <td>NCT02782741</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress</td>\n",
       "      <td>Primary Objective:\\r\\r To determine the effec...</td>\n",
       "      <td>Study to Compare the Efficacy and Safety of En...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>2-Nov-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Other...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>685</th>\n",
       "      <td>NCT02786901</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Ocular Inflammation</td>\n",
       "      <td>Loteprednol Etabonate Ophthalmic Gel, (BID an...</td>\n",
       "      <td>LE Gel for the Treatment of Ocular Inflammatio...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Jun-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Physi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>686</th>\n",
       "      <td>NCT02788747</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Heart Failure</td>\n",
       "      <td>This was a randomized, double-blinded, placeb...</td>\n",
       "      <td>Effect of Elamipretide on Left Ventricular Fun...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Jun-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>687</th>\n",
       "      <td>NCT02781311</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress</td>\n",
       "      <td>This study will evaluate the safety, tolerabi...</td>\n",
       "      <td>A Safety and Efficacy Study of Setipiprant Tab...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>14-Jul-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>688</th>\n",
       "      <td>NCT02787083</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Cystitis, Interstitial</td>\n",
       "      <td>Bladder pain syndrome/interstitial cystitis (...</td>\n",
       "      <td>A Pilot Study of the Effects of Mirabegron on ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Aug-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>689</th>\n",
       "      <td>NCT02781558</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hepatitis C Virus Infection</td>\n",
       "      <td>The primary objectives of this study are to e...</td>\n",
       "      <td>Efficacy and Safety of Sofosbuvir/Velpatasvir ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Jul-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>690</th>\n",
       "      <td>NCT02784704</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Complicated Appendicitis</td>\n",
       "      <td>This is a Phase 3, randomized, double-blind, ...</td>\n",
       "      <td>Efficacy and Safety Study of Eravacycline Comp...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>13-Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>691</th>\n",
       "      <td>NCT02780115</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Eye Disorder</td>\n",
       "      <td>This is a safety, efficacy and pharmacokineti...</td>\n",
       "      <td>A Safety, Efficacy and Pharmacokinetic Study o...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>26-May-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>692</th>\n",
       "      <td>NCT03657095</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Respiratory</td>\n",
       "      <td>This is a multi-center, open-label study for ...</td>\n",
       "      <td>A Study With BPS-314d-MR-PAH-303 in Participan...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>10-Dec-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>693</th>\n",
       "      <td>NCT03909295</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Heart Failure With Preserved Ejection Fraction...</td>\n",
       "      <td>This study evaluated the safety and tolerabil...</td>\n",
       "      <td>An Open-label Extension Study Evaluating Safet...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>7-May-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>694</th>\n",
       "      <td>NCT03908970</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Eye Disorder</td>\n",
       "      <td>To demonstrate the superiority of IMP (1% OPA...</td>\n",
       "      <td>Comparison Trial of OPA-15406 Ointment in Adul...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>25-Mar-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Physi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>695</th>\n",
       "      <td>NCT02648217</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>This trial is conducted in Africa and Asia. T...</td>\n",
       "      <td>Comparing Efficacy and Safety of Insulin Deglu...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>4-Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>696</th>\n",
       "      <td>NCT02644668</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS disorder</td>\n",
       "      <td>This study will evaluate the pharmacodynamic ...</td>\n",
       "      <td>A Study of CK-2127107 in Patients With Spinal ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>14-Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>697</th>\n",
       "      <td>NCT02649231</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alcohol/Liver</td>\n",
       "      <td>96 recently detoxified alcoholics will be ran...</td>\n",
       "      <td>Ketamine for Reduction of Alcoholic Relapse</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>698</th>\n",
       "      <td>NCT02647866</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Abdominal Pain</td>\n",
       "      <td>The purpose of this study is to determine the...</td>\n",
       "      <td>Study of a Monoclonal Antibody KHK4083 in Mode...</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>Jun-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Disea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>699</th>\n",
       "      <td>NCT02648204</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>This trial is conducted in Asia, Europe and t...</td>\n",
       "      <td>Efficacy and Safety of Semaglutide Versus Dula...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>6-Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>700</th>\n",
       "      <td>NCT02580877</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>The study is a 2 arm, multi-center, randomize...</td>\n",
       "      <td>Immune Effects of Oral Insulin in Relatives at...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>701</th>\n",
       "      <td>NCT02586805</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hereditary Angioedema (HAE)</td>\n",
       "      <td>This is a phase 3, multicenter, randomized, d...</td>\n",
       "      <td>Efficacy and Safety Study of DX-2930 to Preven...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>3-Mar-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>702</th>\n",
       "      <td>NCT02587221</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>A Phase III, Randomized, Observer-Blind, Cont...</td>\n",
       "      <td>Clinical Study to Evaluate the Efficacy, Safet...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>30-Sep-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>703</th>\n",
       "      <td>NCT02584257</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Mild Persistent Asthma</td>\n",
       "      <td>The purpose of this study is to demonstrate t...</td>\n",
       "      <td>Pharmacodynamic Bioequivalence of Metered Dose...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>Apr-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>704</th>\n",
       "      <td>NCT03150589</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress</td>\n",
       "      <td>This is a randomised, double-masked, parallel...</td>\n",
       "      <td>A Study to Compare SB11 (Proposed Ranibizumab ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>14-Mar-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>705</th>\n",
       "      <td>NCT03152019</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Blood disorder</td>\n",
       "      <td>The recognized manifestations of HHT are all ...</td>\n",
       "      <td>Efficacy and Safety of a 0.1% Tacrolimus Nasal...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>22-May-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>706</th>\n",
       "      <td>NCT03150719</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Respiratory</td>\n",
       "      <td>Study VX16-661-114 (Study 114) is a Phase 3b,...</td>\n",
       "      <td>A Study to Evaluate Safety, Efficacy, and Tole...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>24-May-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>707</th>\n",
       "      <td>NCT03159611</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Reproduction</td>\n",
       "      <td>Purpose of the study:\\r\\r - To assess the cli...</td>\n",
       "      <td>Efficacy and Safety Clinical Trial of Tenoten ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>19-Feb-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Did Not Meet Inclusi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>708</th>\n",
       "      <td>NCT03158311</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Asthma</td>\n",
       "      <td>The purpose of this trial was to demonstrate ...</td>\n",
       "      <td>Study to Compare QVM149 and Free Triple Combin...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>5-Feb-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Subject/Guardian Dec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>709</th>\n",
       "      <td>NCT03156621</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Homozygous Familial Hypercholesterolemia</td>\n",
       "      <td>The primary objective of the study is to demo...</td>\n",
       "      <td>Study in Participants With Homozygous Familial...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>3-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>710</th>\n",
       "      <td>NCT03846219</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>This is a Phase 2 multicenter, double-blind, ...</td>\n",
       "      <td>MRI Trial to exPlore the efficAcy and Safety o...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>28-Jan-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>711</th>\n",
       "      <td>NCT02635386</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>This is a randomized, single-blind, parallel ...</td>\n",
       "      <td>EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>22-Mar-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Pregnancy, Withdrawa...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>712 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          Nct_id    Phase                                          Condition  \\\n",
       "0    NCT03118765  Phase 2                                        Respiratory   \n",
       "1    NCT03114657  Phase 3                                       CNS disorder   \n",
       "2    NCT03110380  Phase 3                                    HIV-1-infection   \n",
       "3    NCT03115112  Phase 3                                           Diabetes   \n",
       "4    NCT03119701  Phase 2                                Multi Organ Failure   \n",
       "5    NCT03181503  Phase 2                             Skin Infection/Allergy   \n",
       "6    NCT03180801  Phase 2                                          Antiviral   \n",
       "7    NCT03180528  Phase 2                                             Cancer   \n",
       "8    NCT03187301  Phase 2                                     CNS autoimmune   \n",
       "9    NCT03185481  Phase 2                                     CNS autoimmune   \n",
       "10   NCT03184987  Phase 3                                             Asthma   \n",
       "11   NCT03180619  Phase 2                                Chronic Hepatitis B   \n",
       "12   NCT03189446  Phase 2                                             Cancer   \n",
       "13   NCT03722576  Phase 2                                     CNS autoimmune   \n",
       "14   NCT03922750  Phase 2                                           Diabetes   \n",
       "15   NCT03686033  Phase 2                                       CNS disorder   \n",
       "16   NCT03684044  Phase 3                                          Antiviral   \n",
       "17   NCT03682705  Phase 2                          Bones/Joints Inflammation   \n",
       "18   NCT04401202  Phase 2                                          Antiviral   \n",
       "19   NCT02942017  Phase 3                                       Reproduction   \n",
       "20   NCT02945657  Phase 2                                       Eye Disorder   \n",
       "21   NCT02943460  Phase 2                                     CNS autoimmune   \n",
       "22   NCT02942576  Phase 3                                Atrial Fibrillation   \n",
       "23   NCT02949128  Phase 3                                     Blood disorder   \n",
       "24   NCT02943577  Phase 3                         Depressive Disorder, Major   \n",
       "25   NCT03694275  Phase 2                           CDKL5 Deficiency Disease   \n",
       "26   NCT03697252  Phase 2                                     CNS autoimmune   \n",
       "27   NCT03693625  Phase 2                             Skin Infection/Allergy   \n",
       "28   NCT03699124  Phase 3                                          Antiviral   \n",
       "29   NCT03610048  Phase 3               Refractory Major Depressive Disorder   \n",
       "..           ...      ...                                                ...   \n",
       "682  NCT03452189  Phase 2                        Hair/Cosmetics/Aging/Stress   \n",
       "683  NCT02787304  Phase 2                                      Alcohol/Liver   \n",
       "684  NCT02782741  Phase 3                        Hair/Cosmetics/Aging/Stress   \n",
       "685  NCT02786901  Phase 3                                Ocular Inflammation   \n",
       "686  NCT02788747  Phase 2                                      Heart Failure   \n",
       "687  NCT02781311  Phase 2                        Hair/Cosmetics/Aging/Stress   \n",
       "688  NCT02787083  Phase 3                             Cystitis, Interstitial   \n",
       "689  NCT02781558  Phase 2                        Hepatitis C Virus Infection   \n",
       "690  NCT02784704  Phase 3                           Complicated Appendicitis   \n",
       "691  NCT02780115  Phase 2                                       Eye Disorder   \n",
       "692  NCT03657095  Phase 3                                        Respiratory   \n",
       "693  NCT03909295  Phase 3  Heart Failure With Preserved Ejection Fraction...   \n",
       "694  NCT03908970  Phase 3                                       Eye Disorder   \n",
       "695  NCT02648217  Phase 3                                           Diabetes   \n",
       "696  NCT02644668  Phase 2                                       CNS disorder   \n",
       "697  NCT02649231  Phase 2                                      Alcohol/Liver   \n",
       "698  NCT02647866  Phase 2                                     Abdominal Pain   \n",
       "699  NCT02648204  Phase 3                                           Diabetes   \n",
       "700  NCT02580877  Phase 2                                           Diabetes   \n",
       "701  NCT02586805  Phase 3                        Hereditary Angioedema (HAE)   \n",
       "702  NCT02587221  Phase 3                                          Antiviral   \n",
       "703  NCT02584257  Phase 3                             Mild Persistent Asthma   \n",
       "704  NCT03150589  Phase 3                        Hair/Cosmetics/Aging/Stress   \n",
       "705  NCT03152019  Phase 2                                     Blood disorder   \n",
       "706  NCT03150719  Phase 3                                        Respiratory   \n",
       "707  NCT03159611  Phase 3                                       Reproduction   \n",
       "708  NCT03158311  Phase 3                                             Asthma   \n",
       "709  NCT03156621  Phase 3           Homozygous Familial Hypercholesterolemia   \n",
       "710  NCT03846219  Phase 2                                     CNS autoimmune   \n",
       "711  NCT02635386  Phase 3                                            Obesity   \n",
       "\n",
       "                                               Summary  \\\n",
       "0     Pharmacodynamic and Pharmacokinetic Dose Rang...   \n",
       "1     This randomized, double-blind, placebo-contro...   \n",
       "2     The primary objective of this study is to eva...   \n",
       "3     The purpose of this study is to investigate t...   \n",
       "4     A study to assess effectiveness and safety of...   \n",
       "5     The aim of this study is to assess the safety...   \n",
       "6     FLU-v is a broad spectrum influenza vaccine t...   \n",
       "7     This phase 2 trial studies how well remetinos...   \n",
       "8     A cardiac safety study of an investigational ...   \n",
       "9     The purpose of this study is to evaluate the ...   \n",
       "10    Despite availability of treatments and publis...   \n",
       "11    The primary objective of this study is to eva...   \n",
       "12    The purpose of this study is to determine the...   \n",
       "13    To examine the safety, tolerability, and effi...   \n",
       "14    This study compares insulin 287 (a possible n...   \n",
       "15    The primary purpose of the study is to assess...   \n",
       "16    This study will evaluate the efficacy, safety...   \n",
       "17    This was a phase 2 study to evaluate the safe...   \n",
       "18    Natural products with immunomodulation and an...   \n",
       "19    The purpose of this study was to determine if...   \n",
       "20    The purpose of this study is to assess the ph...   \n",
       "21    The primary objective of this study is to eva...   \n",
       "22    There are insufficient data on the safety and...   \n",
       "23    The purpose of the study is to assess the saf...   \n",
       "24    This study will evaluate the efficacy, safety...   \n",
       "25    The purpose of this study is to investigate t...   \n",
       "26    This is a Phase 2, randomized, double-blinded...   \n",
       "27    This is a Phase II, multicenter, open-label e...   \n",
       "28    This is a Phase 3 multicenter trial to evalua...   \n",
       "29    This study will assess the long-term safety a...   \n",
       "..                                                 ...   \n",
       "682   The purpose of this study is to determine if ...   \n",
       "683   The purpose of this study is to determine if ...   \n",
       "684   Primary Objective:\\r\\r To determine the effec...   \n",
       "685   Loteprednol Etabonate Ophthalmic Gel, (BID an...   \n",
       "686   This was a randomized, double-blinded, placeb...   \n",
       "687   This study will evaluate the safety, tolerabi...   \n",
       "688   Bladder pain syndrome/interstitial cystitis (...   \n",
       "689   The primary objectives of this study are to e...   \n",
       "690   This is a Phase 3, randomized, double-blind, ...   \n",
       "691   This is a safety, efficacy and pharmacokineti...   \n",
       "692   This is a multi-center, open-label study for ...   \n",
       "693   This study evaluated the safety and tolerabil...   \n",
       "694   To demonstrate the superiority of IMP (1% OPA...   \n",
       "695   This trial is conducted in Africa and Asia. T...   \n",
       "696   This study will evaluate the pharmacodynamic ...   \n",
       "697   96 recently detoxified alcoholics will be ran...   \n",
       "698   The purpose of this study is to determine the...   \n",
       "699   This trial is conducted in Asia, Europe and t...   \n",
       "700   The study is a 2 arm, multi-center, randomize...   \n",
       "701   This is a phase 3, multicenter, randomized, d...   \n",
       "702   A Phase III, Randomized, Observer-Blind, Cont...   \n",
       "703   The purpose of this study is to demonstrate t...   \n",
       "704   This is a randomised, double-masked, parallel...   \n",
       "705   The recognized manifestations of HHT are all ...   \n",
       "706   Study VX16-661-114 (Study 114) is a Phase 3b,...   \n",
       "707   Purpose of the study:\\r\\r - To assess the cli...   \n",
       "708   The purpose of this trial was to demonstrate ...   \n",
       "709   The primary objective of the study is to demo...   \n",
       "710   This is a Phase 2 multicenter, double-blind, ...   \n",
       "711   This is a randomized, single-blind, parallel ...   \n",
       "\n",
       "                                                 Title  \\\n",
       "0    Pharmacodynamic and Pharmacokinetic Dose Rangi...   \n",
       "1    A Study of Crenezumab Versus Placebo to Evalua...   \n",
       "2    Switching to a Fixed Dose Combination of Bicte...   \n",
       "3    Safety and Efficacy of Bexagliflozin Compared ...   \n",
       "4    Efficacy and Safety of FP-1201-lyo (Interferon...   \n",
       "5             Safety and Efficacy of Nemolizumab in PN   \n",
       "6    Efficacy of FLU-v in an H1N1 Influenza Human C...   \n",
       "7    Topical Remetinostat in Treating Patient With ...   \n",
       "8    A Cardiac Safety Study of an Investigational D...   \n",
       "9    Safety and Tolerability of PF-06649751 in Park...   \n",
       "10   A Long-term Safety Study of Fixed Dose Combina...   \n",
       "11   Study to Evaluate the Safety and Efficacy of S...   \n",
       "12   Vaginal Cuff Brachytherapy Followed by Chemoth...   \n",
       "13   Vidofludimus Calcium for Primary Sclerosing Ch...   \n",
       "14   A Research Study in People With Type 2 Diabete...   \n",
       "15   A Study to Evaluate the Pharmacodynamic Activi...   \n",
       "16   Study to Assess Efficacy and Safety of Baloxav...   \n",
       "17   A Study to Investigate the Safety and Efficacy...   \n",
       "18                          Nigella Sativa in COVID-19   \n",
       "19   A Study to Evaluate Safety and Efficacy of SAG...   \n",
       "20   Pharmacokinetics and Safety of MM36 Topical Oi...   \n",
       "21   Study to Evaluate the Safety, Tolerability, an...   \n",
       "22   Edoxaban Treatment Versus Vitamin K Antagonist...   \n",
       "23   Study of ALXN1210 in Complement Inhibitor Trea...   \n",
       "24   A Study of Rapastinel as Adjunctive Therapy in...   \n",
       "25   A Multicenter, Open-label, Pilot Study of Soti...   \n",
       "26   A Study to Assess Safety and Efficacy of KarXT...   \n",
       "27   A Study to Evaluate the Long-term Safety and E...   \n",
       "28   Freeze-Dried MVA-BN® Lot Consistency Smallpox ...   \n",
       "29   A Long Term Study of ALKS 5461 in the Treatmen...   \n",
       "..                                                 ...   \n",
       "682  The Effect of an Antibiotic on the Production ...   \n",
       "683  Volixibat (SHP626) in the Treatment of Adults ...   \n",
       "684  Study to Compare the Efficacy and Safety of En...   \n",
       "685  LE Gel for the Treatment of Ocular Inflammatio...   \n",
       "686  Effect of Elamipretide on Left Ventricular Fun...   \n",
       "687  A Safety and Efficacy Study of Setipiprant Tab...   \n",
       "688  A Pilot Study of the Effects of Mirabegron on ...   \n",
       "689  Efficacy and Safety of Sofosbuvir/Velpatasvir ...   \n",
       "690  Efficacy and Safety Study of Eravacycline Comp...   \n",
       "691  A Safety, Efficacy and Pharmacokinetic Study o...   \n",
       "692  A Study With BPS-314d-MR-PAH-303 in Participan...   \n",
       "693  An Open-label Extension Study Evaluating Safet...   \n",
       "694  Comparison Trial of OPA-15406 Ointment in Adul...   \n",
       "695  Comparing Efficacy and Safety of Insulin Deglu...   \n",
       "696  A Study of CK-2127107 in Patients With Spinal ...   \n",
       "697        Ketamine for Reduction of Alcoholic Relapse   \n",
       "698  Study of a Monoclonal Antibody KHK4083 in Mode...   \n",
       "699  Efficacy and Safety of Semaglutide Versus Dula...   \n",
       "700  Immune Effects of Oral Insulin in Relatives at...   \n",
       "701  Efficacy and Safety Study of DX-2930 to Preven...   \n",
       "702  Clinical Study to Evaluate the Efficacy, Safet...   \n",
       "703  Pharmacodynamic Bioequivalence of Metered Dose...   \n",
       "704  A Study to Compare SB11 (Proposed Ranibizumab ...   \n",
       "705  Efficacy and Safety of a 0.1% Tacrolimus Nasal...   \n",
       "706  A Study to Evaluate Safety, Efficacy, and Tole...   \n",
       "707  Efficacy and Safety Clinical Trial of Tenoten ...   \n",
       "708  Study to Compare QVM149 and Free Triple Combin...   \n",
       "709  Study in Participants With Homozygous Familial...   \n",
       "710  MRI Trial to exPlore the efficAcy and Safety o...   \n",
       "711  EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ...   \n",
       "\n",
       "                       Model       Date  \\\n",
       "0        Parallel Assignment  24-Mar-17   \n",
       "1        Parallel Assignment  29-Mar-17   \n",
       "2        Parallel Assignment  12-Jun-17   \n",
       "3        Parallel Assignment  12-Oct-17   \n",
       "4        Parallel Assignment  18-Feb-17   \n",
       "5        Parallel Assignment   2-Oct-17   \n",
       "6        Parallel Assignment  18-Aug-16   \n",
       "7    Single Group Assignment   7-Jul-18   \n",
       "8       Crossover Assignment   3-Aug-17   \n",
       "9        Parallel Assignment   6-Jul-17   \n",
       "10       Parallel Assignment  22-Jun-17   \n",
       "11       Parallel Assignment  29-Jun-17   \n",
       "12   Single Group Assignment   2-Oct-17   \n",
       "13   Single Group Assignment  17-Jun-19   \n",
       "14       Parallel Assignment   9-May-19   \n",
       "15      Crossover Assignment  31-Oct-18   \n",
       "16       Parallel Assignment   8-Jan-19   \n",
       "17       Parallel Assignment   8-Oct-18   \n",
       "18       Parallel Assignment  21-May-20   \n",
       "19       Parallel Assignment     Jul-16   \n",
       "20   Single Group Assignment     Oct-16   \n",
       "21       Parallel Assignment  29-Nov-16   \n",
       "22       Parallel Assignment  21-Mar-17   \n",
       "23   Single Group Assignment  18-Mar-17   \n",
       "24       Parallel Assignment   2-Nov-16   \n",
       "25   Single Group Assignment  10-Sep-18   \n",
       "26       Parallel Assignment  18-Sep-18   \n",
       "27   Single Group Assignment  27-Sep-18   \n",
       "28       Parallel Assignment  19-Jun-19   \n",
       "29   Single Group Assignment   9-Aug-18   \n",
       "..                       ...        ...   \n",
       "682     Crossover Assignment  27-Nov-17   \n",
       "683      Parallel Assignment  24-Oct-16   \n",
       "684      Parallel Assignment   2-Nov-16   \n",
       "685      Parallel Assignment     Jun-16   \n",
       "686      Parallel Assignment     Jun-16   \n",
       "687      Parallel Assignment  14-Jul-16   \n",
       "688      Parallel Assignment     Aug-16   \n",
       "689      Parallel Assignment  29-Jul-16   \n",
       "690      Parallel Assignment  13-Oct-16   \n",
       "691      Parallel Assignment  26-May-16   \n",
       "692      Parallel Assignment  10-Dec-18   \n",
       "693  Single Group Assignment   7-May-19   \n",
       "694      Parallel Assignment  25-Mar-19   \n",
       "695      Parallel Assignment   4-Jan-16   \n",
       "696      Parallel Assignment  14-Jan-16   \n",
       "697      Parallel Assignment     Oct-16   \n",
       "698    Sequential Assignment     Jun-16   \n",
       "699      Parallel Assignment   6-Jan-16   \n",
       "700      Parallel Assignment     Jan-16   \n",
       "701      Parallel Assignment   3-Mar-16   \n",
       "702      Parallel Assignment  30-Sep-16   \n",
       "703     Crossover Assignment     Apr-16   \n",
       "704      Parallel Assignment  14-Mar-18   \n",
       "705      Parallel Assignment  22-May-17   \n",
       "706      Parallel Assignment  24-May-17   \n",
       "707      Parallel Assignment  19-Feb-16   \n",
       "708      Parallel Assignment   5-Feb-18   \n",
       "709      Parallel Assignment   3-Oct-17   \n",
       "710      Parallel Assignment  28-Jan-19   \n",
       "711      Parallel Assignment  22-Mar-16   \n",
       "\n",
       "                                                reason  \n",
       "0    NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "1    NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "2    NOT COMPLETED BECAUSE OF, Randomized and Never...  \n",
       "3    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "4    NOT COMPLETED BECAUSE OF, Death, Adverse Event...  \n",
       "5    NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  \n",
       "6    NOT COMPLETED BECAUSE OF, Physician Decision, ...  \n",
       "7    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "8    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "9    NOT COMPLETED BECAUSE OF, Adverse Event, Study...  \n",
       "10   NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "11   NOT COMPLETED BECAUSE OF, Withdrew Consent, De...  \n",
       "12   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "13   NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "14   NOT COMPLETED BECAUSE OF, Unclassified, Advers...  \n",
       "15             NOT COMPLETED BECAUSE OF, Adverse Event  \n",
       "16   NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "17   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "18   NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...  \n",
       "19   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "20   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "21   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "22   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "23   NOT COMPLETED BECAUSE OF, Failed to Meet Eligi...  \n",
       "24   NOT COMPLETED BECAUSE OF, Protocol Violation, ...  \n",
       "25   NOT COMPLETED BECAUSE OF, Adverse Event, Reaso...  \n",
       "26   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "27   NOT COMPLETED BECAUSE OF, Adverse Event, Study...  \n",
       "28   NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "29   NOT COMPLETED BECAUSE OF, Study terminated by ...  \n",
       "..                                                 ...  \n",
       "682  NOT COMPLETED BECAUSE OF, Adverse Event, insuf...  \n",
       "683  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "684  NOT COMPLETED BECAUSE OF, Adverse Event, Other...  \n",
       "685  NOT COMPLETED BECAUSE OF, Adverse Event, Physi...  \n",
       "686            NOT COMPLETED BECAUSE OF, Adverse Event  \n",
       "687  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "688  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "689  NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...  \n",
       "690  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "691  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "692  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "693  NOT COMPLETED BECAUSE OF, Adverse Event, Study...  \n",
       "694  NOT COMPLETED BECAUSE OF, Adverse Event, Physi...  \n",
       "695  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "696  NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  \n",
       "697  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "698  NOT COMPLETED BECAUSE OF, Adverse Event, Disea...  \n",
       "699  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "700  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "701  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "702  NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "703  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "704  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "705            NOT COMPLETED BECAUSE OF, Adverse Event  \n",
       "706  NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "707  NOT COMPLETED BECAUSE OF, Did Not Meet Inclusi...  \n",
       "708  NOT COMPLETED BECAUSE OF, Subject/Guardian Dec...  \n",
       "709  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "710  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "711  NOT COMPLETED BECAUSE OF, Pregnancy, Withdrawa...  \n",
       "\n",
       "[712 rows x 8 columns]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "display(adverse_df)\n",
    "\n",
    "adverse_df.to_csv('adverse_df_classified.csv',index=False, encoding='utf-8', quoting=csv.QUOTE_NONNUMERIC)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Nct_id</th>\n",
       "      <th>Phase</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Title</th>\n",
       "      <th>Model</th>\n",
       "      <th>Date</th>\n",
       "      <th>reason</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03118765</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Respiratory</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rang...</td>\n",
       "      <td>Pharmacodynamic and Pharmacokinetic Dose Rangi...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>24-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03114657</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>CNS disorder</td>\n",
       "      <td>This randomized, double-blind, placebo-contro...</td>\n",
       "      <td>A Study of Crenezumab Versus Placebo to Evalua...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03110380</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Switching to a Fixed Dose Combination of Bicte...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>12-Jun-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Randomized and Never...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT03115112</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>The purpose of this study is to investigate t...</td>\n",
       "      <td>Safety and Efficacy of Bexagliflozin Compared ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>12-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT03119701</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hospital Care</td>\n",
       "      <td>A study to assess effectiveness and safety of...</td>\n",
       "      <td>Efficacy and Safety of FP-1201-lyo (Interferon...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>18-Feb-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Death, Adverse Event...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT03181503</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Skin Infection/Allergy</td>\n",
       "      <td>The aim of this study is to assess the safety...</td>\n",
       "      <td>Safety and Efficacy of Nemolizumab in PN</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>2-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT03180801</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>FLU-v is a broad spectrum influenza vaccine t...</td>\n",
       "      <td>Efficacy of FLU-v in an H1N1 Influenza Human C...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>18-Aug-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Physician Decision, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT03180528</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>This phase 2 trial studies how well remetinos...</td>\n",
       "      <td>Topical Remetinostat in Treating Patient With ...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>7-Jul-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT03187301</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>A cardiac safety study of an investigational ...</td>\n",
       "      <td>A Cardiac Safety Study of an Investigational D...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>3-Aug-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT03185481</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>The purpose of this study is to evaluate the ...</td>\n",
       "      <td>Safety and Tolerability of PF-06649751 in Park...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>6-Jul-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NCT03184987</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Respiratory</td>\n",
       "      <td>Despite availability of treatments and publis...</td>\n",
       "      <td>A Long-term Safety Study of Fixed Dose Combina...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>22-Jun-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>NCT03180619</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Study to Evaluate the Safety and Efficacy of S...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Jun-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrew Consent, De...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NCT03189446</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>The purpose of this study is to determine the...</td>\n",
       "      <td>Vaginal Cuff Brachytherapy Followed by Chemoth...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>2-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT03722576</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>To examine the safety, tolerability, and effi...</td>\n",
       "      <td>Vidofludimus Calcium for Primary Sclerosing Ch...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>17-Jun-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NCT03922750</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>This study compares insulin 287 (a possible n...</td>\n",
       "      <td>A Research Study in People With Type 2 Diabete...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>9-May-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Unclassified, Advers...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NCT03686033</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS disorder</td>\n",
       "      <td>The primary purpose of the study is to assess...</td>\n",
       "      <td>A Study to Evaluate the Pharmacodynamic Activi...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>31-Oct-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NCT03684044</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>This study will evaluate the efficacy, safety...</td>\n",
       "      <td>Study to Assess Efficacy and Safety of Baloxav...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>8-Jan-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NCT03682705</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Bones/Joints Inflammation</td>\n",
       "      <td>This was a phase 2 study to evaluate the safe...</td>\n",
       "      <td>A Study to Investigate the Safety and Efficacy...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>8-Oct-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>NCT04401202</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>Natural products with immunomodulation and an...</td>\n",
       "      <td>Nigella Sativa in COVID-19</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>21-May-20</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>NCT02942017</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Reproduction</td>\n",
       "      <td>The purpose of this study was to determine if...</td>\n",
       "      <td>A Study to Evaluate Safety and Efficacy of SAG...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>16-Jul</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NCT02945657</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Eye Disorder</td>\n",
       "      <td>The purpose of this study is to assess the ph...</td>\n",
       "      <td>Pharmacokinetics and Safety of MM36 Topical Oi...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>16-Oct</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NCT02943460</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>The primary objective of this study is to eva...</td>\n",
       "      <td>Study to Evaluate the Safety, Tolerability, an...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Nov-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>NCT02942576</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Heart (Circulation) condition</td>\n",
       "      <td>There are insufficient data on the safety and...</td>\n",
       "      <td>Edoxaban Treatment Versus Vitamin K Antagonist...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>21-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>NCT02949128</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Blood disorder and Immunity</td>\n",
       "      <td>The purpose of the study is to assess the saf...</td>\n",
       "      <td>Study of ALXN1210 in Complement Inhibitor Trea...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>18-Mar-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Failed to Meet Eligi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>NCT02943577</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress/Sleep/Obesity</td>\n",
       "      <td>This study will evaluate the efficacy, safety...</td>\n",
       "      <td>A Study of Rapastinel as Adjunctive Therapy in...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>2-Nov-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Protocol Violation, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>NCT03694275</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Muscle Disorder CNS/Others</td>\n",
       "      <td>The purpose of this study is to investigate t...</td>\n",
       "      <td>A Multicenter, Open-label, Pilot Study of Soti...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>10-Sep-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Reaso...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>NCT03697252</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>This is a Phase 2, randomized, double-blinded...</td>\n",
       "      <td>A Study to Assess Safety and Efficacy of KarXT...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>18-Sep-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NCT03693625</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Skin Infection/Allergy</td>\n",
       "      <td>This is a Phase II, multicenter, open-label e...</td>\n",
       "      <td>A Study to Evaluate the Long-term Safety and E...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>27-Sep-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NCT03699124</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>This is a Phase 3 multicenter trial to evalua...</td>\n",
       "      <td>Freeze-Dried MVA-BN® Lot Consistency Smallpox ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>19-Jun-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NCT03610048</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress/Sleep/Obesity</td>\n",
       "      <td>This study will assess the long-term safety a...</td>\n",
       "      <td>A Long Term Study of ALKS 5461 in the Treatmen...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>9-Aug-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Study terminated by ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>682</th>\n",
       "      <td>NCT03452189</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress/Sleep/Obesity</td>\n",
       "      <td>The purpose of this study is to determine if ...</td>\n",
       "      <td>The Effect of an Antibiotic on the Production ...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>27-Nov-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, insuf...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>683</th>\n",
       "      <td>NCT02787304</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alcohol/Liver</td>\n",
       "      <td>The purpose of this study is to determine if ...</td>\n",
       "      <td>Volixibat (SHP626) in the Treatment of Adults ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>24-Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>684</th>\n",
       "      <td>NCT02782741</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress/Sleep/Obesity</td>\n",
       "      <td>Primary Objective:\\r\\r To determine the effec...</td>\n",
       "      <td>Study to Compare the Efficacy and Safety of En...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>2-Nov-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Other...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>685</th>\n",
       "      <td>NCT02786901</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Eye Disorder</td>\n",
       "      <td>Loteprednol Etabonate Ophthalmic Gel, (BID an...</td>\n",
       "      <td>LE Gel for the Treatment of Ocular Inflammatio...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>16-Jun</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Physi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>686</th>\n",
       "      <td>NCT02788747</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Heart (Circulation) condition</td>\n",
       "      <td>This was a randomized, double-blinded, placeb...</td>\n",
       "      <td>Effect of Elamipretide on Left Ventricular Fun...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>16-Jun</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>687</th>\n",
       "      <td>NCT02781311</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress/Sleep/Obesity</td>\n",
       "      <td>This study will evaluate the safety, tolerabi...</td>\n",
       "      <td>A Safety and Efficacy Study of Setipiprant Tab...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>14-Jul-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>688</th>\n",
       "      <td>NCT02787083</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Inflammation/Autoimmune (Others)</td>\n",
       "      <td>Bladder pain syndrome/interstitial cystitis (...</td>\n",
       "      <td>A Pilot Study of the Effects of Mirabegron on ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>16-Aug</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>689</th>\n",
       "      <td>NCT02781558</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>The primary objectives of this study are to e...</td>\n",
       "      <td>Efficacy and Safety of Sofosbuvir/Velpatasvir ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>29-Jul-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>690</th>\n",
       "      <td>NCT02784704</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Inflammation/Autoimmune (Others)</td>\n",
       "      <td>This is a Phase 3, randomized, double-blind, ...</td>\n",
       "      <td>Efficacy and Safety Study of Eravacycline Comp...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>13-Oct-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>691</th>\n",
       "      <td>NCT02780115</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Eye Disorder</td>\n",
       "      <td>This is a safety, efficacy and pharmacokineti...</td>\n",
       "      <td>A Safety, Efficacy and Pharmacokinetic Study o...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>26-May-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>692</th>\n",
       "      <td>NCT03657095</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Respiratory</td>\n",
       "      <td>This is a multi-center, open-label study for ...</td>\n",
       "      <td>A Study With BPS-314d-MR-PAH-303 in Participan...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>10-Dec-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>693</th>\n",
       "      <td>NCT03909295</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Heart (Circulation) condition</td>\n",
       "      <td>This study evaluated the safety and tolerabil...</td>\n",
       "      <td>An Open-label Extension Study Evaluating Safet...</td>\n",
       "      <td>Single Group Assignment</td>\n",
       "      <td>7-May-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Study...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>694</th>\n",
       "      <td>NCT03908970</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Eye Disorder</td>\n",
       "      <td>To demonstrate the superiority of IMP (1% OPA...</td>\n",
       "      <td>Comparison Trial of OPA-15406 Ointment in Adul...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>25-Mar-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Physi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>695</th>\n",
       "      <td>NCT02648217</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>This trial is conducted in Africa and Asia. T...</td>\n",
       "      <td>Comparing Efficacy and Safety of Insulin Deglu...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>4-Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>696</th>\n",
       "      <td>NCT02644668</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS disorder</td>\n",
       "      <td>This study will evaluate the pharmacodynamic ...</td>\n",
       "      <td>A Study of CK-2127107 in Patients With Spinal ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>14-Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Proto...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>697</th>\n",
       "      <td>NCT02649231</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Alcohol/Liver</td>\n",
       "      <td>96 recently detoxified alcoholics will be ran...</td>\n",
       "      <td>Ketamine for Reduction of Alcoholic Relapse</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>16-Oct</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>698</th>\n",
       "      <td>NCT02647866</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Inflammation/Autoimmune (Others)</td>\n",
       "      <td>The purpose of this study is to determine the...</td>\n",
       "      <td>Study of a Monoclonal Antibody KHK4083 in Mode...</td>\n",
       "      <td>Sequential Assignment</td>\n",
       "      <td>16-Jun</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Disea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>699</th>\n",
       "      <td>NCT02648204</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>This trial is conducted in Asia, Europe and t...</td>\n",
       "      <td>Efficacy and Safety of Semaglutide Versus Dula...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>6-Jan-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>700</th>\n",
       "      <td>NCT02580877</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Diabetes</td>\n",
       "      <td>The study is a 2 arm, multi-center, randomize...</td>\n",
       "      <td>Immune Effects of Oral Insulin in Relatives at...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>16-Jan</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>701</th>\n",
       "      <td>NCT02586805</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Inflammation/Autoimmune (Others)</td>\n",
       "      <td>This is a phase 3, multicenter, randomized, d...</td>\n",
       "      <td>Efficacy and Safety Study of DX-2930 to Preven...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>3-Mar-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>702</th>\n",
       "      <td>NCT02587221</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Antiviral</td>\n",
       "      <td>A Phase III, Randomized, Observer-Blind, Cont...</td>\n",
       "      <td>Clinical Study to Evaluate the Efficacy, Safet...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>30-Sep-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>703</th>\n",
       "      <td>NCT02584257</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Respiratory</td>\n",
       "      <td>The purpose of this study is to demonstrate t...</td>\n",
       "      <td>Pharmacodynamic Bioequivalence of Metered Dose...</td>\n",
       "      <td>Crossover Assignment</td>\n",
       "      <td>16-Apr</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>704</th>\n",
       "      <td>NCT03150589</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress/Sleep/Obesity</td>\n",
       "      <td>This is a randomised, double-masked, parallel...</td>\n",
       "      <td>A Study to Compare SB11 (Proposed Ranibizumab ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>14-Mar-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>705</th>\n",
       "      <td>NCT03152019</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Blood disorder and Immunity</td>\n",
       "      <td>The recognized manifestations of HHT are all ...</td>\n",
       "      <td>Efficacy and Safety of a 0.1% Tacrolimus Nasal...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>22-May-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>706</th>\n",
       "      <td>NCT03150719</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Respiratory</td>\n",
       "      <td>Study VX16-661-114 (Study 114) is a Phase 3b,...</td>\n",
       "      <td>A Study to Evaluate Safety, Efficacy, and Tole...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>24-May-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Death...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>707</th>\n",
       "      <td>NCT03159611</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Reproduction</td>\n",
       "      <td>Purpose of the study:\\r\\r - To assess the cli...</td>\n",
       "      <td>Efficacy and Safety Clinical Trial of Tenoten ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>19-Feb-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Did Not Meet Inclusi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>708</th>\n",
       "      <td>NCT03158311</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Respiratory</td>\n",
       "      <td>The purpose of this trial was to demonstrate ...</td>\n",
       "      <td>Study to Compare QVM149 and Free Triple Combin...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>5-Feb-18</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Subject/Guardian Dec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>709</th>\n",
       "      <td>NCT03156621</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Heart (Circulation) condition</td>\n",
       "      <td>The primary objective of the study is to demo...</td>\n",
       "      <td>Study in Participants With Homozygous Familial...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>3-Oct-17</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Adverse Event, Withd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>710</th>\n",
       "      <td>NCT03846219</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>CNS autoimmune</td>\n",
       "      <td>This is a Phase 2 multicenter, double-blind, ...</td>\n",
       "      <td>MRI Trial to exPlore the efficAcy and Safety o...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>28-Jan-19</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>711</th>\n",
       "      <td>NCT02635386</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Hair/Cosmetics/Aging/Stress/Sleep/Obesity</td>\n",
       "      <td>This is a randomized, single-blind, parallel ...</td>\n",
       "      <td>EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ...</td>\n",
       "      <td>Parallel Assignment</td>\n",
       "      <td>22-Mar-16</td>\n",
       "      <td>NOT COMPLETED BECAUSE OF, Pregnancy, Withdrawa...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>712 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "          Nct_id    Phase                                  Condition  \\\n",
       "0    NCT03118765  Phase 2                                Respiratory   \n",
       "1    NCT03114657  Phase 3                               CNS disorder   \n",
       "2    NCT03110380  Phase 3                                  Antiviral   \n",
       "3    NCT03115112  Phase 3                                   Diabetes   \n",
       "4    NCT03119701  Phase 2                              Hospital Care   \n",
       "5    NCT03181503  Phase 2                     Skin Infection/Allergy   \n",
       "6    NCT03180801  Phase 2                                  Antiviral   \n",
       "7    NCT03180528  Phase 2                                     Cancer   \n",
       "8    NCT03187301  Phase 2                             CNS autoimmune   \n",
       "9    NCT03185481  Phase 2                             CNS autoimmune   \n",
       "10   NCT03184987  Phase 3                                Respiratory   \n",
       "11   NCT03180619  Phase 2                                  Antiviral   \n",
       "12   NCT03189446  Phase 2                                     Cancer   \n",
       "13   NCT03722576  Phase 2                             CNS autoimmune   \n",
       "14   NCT03922750  Phase 2                                   Diabetes   \n",
       "15   NCT03686033  Phase 2                               CNS disorder   \n",
       "16   NCT03684044  Phase 3                                  Antiviral   \n",
       "17   NCT03682705  Phase 2                  Bones/Joints Inflammation   \n",
       "18   NCT04401202  Phase 2                                  Antiviral   \n",
       "19   NCT02942017  Phase 3                               Reproduction   \n",
       "20   NCT02945657  Phase 2                               Eye Disorder   \n",
       "21   NCT02943460  Phase 2                             CNS autoimmune   \n",
       "22   NCT02942576  Phase 3              Heart (Circulation) condition   \n",
       "23   NCT02949128  Phase 3                Blood disorder and Immunity   \n",
       "24   NCT02943577  Phase 3  Hair/Cosmetics/Aging/Stress/Sleep/Obesity   \n",
       "25   NCT03694275  Phase 2                 Muscle Disorder CNS/Others   \n",
       "26   NCT03697252  Phase 2                             CNS autoimmune   \n",
       "27   NCT03693625  Phase 2                     Skin Infection/Allergy   \n",
       "28   NCT03699124  Phase 3                                  Antiviral   \n",
       "29   NCT03610048  Phase 3  Hair/Cosmetics/Aging/Stress/Sleep/Obesity   \n",
       "..           ...      ...                                        ...   \n",
       "682  NCT03452189  Phase 2  Hair/Cosmetics/Aging/Stress/Sleep/Obesity   \n",
       "683  NCT02787304  Phase 2                              Alcohol/Liver   \n",
       "684  NCT02782741  Phase 3  Hair/Cosmetics/Aging/Stress/Sleep/Obesity   \n",
       "685  NCT02786901  Phase 3                               Eye Disorder   \n",
       "686  NCT02788747  Phase 2              Heart (Circulation) condition   \n",
       "687  NCT02781311  Phase 2  Hair/Cosmetics/Aging/Stress/Sleep/Obesity   \n",
       "688  NCT02787083  Phase 3           Inflammation/Autoimmune (Others)   \n",
       "689  NCT02781558  Phase 2                                  Antiviral   \n",
       "690  NCT02784704  Phase 3           Inflammation/Autoimmune (Others)   \n",
       "691  NCT02780115  Phase 2                               Eye Disorder   \n",
       "692  NCT03657095  Phase 3                                Respiratory   \n",
       "693  NCT03909295  Phase 3              Heart (Circulation) condition   \n",
       "694  NCT03908970  Phase 3                               Eye Disorder   \n",
       "695  NCT02648217  Phase 3                                   Diabetes   \n",
       "696  NCT02644668  Phase 2                               CNS disorder   \n",
       "697  NCT02649231  Phase 2                              Alcohol/Liver   \n",
       "698  NCT02647866  Phase 2           Inflammation/Autoimmune (Others)   \n",
       "699  NCT02648204  Phase 3                                   Diabetes   \n",
       "700  NCT02580877  Phase 2                                   Diabetes   \n",
       "701  NCT02586805  Phase 3           Inflammation/Autoimmune (Others)   \n",
       "702  NCT02587221  Phase 3                                  Antiviral   \n",
       "703  NCT02584257  Phase 3                                Respiratory   \n",
       "704  NCT03150589  Phase 3  Hair/Cosmetics/Aging/Stress/Sleep/Obesity   \n",
       "705  NCT03152019  Phase 2                Blood disorder and Immunity   \n",
       "706  NCT03150719  Phase 3                                Respiratory   \n",
       "707  NCT03159611  Phase 3                               Reproduction   \n",
       "708  NCT03158311  Phase 3                                Respiratory   \n",
       "709  NCT03156621  Phase 3              Heart (Circulation) condition   \n",
       "710  NCT03846219  Phase 2                             CNS autoimmune   \n",
       "711  NCT02635386  Phase 3  Hair/Cosmetics/Aging/Stress/Sleep/Obesity   \n",
       "\n",
       "                                               Summary  \\\n",
       "0     Pharmacodynamic and Pharmacokinetic Dose Rang...   \n",
       "1     This randomized, double-blind, placebo-contro...   \n",
       "2     The primary objective of this study is to eva...   \n",
       "3     The purpose of this study is to investigate t...   \n",
       "4     A study to assess effectiveness and safety of...   \n",
       "5     The aim of this study is to assess the safety...   \n",
       "6     FLU-v is a broad spectrum influenza vaccine t...   \n",
       "7     This phase 2 trial studies how well remetinos...   \n",
       "8     A cardiac safety study of an investigational ...   \n",
       "9     The purpose of this study is to evaluate the ...   \n",
       "10    Despite availability of treatments and publis...   \n",
       "11    The primary objective of this study is to eva...   \n",
       "12    The purpose of this study is to determine the...   \n",
       "13    To examine the safety, tolerability, and effi...   \n",
       "14    This study compares insulin 287 (a possible n...   \n",
       "15    The primary purpose of the study is to assess...   \n",
       "16    This study will evaluate the efficacy, safety...   \n",
       "17    This was a phase 2 study to evaluate the safe...   \n",
       "18    Natural products with immunomodulation and an...   \n",
       "19    The purpose of this study was to determine if...   \n",
       "20    The purpose of this study is to assess the ph...   \n",
       "21    The primary objective of this study is to eva...   \n",
       "22    There are insufficient data on the safety and...   \n",
       "23    The purpose of the study is to assess the saf...   \n",
       "24    This study will evaluate the efficacy, safety...   \n",
       "25    The purpose of this study is to investigate t...   \n",
       "26    This is a Phase 2, randomized, double-blinded...   \n",
       "27    This is a Phase II, multicenter, open-label e...   \n",
       "28    This is a Phase 3 multicenter trial to evalua...   \n",
       "29    This study will assess the long-term safety a...   \n",
       "..                                                 ...   \n",
       "682   The purpose of this study is to determine if ...   \n",
       "683   The purpose of this study is to determine if ...   \n",
       "684   Primary Objective:\\r\\r To determine the effec...   \n",
       "685   Loteprednol Etabonate Ophthalmic Gel, (BID an...   \n",
       "686   This was a randomized, double-blinded, placeb...   \n",
       "687   This study will evaluate the safety, tolerabi...   \n",
       "688   Bladder pain syndrome/interstitial cystitis (...   \n",
       "689   The primary objectives of this study are to e...   \n",
       "690   This is a Phase 3, randomized, double-blind, ...   \n",
       "691   This is a safety, efficacy and pharmacokineti...   \n",
       "692   This is a multi-center, open-label study for ...   \n",
       "693   This study evaluated the safety and tolerabil...   \n",
       "694   To demonstrate the superiority of IMP (1% OPA...   \n",
       "695   This trial is conducted in Africa and Asia. T...   \n",
       "696   This study will evaluate the pharmacodynamic ...   \n",
       "697   96 recently detoxified alcoholics will be ran...   \n",
       "698   The purpose of this study is to determine the...   \n",
       "699   This trial is conducted in Asia, Europe and t...   \n",
       "700   The study is a 2 arm, multi-center, randomize...   \n",
       "701   This is a phase 3, multicenter, randomized, d...   \n",
       "702   A Phase III, Randomized, Observer-Blind, Cont...   \n",
       "703   The purpose of this study is to demonstrate t...   \n",
       "704   This is a randomised, double-masked, parallel...   \n",
       "705   The recognized manifestations of HHT are all ...   \n",
       "706   Study VX16-661-114 (Study 114) is a Phase 3b,...   \n",
       "707   Purpose of the study:\\r\\r - To assess the cli...   \n",
       "708   The purpose of this trial was to demonstrate ...   \n",
       "709   The primary objective of the study is to demo...   \n",
       "710   This is a Phase 2 multicenter, double-blind, ...   \n",
       "711   This is a randomized, single-blind, parallel ...   \n",
       "\n",
       "                                                 Title  \\\n",
       "0    Pharmacodynamic and Pharmacokinetic Dose Rangi...   \n",
       "1    A Study of Crenezumab Versus Placebo to Evalua...   \n",
       "2    Switching to a Fixed Dose Combination of Bicte...   \n",
       "3    Safety and Efficacy of Bexagliflozin Compared ...   \n",
       "4    Efficacy and Safety of FP-1201-lyo (Interferon...   \n",
       "5             Safety and Efficacy of Nemolizumab in PN   \n",
       "6    Efficacy of FLU-v in an H1N1 Influenza Human C...   \n",
       "7    Topical Remetinostat in Treating Patient With ...   \n",
       "8    A Cardiac Safety Study of an Investigational D...   \n",
       "9    Safety and Tolerability of PF-06649751 in Park...   \n",
       "10   A Long-term Safety Study of Fixed Dose Combina...   \n",
       "11   Study to Evaluate the Safety and Efficacy of S...   \n",
       "12   Vaginal Cuff Brachytherapy Followed by Chemoth...   \n",
       "13   Vidofludimus Calcium for Primary Sclerosing Ch...   \n",
       "14   A Research Study in People With Type 2 Diabete...   \n",
       "15   A Study to Evaluate the Pharmacodynamic Activi...   \n",
       "16   Study to Assess Efficacy and Safety of Baloxav...   \n",
       "17   A Study to Investigate the Safety and Efficacy...   \n",
       "18                          Nigella Sativa in COVID-19   \n",
       "19   A Study to Evaluate Safety and Efficacy of SAG...   \n",
       "20   Pharmacokinetics and Safety of MM36 Topical Oi...   \n",
       "21   Study to Evaluate the Safety, Tolerability, an...   \n",
       "22   Edoxaban Treatment Versus Vitamin K Antagonist...   \n",
       "23   Study of ALXN1210 in Complement Inhibitor Trea...   \n",
       "24   A Study of Rapastinel as Adjunctive Therapy in...   \n",
       "25   A Multicenter, Open-label, Pilot Study of Soti...   \n",
       "26   A Study to Assess Safety and Efficacy of KarXT...   \n",
       "27   A Study to Evaluate the Long-term Safety and E...   \n",
       "28   Freeze-Dried MVA-BN® Lot Consistency Smallpox ...   \n",
       "29   A Long Term Study of ALKS 5461 in the Treatmen...   \n",
       "..                                                 ...   \n",
       "682  The Effect of an Antibiotic on the Production ...   \n",
       "683  Volixibat (SHP626) in the Treatment of Adults ...   \n",
       "684  Study to Compare the Efficacy and Safety of En...   \n",
       "685  LE Gel for the Treatment of Ocular Inflammatio...   \n",
       "686  Effect of Elamipretide on Left Ventricular Fun...   \n",
       "687  A Safety and Efficacy Study of Setipiprant Tab...   \n",
       "688  A Pilot Study of the Effects of Mirabegron on ...   \n",
       "689  Efficacy and Safety of Sofosbuvir/Velpatasvir ...   \n",
       "690  Efficacy and Safety Study of Eravacycline Comp...   \n",
       "691  A Safety, Efficacy and Pharmacokinetic Study o...   \n",
       "692  A Study With BPS-314d-MR-PAH-303 in Participan...   \n",
       "693  An Open-label Extension Study Evaluating Safet...   \n",
       "694  Comparison Trial of OPA-15406 Ointment in Adul...   \n",
       "695  Comparing Efficacy and Safety of Insulin Deglu...   \n",
       "696  A Study of CK-2127107 in Patients With Spinal ...   \n",
       "697        Ketamine for Reduction of Alcoholic Relapse   \n",
       "698  Study of a Monoclonal Antibody KHK4083 in Mode...   \n",
       "699  Efficacy and Safety of Semaglutide Versus Dula...   \n",
       "700  Immune Effects of Oral Insulin in Relatives at...   \n",
       "701  Efficacy and Safety Study of DX-2930 to Preven...   \n",
       "702  Clinical Study to Evaluate the Efficacy, Safet...   \n",
       "703  Pharmacodynamic Bioequivalence of Metered Dose...   \n",
       "704  A Study to Compare SB11 (Proposed Ranibizumab ...   \n",
       "705  Efficacy and Safety of a 0.1% Tacrolimus Nasal...   \n",
       "706  A Study to Evaluate Safety, Efficacy, and Tole...   \n",
       "707  Efficacy and Safety Clinical Trial of Tenoten ...   \n",
       "708  Study to Compare QVM149 and Free Triple Combin...   \n",
       "709  Study in Participants With Homozygous Familial...   \n",
       "710  MRI Trial to exPlore the efficAcy and Safety o...   \n",
       "711  EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ...   \n",
       "\n",
       "                       Model       Date  \\\n",
       "0        Parallel Assignment  24-Mar-17   \n",
       "1        Parallel Assignment  29-Mar-17   \n",
       "2        Parallel Assignment  12-Jun-17   \n",
       "3        Parallel Assignment  12-Oct-17   \n",
       "4        Parallel Assignment  18-Feb-17   \n",
       "5        Parallel Assignment   2-Oct-17   \n",
       "6        Parallel Assignment  18-Aug-16   \n",
       "7    Single Group Assignment   7-Jul-18   \n",
       "8       Crossover Assignment   3-Aug-17   \n",
       "9        Parallel Assignment   6-Jul-17   \n",
       "10       Parallel Assignment  22-Jun-17   \n",
       "11       Parallel Assignment  29-Jun-17   \n",
       "12   Single Group Assignment   2-Oct-17   \n",
       "13   Single Group Assignment  17-Jun-19   \n",
       "14       Parallel Assignment   9-May-19   \n",
       "15      Crossover Assignment  31-Oct-18   \n",
       "16       Parallel Assignment   8-Jan-19   \n",
       "17       Parallel Assignment   8-Oct-18   \n",
       "18       Parallel Assignment  21-May-20   \n",
       "19       Parallel Assignment     16-Jul   \n",
       "20   Single Group Assignment     16-Oct   \n",
       "21       Parallel Assignment  29-Nov-16   \n",
       "22       Parallel Assignment  21-Mar-17   \n",
       "23   Single Group Assignment  18-Mar-17   \n",
       "24       Parallel Assignment   2-Nov-16   \n",
       "25   Single Group Assignment  10-Sep-18   \n",
       "26       Parallel Assignment  18-Sep-18   \n",
       "27   Single Group Assignment  27-Sep-18   \n",
       "28       Parallel Assignment  19-Jun-19   \n",
       "29   Single Group Assignment   9-Aug-18   \n",
       "..                       ...        ...   \n",
       "682     Crossover Assignment  27-Nov-17   \n",
       "683      Parallel Assignment  24-Oct-16   \n",
       "684      Parallel Assignment   2-Nov-16   \n",
       "685      Parallel Assignment     16-Jun   \n",
       "686      Parallel Assignment     16-Jun   \n",
       "687      Parallel Assignment  14-Jul-16   \n",
       "688      Parallel Assignment     16-Aug   \n",
       "689      Parallel Assignment  29-Jul-16   \n",
       "690      Parallel Assignment  13-Oct-16   \n",
       "691      Parallel Assignment  26-May-16   \n",
       "692      Parallel Assignment  10-Dec-18   \n",
       "693  Single Group Assignment   7-May-19   \n",
       "694      Parallel Assignment  25-Mar-19   \n",
       "695      Parallel Assignment   4-Jan-16   \n",
       "696      Parallel Assignment  14-Jan-16   \n",
       "697      Parallel Assignment     16-Oct   \n",
       "698    Sequential Assignment     16-Jun   \n",
       "699      Parallel Assignment   6-Jan-16   \n",
       "700      Parallel Assignment     16-Jan   \n",
       "701      Parallel Assignment   3-Mar-16   \n",
       "702      Parallel Assignment  30-Sep-16   \n",
       "703     Crossover Assignment     16-Apr   \n",
       "704      Parallel Assignment  14-Mar-18   \n",
       "705      Parallel Assignment  22-May-17   \n",
       "706      Parallel Assignment  24-May-17   \n",
       "707      Parallel Assignment  19-Feb-16   \n",
       "708      Parallel Assignment   5-Feb-18   \n",
       "709      Parallel Assignment   3-Oct-17   \n",
       "710      Parallel Assignment  28-Jan-19   \n",
       "711      Parallel Assignment  22-Mar-16   \n",
       "\n",
       "                                                reason  \n",
       "0    NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "1    NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "2    NOT COMPLETED BECAUSE OF, Randomized and Never...  \n",
       "3    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "4    NOT COMPLETED BECAUSE OF, Death, Adverse Event...  \n",
       "5    NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  \n",
       "6    NOT COMPLETED BECAUSE OF, Physician Decision, ...  \n",
       "7    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "8    NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "9    NOT COMPLETED BECAUSE OF, Adverse Event, Study...  \n",
       "10   NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "11   NOT COMPLETED BECAUSE OF, Withdrew Consent, De...  \n",
       "12   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "13   NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "14   NOT COMPLETED BECAUSE OF, Unclassified, Advers...  \n",
       "15             NOT COMPLETED BECAUSE OF, Adverse Event  \n",
       "16   NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "17   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "18   NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...  \n",
       "19   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "20   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "21   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "22   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "23   NOT COMPLETED BECAUSE OF, Failed to Meet Eligi...  \n",
       "24   NOT COMPLETED BECAUSE OF, Protocol Violation, ...  \n",
       "25   NOT COMPLETED BECAUSE OF, Adverse Event, Reaso...  \n",
       "26   NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "27   NOT COMPLETED BECAUSE OF, Adverse Event, Study...  \n",
       "28   NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "29   NOT COMPLETED BECAUSE OF, Study terminated by ...  \n",
       "..                                                 ...  \n",
       "682  NOT COMPLETED BECAUSE OF, Adverse Event, insuf...  \n",
       "683  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "684  NOT COMPLETED BECAUSE OF, Adverse Event, Other...  \n",
       "685  NOT COMPLETED BECAUSE OF, Adverse Event, Physi...  \n",
       "686            NOT COMPLETED BECAUSE OF, Adverse Event  \n",
       "687  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "688  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "689  NOT COMPLETED BECAUSE OF, Lost to Follow-up, A...  \n",
       "690  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "691  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "692  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "693  NOT COMPLETED BECAUSE OF, Adverse Event, Study...  \n",
       "694  NOT COMPLETED BECAUSE OF, Adverse Event, Physi...  \n",
       "695  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "696  NOT COMPLETED BECAUSE OF, Adverse Event, Proto...  \n",
       "697  NOT COMPLETED BECAUSE OF, Adverse Event, Lost ...  \n",
       "698  NOT COMPLETED BECAUSE OF, Adverse Event, Disea...  \n",
       "699  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "700  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "701  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "702  NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "703  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "704  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "705            NOT COMPLETED BECAUSE OF, Adverse Event  \n",
       "706  NOT COMPLETED BECAUSE OF, Adverse Event, Death...  \n",
       "707  NOT COMPLETED BECAUSE OF, Did Not Meet Inclusi...  \n",
       "708  NOT COMPLETED BECAUSE OF, Subject/Guardian Dec...  \n",
       "709  NOT COMPLETED BECAUSE OF, Adverse Event, Withd...  \n",
       "710  NOT COMPLETED BECAUSE OF, Withdrawal by Subjec...  \n",
       "711  NOT COMPLETED BECAUSE OF, Pregnancy, Withdrawa...  \n",
       "\n",
       "[712 rows x 8 columns]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "adverse_df_classified = pd.read_csv(\"adverse_df_classified_manual.csv\")\n",
    "display(adverse_df_classified)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import seaborn as sns\n",
    "sns.set(style=\"whitegrid\")\n",
    "ax1 = sns.countplot(x=\"Condition\", data=adverse_df_classified, order = adverse_df_classified['Condition'].value_counts().index)\n",
    "ax1.set_title(\"Disease Treatment Condition\")\n",
    "plt.ylabel(\"Number of Clinical Trials\")\n",
    "plt.xlabel(\"General Class of Therapy Direction\")\n",
    "for item in ax1.get_xticklabels():\n",
    "    item.set_rotation(90)\n",
    "    \n",
    "plt.savefig('class_disease_treated.png', dpi=300,  bbox_inches='tight')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['alcoholliver', 'and', 'antibioitcs', 'antibiotics', 'antiviral', 'autoimmune', 'blood', 'bonesjoints', 'cancer', 'care', 'circulation', 'cns', 'cnsothers', 'condition', 'crohnsibd', 'diabetes', 'digestive', 'diseases', 'disorder', 'eye', 'haircosmeticsagingstresssleepobesity', 'heart', 'hormone', 'hospital', 'immunity', 'infectionallergy', 'infectious', 'inflammation', 'inflammationautoimmune', 'muscle', 'other', 'others', 'reproduction', 'respiratory', 'skin', 'urinary', 'vaccine']\n"
     ]
    }
   ],
   "source": [
    "unique = set(adverse_df_classified['Condition'].str.replace('[^a-zA-Z ]', '').str.lower().str.split(' ').sum())\n",
    "\n",
    "print(list(sorted(unique)))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# ALL CLINIAL TRIALS"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "                        \n",
    "def csv_row(xml_file):\n",
    "\n",
    "    tree = ET.parse(xml_file)\n",
    "    root = tree.getroot()\n",
    "    \n",
    "    nct_text = \"\"\n",
    "    sum_text = \"\"\n",
    "    model_text = \"\"\n",
    "    ph_text = \"\"\n",
    "    title_text = \"\"\n",
    "    year_text = \"\"\n",
    "    condition_disease_text= \"\"\n",
    "    description_text = \"\"\n",
    "    failed_text_full=\"\"\n",
    "    \n",
    "    if root.iter('drop_withdraw_reason'):\n",
    "        \n",
    "        #This bit finds all roots with nct_id which is a sub_root to id_info\n",
    "        for nct in root.findall('id_info'):\n",
    "            nctId_text = nct.find('nct_id').text\n",
    "            nct_text =nctId_text\n",
    "            #print(nct_text)\n",
    "\n",
    "        # This bit finds the brief summary text\n",
    "        for s in root.findall('brief_summary'):\n",
    "            summary_text = s.find('textblock').text\n",
    "            sum_text= summary_text\n",
    "            sum_text = sum_text.replace('\\n', '') # Replaces newline with a whitespace\n",
    "            sum_text = re.sub(' +',' ',sum_text) # Compresses multiple whitespaces to only one\n",
    "            #print(\"Summary Text:\", sum_text)\n",
    "\n",
    "        # Get's the official title for the study\n",
    "        for t in root.iter('brief_title'):\n",
    "            title_text = t.text\n",
    "\n",
    "        # This get's the type of intervention_model\n",
    "        for y in root.iter('intervention_model'):\n",
    "            model_text = y.text\n",
    "\n",
    "        for date in root.iter('start_date'):\n",
    "            year_text = date.text\n",
    "            #print(year_text)\n",
    "\n",
    "        for condition in root.iter('condition'):\n",
    "            condition_disease_text = condition.text\n",
    "            #print(condition_disease_text)\n",
    "\n",
    "\n",
    "        for reason in root.iter('drop_withdraw_reason'):\n",
    "            failed_text_full= failed_text_full+', ' +f'{reason[0].text}'\n",
    "        #print(\"withdraw reason\", failed_text_full)\n",
    "\n",
    "\n",
    "    total_text = \"\\\"\" + nct_text+ \"\\\"\" + \";\" + \"\\\"\"+ ph_text+ \"\\\"\" + \";\" + \"\\\"\" + condition_disease_text+ \"\\\"\" + \";\" + \"\\\"\"+ sum_text + \"\\\"\" + \";\"  + \"\\\"\" + title_text + \"\\\"\" + \";\"  +  \"\\\"\" + model_text + \"\\\"\" + \";\" + \"\\\"\"+ year_text + \"\\\"\" + \";\" + \"\\\"\"+ 'NOT COMPLETED BECAUSE OF' + failed_text_full+ \"\\\"\"\n",
    "\n",
    "    # This functions returns a text with Nct_Id, brief_summary, title and type of intervention model on the form we intended\n",
    "\n",
    "    return total_text\n",
    "\n",
    "#csv_row(\"/groups/cherkasvgrp/share/progressive_docking/pd_python_pose/clinical_trials/NCT0126xxxx/NCT01266460.xml\")# This is for checking that the function works"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "your file /groups/cherkasvgrp/share/progressive_docking/pd_python_pose/clinical_trials/.ipynb_checkpoints/Untitled-checkpoint.ipynb did not get parsed probably\n",
      "your file /groups/cherkasvgrp/share/progressive_docking/pd_python_pose/clinical_trials/.ipynb_checkpoints/Untitled1-checkpoint.ipynb did not get parsed probably\n"
     ]
    }
   ],
   "source": [
    "\n",
    "rdir = '/groups/cherkasvgrp/share/progressive_docking/pd_python_pose/clinical_trials' # Folders in directory where the all the xml files are placed\n",
    "\n",
    "with open('all_years_clincal_trials.csv', 'w', encoding=\"utf-8\") as csvfile: # Opens a blank csv file\n",
    "    for _, dirs, _ in os.walk(rdir):\n",
    "        for dir in dirs: # Looks at  all the xml folders\n",
    "            for subdir, _, files in os.walk(os.path.join(rdir,dir)):\n",
    "                for file in files:\n",
    "                    name = os.path.join(subdir, file)\n",
    "                    try: \n",
    "                        csvfile.write(csv_row(name)) #Writes total_text into a row in to all_clinical_trials.csv\n",
    "                        csvfile.write(\"\\n\") # Skips to next line and do the same\n",
    "                    except:\n",
    "                        print(f'your file {name} did not get parsed probably')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Earlier we saw that the returned text from our function was seperated by ';', so we use this as seperator when reading in the files\n",
    "all_clinical_trials = pd.read_csv(\"all_years_clincal_trials.csv\", sep=';', header=None,error_bad_lines=False, warn_bad_lines=False,\n",
    "                 lineterminator='\\n')\n",
    "\n",
    "all_clinical_trials.columns =  ['Nct_id', 'Phase' , 'Condition' , 'Summary', 'Title', \"Model\" , 'Date' , 'Failure Reason(s)']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Nct_id</th>\n",
       "      <th>Phase</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Summary</th>\n",
       "      <th>Title</th>\n",
       "      <th>Model</th>\n",
       "      <th>Date</th>\n",
       "      <th>reason</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: [Nct_id, Phase, Condition, Summary, Title, Model, Date, reason]\n",
       "Index: []"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_clinical_trials_na_removed=all_clinical_trials.dropna()\n",
    "all_clinical_trials_na_removed.columns =  ['Nct_id', 'Phase' , 'Condition' , 'Summary', 'Title', \"Model\" , 'Date' , 'reason']\n",
    "all_clinical_trials_na_removed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "all_clinical_trials.columns =  ['Nct_id', 'Phase' , 'Condition' , 'Summary', 'Title', \"Model\" , 'Date' , 'reason']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "388329"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df=all_clinical_trials\n",
    "len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "31469"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = df[df.reason.str.len() > 26]\n",
    "len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [],
   "source": [
    "#df['reason']=df.loc[df.reason.str.contains('Adverse')]\n",
    "df=df[df['reason'].str.contains(\"Adverse|adverse\")]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv('all_years_clinical_trials_only_adverse_retained.csv', index=False, encoding='utf-8', quoting=csv.QUOTE_NONNUMERIC)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n",
      "DID NOT WORK\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-16-d3acb2204064>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     26\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0mcmp\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     27\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 28\u001b[0;31m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'isomeric_smiles'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'api_name'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mgt_cmpds\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m~/.local/lib/python3.6/site-packages/pandas/core/series.py\u001b[0m in \u001b[0;36mapply\u001b[0;34m(self, func, convert_dtype, args, **kwds)\u001b[0m\n\u001b[1;32m   4198\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   4199\u001b[0m                 \u001b[0mvalues\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mastype\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mobject\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_values\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 4200\u001b[0;31m                 \u001b[0mmapped\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mlib\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmap_infer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mvalues\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mf\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mconvert\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mconvert_dtype\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   4201\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   4202\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmapped\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0misinstance\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmapped\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;36m0\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mSeries\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32mpandas/_libs/lib.pyx\u001b[0m in \u001b[0;36mpandas._libs.lib.map_infer\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32m<ipython-input-16-d3acb2204064>\u001b[0m in \u001b[0;36m<lambda>\u001b[0;34m(x)\u001b[0m\n\u001b[1;32m     26\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0mcmp\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     27\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 28\u001b[0;31m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'isomeric_smiles'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'api_name'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mgt_cmpds\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m<ipython-input-16-d3acb2204064>\u001b[0m in \u001b[0;36mgt_cmpds\u001b[0;34m(cmpd)\u001b[0m\n\u001b[1;32m      9\u001b[0m \u001b[0;32mdef\u001b[0m \u001b[0mgt_cmpds\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcmpd\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     10\u001b[0m     \u001b[0mcmpds\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 11\u001b[0;31m     \u001b[0;32mfor\u001b[0m \u001b[0mcompound\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mpcp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget_compounds\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcmpd\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'name'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     12\u001b[0m         \u001b[0mcmpds\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mcompound\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0misomeric_smiles\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     13\u001b[0m     \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/.local/lib/python3.6/site-packages/pubchempy.py\u001b[0m in \u001b[0;36mget_compounds\u001b[0;34m(identifier, namespace, searchtype, as_dataframe, **kwargs)\u001b[0m\n\u001b[1;32m    319\u001b[0m                          \u001b[0;34m:\u001b[0m\u001b[0;32mclass\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;31m`\u001b[0m\u001b[0;34m~\u001b[0m\u001b[0mpandas\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mDataFrame\u001b[0m\u001b[0;31m`\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0;32mreturn\u001b[0m \u001b[0mthat\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    320\u001b[0m     \"\"\"\n\u001b[0;32m--> 321\u001b[0;31m     \u001b[0mresults\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mget_json\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0midentifier\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnamespace\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msearchtype\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0msearchtype\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    322\u001b[0m     \u001b[0mcompounds\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mCompound\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mr\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfor\u001b[0m \u001b[0mr\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mresults\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'PC_Compounds'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0mresults\u001b[0m \u001b[0;32melse\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    323\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mas_dataframe\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/.local/lib/python3.6/site-packages/pubchempy.py\u001b[0m in \u001b[0;36mget_json\u001b[0;34m(identifier, namespace, domain, operation, searchtype, **kwargs)\u001b[0m\n\u001b[1;32m    297\u001b[0m     \u001b[0;34m\"\"\"Request wrapper that automatically parses JSON response and supresses NotFoundError.\"\"\"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    298\u001b[0m     \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 299\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mjson\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mloads\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mget\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0midentifier\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnamespace\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdomain\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0moperation\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'JSON'\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msearchtype\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdecode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    300\u001b[0m     \u001b[0;32mexcept\u001b[0m \u001b[0mNotFoundError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    301\u001b[0m         \u001b[0mlog\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0minfo\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0me\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/.local/lib/python3.6/site-packages/pubchempy.py\u001b[0m in \u001b[0;36mget\u001b[0;34m(identifier, namespace, domain, operation, output, searchtype, **kwargs)\u001b[0m\n\u001b[1;32m    290\u001b[0m                 \u001b[0mresponse\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mrequest\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0midentifier\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnamespace\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdomain\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0moperation\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0moutput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msearchtype\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    291\u001b[0m     \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 292\u001b[0;31m         \u001b[0mresponse\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mrequest\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0midentifier\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnamespace\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdomain\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0moperation\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0moutput\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0msearchtype\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    293\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0mresponse\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    294\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/.local/lib/python3.6/site-packages/pubchempy.py\u001b[0m in \u001b[0;36mrequest\u001b[0;34m(identifier, namespace, domain, operation, output, searchtype, **kwargs)\u001b[0m\n\u001b[1;32m    269\u001b[0m         \u001b[0mlog\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdebug\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'Request URL: %s'\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mapiurl\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    270\u001b[0m         \u001b[0mlog\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdebug\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'Request data: %s'\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mpostdata\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 271\u001b[0;31m         \u001b[0mresponse\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0murlopen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mapiurl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mpostdata\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    272\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mresponse\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    273\u001b[0m     \u001b[0;32mexcept\u001b[0m \u001b[0mHTTPError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/urllib/request.py\u001b[0m in \u001b[0;36murlopen\u001b[0;34m(url, data, timeout, cafile, capath, cadefault, context)\u001b[0m\n\u001b[1;32m    221\u001b[0m     \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    222\u001b[0m         \u001b[0mopener\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0m_opener\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 223\u001b[0;31m     \u001b[0;32mreturn\u001b[0m \u001b[0mopener\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mopen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdata\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtimeout\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    224\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    225\u001b[0m \u001b[0;32mdef\u001b[0m \u001b[0minstall_opener\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mopener\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/urllib/request.py\u001b[0m in \u001b[0;36mopen\u001b[0;34m(self, fullurl, data, timeout)\u001b[0m\n\u001b[1;32m    524\u001b[0m             \u001b[0mreq\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mmeth\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mreq\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    525\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 526\u001b[0;31m         \u001b[0mresponse\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_open\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mreq\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mdata\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    527\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    528\u001b[0m         \u001b[0;31m# post-process response\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/urllib/request.py\u001b[0m in \u001b[0;36m_open\u001b[0;34m(self, req, data)\u001b[0m\n\u001b[1;32m    542\u001b[0m         \u001b[0mprotocol\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mreq\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtype\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    543\u001b[0m         result = self._call_chain(self.handle_open, protocol, protocol +\n\u001b[0;32m--> 544\u001b[0;31m                                   '_open', req)\n\u001b[0m\u001b[1;32m    545\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    546\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/urllib/request.py\u001b[0m in \u001b[0;36m_call_chain\u001b[0;34m(self, chain, kind, meth_name, *args)\u001b[0m\n\u001b[1;32m    502\u001b[0m         \u001b[0;32mfor\u001b[0m \u001b[0mhandler\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mhandlers\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    503\u001b[0m             \u001b[0mfunc\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mgetattr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mhandler\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmeth_name\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 504\u001b[0;31m             \u001b[0mresult\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mfunc\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    505\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mresult\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    506\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/urllib/request.py\u001b[0m in \u001b[0;36mhttps_open\u001b[0;34m(self, req)\u001b[0m\n\u001b[1;32m   1359\u001b[0m         \u001b[0;32mdef\u001b[0m \u001b[0mhttps_open\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mreq\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1360\u001b[0m             return self.do_open(http.client.HTTPSConnection, req,\n\u001b[0;32m-> 1361\u001b[0;31m                 context=self._context, check_hostname=self._check_hostname)\n\u001b[0m\u001b[1;32m   1362\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1363\u001b[0m         \u001b[0mhttps_request\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mAbstractHTTPHandler\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdo_request_\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/urllib/request.py\u001b[0m in \u001b[0;36mdo_open\u001b[0;34m(self, http_class, req, **http_conn_args)\u001b[0m\n\u001b[1;32m   1316\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1317\u001b[0m                 h.request(req.get_method(), req.selector, req.data, headers,\n\u001b[0;32m-> 1318\u001b[0;31m                           encode_chunked=req.has_header('Transfer-encoding'))\n\u001b[0m\u001b[1;32m   1319\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mOSError\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0merr\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;31m# timeout error\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1320\u001b[0m                 \u001b[0;32mraise\u001b[0m \u001b[0mURLError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0merr\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/http/client.py\u001b[0m in \u001b[0;36mrequest\u001b[0;34m(self, method, url, body, headers, encode_chunked)\u001b[0m\n\u001b[1;32m   1252\u001b[0m                 encode_chunked=False):\n\u001b[1;32m   1253\u001b[0m         \u001b[0;34m\"\"\"Send a complete request to the server.\"\"\"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1254\u001b[0;31m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_send_request\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbody\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mheaders\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mencode_chunked\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1255\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1256\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_send_request\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbody\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mheaders\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mencode_chunked\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/http/client.py\u001b[0m in \u001b[0;36m_send_request\u001b[0;34m(self, method, url, body, headers, encode_chunked)\u001b[0m\n\u001b[1;32m   1298\u001b[0m             \u001b[0;31m# default charset of iso-8859-1.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1299\u001b[0m             \u001b[0mbody\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0m_encode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mbody\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'body'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1300\u001b[0;31m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mendheaders\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mbody\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mencode_chunked\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mencode_chunked\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1301\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1302\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mgetresponse\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/http/client.py\u001b[0m in \u001b[0;36mendheaders\u001b[0;34m(self, message_body, encode_chunked)\u001b[0m\n\u001b[1;32m   1247\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1248\u001b[0m             \u001b[0;32mraise\u001b[0m \u001b[0mCannotSendHeader\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1249\u001b[0;31m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_send_output\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmessage_body\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mencode_chunked\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mencode_chunked\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1250\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1251\u001b[0m     def request(self, method, url, body=None, headers={}, *,\n",
      "\u001b[0;32m/usr/lib64/python3.6/http/client.py\u001b[0m in \u001b[0;36m_send_output\u001b[0;34m(self, message_body, encode_chunked)\u001b[0m\n\u001b[1;32m   1034\u001b[0m         \u001b[0mmsg\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34mb\"\\r\\n\"\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mjoin\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_buffer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1035\u001b[0m         \u001b[0;32mdel\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_buffer\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1036\u001b[0;31m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmsg\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1037\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1038\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mmessage_body\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/http/client.py\u001b[0m in \u001b[0;36msend\u001b[0;34m(self, data)\u001b[0m\n\u001b[1;32m    972\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msock\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    973\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mauto_open\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 974\u001b[0;31m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mconnect\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    975\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    976\u001b[0m                 \u001b[0;32mraise\u001b[0m \u001b[0mNotConnected\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/http/client.py\u001b[0m in \u001b[0;36mconnect\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1413\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1414\u001b[0m             self.sock = self._context.wrap_socket(self.sock,\n\u001b[0;32m-> 1415\u001b[0;31m                                                   server_hostname=server_hostname)\n\u001b[0m\u001b[1;32m   1416\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_context\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcheck_hostname\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_check_hostname\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1417\u001b[0m                 \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/ssl.py\u001b[0m in \u001b[0;36mwrap_socket\u001b[0;34m(self, sock, server_side, do_handshake_on_connect, suppress_ragged_eofs, server_hostname, session)\u001b[0m\n\u001b[1;32m    363\u001b[0m                          \u001b[0msuppress_ragged_eofs\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0msuppress_ragged_eofs\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    364\u001b[0m                          \u001b[0mserver_hostname\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mserver_hostname\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 365\u001b[0;31m                          _context=self, _session=session)\n\u001b[0m\u001b[1;32m    366\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    367\u001b[0m     def wrap_bio(self, incoming, outgoing, server_side=False,\n",
      "\u001b[0;32m/usr/lib64/python3.6/ssl.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, sock, keyfile, certfile, server_side, cert_reqs, ssl_version, ca_certs, do_handshake_on_connect, family, type, proto, fileno, suppress_ragged_eofs, npn_protocols, ciphers, server_hostname, _context, _session)\u001b[0m\n\u001b[1;32m    771\u001b[0m                         \u001b[0;31m# non-blocking\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    772\u001b[0m                         \u001b[0;32mraise\u001b[0m \u001b[0mValueError\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"do_handshake_on_connect should not be specified for non-blocking sockets\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 773\u001b[0;31m                     \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdo_handshake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    774\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    775\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mOSError\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mValueError\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/ssl.py\u001b[0m in \u001b[0;36mdo_handshake\u001b[0;34m(self, block)\u001b[0m\n\u001b[1;32m   1031\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mtimeout\u001b[0m \u001b[0;34m==\u001b[0m \u001b[0;36m0.0\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0mblock\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1032\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msettimeout\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mNone\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1033\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sslobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdo_handshake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1034\u001b[0m         \u001b[0;32mfinally\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1035\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msettimeout\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtimeout\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib64/python3.6/ssl.py\u001b[0m in \u001b[0;36mdo_handshake\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    643\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mdo_handshake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    644\u001b[0m         \u001b[0;34m\"\"\"Start the SSL/TLS handshake.\"\"\"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 645\u001b[0;31m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sslobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mdo_handshake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    646\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcontext\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcheck_hostname\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    647\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mserver_hostname\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "import pubchempy as pcp\n",
    "import pandas as pd\n",
    "from urllib.request import urlopen\n",
    "from urllib.parse import quote\n",
    "import pandas as pd\n",
    "\n",
    "df=pd.read_csv('Drug_Smiles_api.csv')\n",
    "\n",
    "def gt_cmpds(cmpd):\n",
    "    cmpds=[]\n",
    "    for compound in pcp.get_compounds(cmpd, 'name'):\n",
    "        cmpds.append(compound.isomeric_smiles)\n",
    "    try:\n",
    "        cmpds=max((i for i in cmpds), key=len)    \n",
    "        cmp=max((i for i in cmpds.split('.')), key=len)\n",
    "    except:\n",
    "        cmp='DID NOT WORK'\n",
    "    if cmp=='DID NOT WORK':\n",
    "        try:\n",
    "            url = 'http://cactus.nci.nih.gov/chemical/structure/' + quote(cmpd) + '/smiles'\n",
    "            cmp = urlopen(url).read().decode('utf8')\n",
    "            cmp=max((i for i in cmp.split('.')), key=len)\n",
    "        except:\n",
    "            cmp='DID NOT WORK'\n",
    "            print(cmp)\n",
    "    return cmp\n",
    "\n",
    "df['isomeric_smiles']=df['api_name'].apply(lambda x: gt_cmpds(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
